7		_	\sim	\sim	_	_	$\overline{}$	_	ът	\sim	α
I	-	ĸ	0	(.	н:	н:	1)	- 1	IXI	(-	- 5

- DR. HYMAN: I'm David Hyman, special counsel here
- 3 at the Federal Trade Commission. Let me welcome you all to
- 4 the reconvening of the Hearings on Health Care and
- 5 Competition Law and Policy jointly sponsored by the Federal
- 6 Trade Commission and the Department of Justice.
- 7 This is the latest in a series of hearings that
- 8 started in February and are going to last through September,
- 9 perhaps October, unless I can make it September, and
- 10 represent an ongoing investigation of the performance of
- differing parts of the health care market with regard to the
- 12 cost of the services that are provided, the quality of those
- services, and the extent to which ordinary Americans can
- 14 access information about those services and obtain those
- 15 services at a time and in a fashion that is desirable to
- 16 them.
- 17 This morning we have a very distinguished panel and
- 18 extensive bios for each of the speakers, not all of whom,
- 19 unfortunately, are here just yet, and are published in this
- 20 beautiful book that's available outside. Our rule is,
- 21 accordingly, short introductions because you can read about
- the people in the book.
- The format we're going to follow this morning is
- 24 our first speaker, Newt Gingrich, is going to make somewhat
- 25 extended remarks. And then there will be a panel discussion

- 1 Health Transformation, which advocates for market-oriented
- 2 health care.
- And just two other preliminary announcements. If
- 4 everyone can turn off their cell phones. The Speaker likes
- 5 nothing better than being interrupted by the sound of your
- 6 cell phone. And second, time will be kept by Cecile Kohrs
- 7 over at the table there. So if the speakers can just keep an
- 8 eye out for that, it will ensure that we'll have adequate
- 9 time for discussion.
- 10 Newt, you can either sit or stand at your option.
- 11 MR. GINGRICH: If it's okay, I'll just sit, if
- that's all right. And I'll try to go through this pretty
- 13 rapidly as an outline.
- But first of all, Dave, let me thank you and the
- 15 Federal Trade Commission and the Department of Justice
- 16 Antitrust Division for hosting us today. I think trying to
- think about impediments to competition in health is a very,
- 18 very important topic, first because of the rising cost of
- 19 health care, second because the scientific and technological
- 20 breakthroughs are likely to increase the cost of health care,
- 21 and third, because the aging of the baby boomers guarantees
- 22 that the sheer volume of health care over the next decade of
- 23 15 years is going to continue to go up.
- 24 If you look at the current crisis in Europe and
- Japan, one of my mentors, Steve Hanser, just spent a month in

- 1 Europe. I called him when he got back. I said, "What did
- 2 you learn?" He said, "Well, I was in four countries and
- 3 there were four issues: pensions, pensions, pensions, and
- 4 pensions," he said, "with the cost of health care and
- 5 unemployment being a distant second and third."
- And I think if we don't in the next few years bring
- 7 to bear a much different approach to how we have a
- 8 competitive health system, that in fact we will rapidly move
- 9 towards some kind of bureaucratic redistributionist and, I
- 10 think, mediocre system.
- So what you're focusing on is exactly at the cusp
- of either finding really dramatic solutions or getting in
- 13 trouble. As you mentioned, we just finished a book called
- 14 "Saving Lives and Saving Money," and we just opened up a
- 15 website called the Center for Health Transformation, which is
- 16 at HealthTransformation.net, or you can go to just my first
- 17 name, Newt.org. But in "Saving Lives and Saving Money," we
- 18 outline a model for transforming the health system.
- 19 Let me start by making an argument that I think
- 20 gives the Federal Trade Commission a particularly important
- 21 role in the next ten or fifteen years. It should be the
- 22 natural product of a scientific, technological,
- 23 entrepreneurial, free market system to produce more choices
- of better quality at lower cost.
- 25 And I'm going to repeat this because I think in

- 1 both health and education you see a tremendous impediment of
- 2 government blocking what should be a natural pattern. The
- 3 natural pattern should be more choices of better quality at
- 4 lower cost.
- 5 And in a sense, Wal-Mart is, for the 21st century,
- 6 what Alfred Sloan and General Motors were for the 20th
- 7 century, in the sense that Sloan's investigation of consumer-
- 8 led mass production defined management for most of the 20th
- 9 century.
- 10 Wal-Mart's model, that lower everyday price is a
- 11 function of lower everyday cost, and that they see themselves
- 12 as the largest and most efficient market makers in the world,
- is something really worthy of study.
- 14 And any institution that gets 100 million Americans
- 15 to voluntarily show up every week is worth looking at and
- 16 saying, what is it they're doing right? I mean, without
- arguing about other aspects of Wal-Mart, it seems to me that
- 18 they are an institution worthy of study.
- 19 What we're suggesting is that lowest everyday price
- 20 being a function of lowest everyday cost should apply to
- 21 health and health care, and that producing more choices of
- 22 higher quality at lower cost should apply to health and
- 23 health care, and that to the degree it doesn't, it is largely
- 24 a function of the mis-design of the current system.
- Now, there are three areas where you see real proof

- Now, our argument, both in "Saving Lives and Saving
- 2 Money" and at the Center for Health Transformation, is that
- 3 you can't succeed in reforming the current system, that the
- 4 current system is inherently, by design, mal-designed so that
- 5 a third party payment model is inherently conflict-ridden
- 6 because you have the person receiving goods not responsible,
- 7 the person paying goods confused about who they're
- 8 responsible to, and the person who's paying the money
- 9 irritated with both the provider and the patient.
- In addition, we suggest that you want an
- individually-centered system, not a patient-centered system,
- 12 because you want to use early diagnosis. You want to use
- 13 nutrition, attitude, and activity to extend individual
- 14 healthy behaviors. So we always talk about health and health
- 15 care. We don't start by talking about health care.
- 16 Interestingly, Dr. Zerhouni, the head of NIH,
- believes that if you had a system that was refocused on maximizing health and delngly, Dr. 5 0 in Health care.

- 1 independently from his perception of building expert systems
- 2 at Vanderbilt University believes you could also get about 40
- 3 percent out of the system.
- 4 So what we're describing is a transformation that
- 5 could literally be worth, if you're an optimist, 5 percent of
- 6 the entire economy. If you think that's too high, it could
- 7 be worth 3 or 4 percent, which is still fairly big money.
- 8 We think there are four drivers of this change that
- 9 the FTC ought to look at. The first is patient safety and
- 10 patient outcome. And the reason I start with that is health
- is inherently moral. We called our book "Saving Lives and
- 12 Saving Money" in that order because saving lives is the moral
- cause and saving money is the practical cause.
- 14 If you start with patient safety and patient
- 15 outcome -- and I used to serve as the ranking Republican on
- the Aviation Subcommittee; this was in a distant past when we
- were in the minority -- and I represent the Atlanta Airport.
- 18 We value life in commercial aviation by several orders of
- 19 magnitude more than we value life in the health system.
- 20 So when the Institute of Medicine reports that we
- lose at least one New York to Washington shuttle a day to
- 22 medical error in hospitals, the country says, yes, hospitals
- are dangerous, and we go on to the next topic. If we lose a
- 24 shuttle, the National Transportation Safety Board, the
- 25 Federal Aviation Administration, the airlines, the

- 1 manufacturer, all collaborate in a stunningly intense effort
- 2 to change the system, and when they learn what needs to be
- 3 changed, they retrain the pilot, the manufacturer, or the
- 4 maintenance people within 48 hours.
- By contrast, the Institute of Medicine reports it
- 6 can take up to 17 years for a doctor to learn a new best
- 7 practice, and over 80 percent of doctors do not practice best
- 8 outcome medicine. Now, that's unacceptable in civil
- 9 aviation, and I simply tell every audience we should value
- 10 you as much in the health system as we value you in aviation
- and you'll get to a dramatically better system.
- 12 The second driver should be information technology,
- computing, and communications. The amount of information we
- 14 could get is stunning. I just talked with Dr. Korpman at
- 15 Health Trio, who runs an information system. One of their
- 16 major clients is Brigham & Women's.
- 17 As soon as they went to electronic information,
- 18 they reduced the number of call-backs each month by 30,000
- 19 phone calls a month to verify prescriptions. At \$6 a call,

- 1 medical record in the U.S. that was sustained for around
- 2 \$29 million a month.
- Now, that is an absurdity not to have that. And
- 4 you go down the list of things IT, information technology,
- 5 should bring you, almost all of which are inhibited by the
- 6 current structure of the health system, legal structure,
- 7 cultural structure, and incentive structure.
- 8 The third thing we focus on is quality, a system
- 9 and culture of quality in the sense of Deming and Juran. And
- 10 again, if you look at manufacturing in the last 80 years,
- 11 essentially all of it is coming out of the Western
- 12 Electric/Hawthorne experiment and the rise of systems
- analysis at AT&T's manufacturing system in the 20s, which
- 14 Deming actually was part of. And then you look at Deming
- 15 teaching 75 percent of Japanese industrial capital in 1951 in
- 16 a four-day course which led to the Japanese creating the
- 17 Deming prize for the best-run company in Japan.
- 18 We have had stunning explosions of productivity and
- 19 quality in manufacturing because we recognize it is a system
- 20 and we recognize you need a culture of quality. None of that
- 21 has happened in health. And it is -- despite the best
- 22 efforts of a number of people, it has simply not penetrated
- 23 again because the distribution of power in the health system
- 24 has allowed people to simply say no and walk off.
- The fourth thing we focus on is the notion that you

13

1 have to re-center the health system on the individual. The

- 2 individual has to have the knowledge. They have to have
- 3 access to clear information. They have to have real power in
- 4 order to make real choices.
- 5 And they have to be held accountable. You need an
- 6 incentive system which says, you know, if you're diabetic and
- 7 you don't manage your diabetes, you have a responsibility.
- 8 This is not just a magic system where you can do nothing,
- 9 live badly, and then demand that the doctor fix you.
- 10 And I say this having helped author the welfare
- 11 reform legislation. And the direct parallel I would argue is
- if we as a country are prepared to say to the poorest people
- in the country, you have to go out and get a job or get an
- 14 education, we should have the nerve to say to every American,
- 15 you have a responsibility for monitoring your own health, for
- 16 having a health indicator system.
- 17 And again, one of the things that we should be
- 18 looking at is what is it that inhibits us from creating
- 19 marketing and having a system in which people could literally
- 20 monitor their own health on a regular basis.
- Our goal is to consistently look for better
- outcomes at lower cost, and we think if you aggregate those,
- 23 it is startling how many places there are where you can get
- 24 very dramatic improvements by applying better outcomes at
- 25 lower cost.

- 1 Now, there are essentially four kinds of
- 2 inhibitions. The first is the guilds. And here, Adam Smith
- 3 is very clear in the wealth of nations, for everybody who
- 4 believes in free markets, let me just suggest to you if you
- 5 think of being a doctor as a guild, you understand a great
- 6 deal of what I'm about to talk about. If you think about
- 7 being a lawyer as a quild, you understand a lot of what I'm
- 8 going to talk about.
- 9 The second thing to look at is obsolete laws which
- 10 are based on a different era and which is based on an era of
- 11 a different kind of economy, a different kind of information
- 12 flow, and a different kind of capability.
- The third is the impact of bureaucracies, both
- 14 public and private. I mean, large corporations and large
- insurance companies are truly as bureaucratic as large
- 16 governments, and bureaucracies have inherent patterns of
- 17 avoiding competition and avoiding change that are valid
- 18 whether they're public or private.
- 19 And the fourth is we create the wrong incentives.
- 20 We create incentives which are acute care-focused. We create
- incentives which are doctor-centered rather than
- 22 individually-centered. And we created incentives which do an
- 23 immense amount once you're sick, but almost nothing to incent
- 24 you not to get sick.
- Let me suggest six quick areas where I think the

- 1 insurance by 40 percent for the self-insured -- I mean, for
- 2 individuals, small businesses, and notice that under ERISA
- 3 we're quite cheerful about doing this for the biggest
- 4 companies in America.
- 5 So the biggest companies in America are exempted
- from the 50 state mandates. They're exempted from the 50
- 7 state insurance commissioners. And if you get to be big
- 8 enough, you get to play in one league, but if you're not that
- 9 big, you're actually in an artificially -- and I want to
- 10 emphasize artificially -- dramatically more expensive league.
- The second thing I want to suggest to you is to
- 12 look at medical rules that break America up into 50 states.
- 13 There's no doubt in my mind that many of the restrictions on
- doctors are explicitly guild behavior designed to minimize
- 15 competition.
- 16 But beyond the question -- and I would argue that
- there ought to be some kind of national registry, and if
- 18 you're a board-certified doctor you ought to be able to
- 19 practice in all 50 states. We live in a modern age. We live
- 20 in an age where information flows worldwide. The rules that
- 21 grew out of a 19th century industrial model strike me as
- 22 obsolete.
- But in addition, you want to be able to move
- 24 medical information across state lines. The Mayo Clinic
- 25 exists in three states, Arizona, Minnesota, and Florida.

- 1 They should be able to have a control digital database, have
- 2 you have an MRI in one state, and if the best person in the
- 3 world to read that MRI is in a different state, it is
- 4 irrational and destructive of life and money to say that you
- 5 can't have access to that.
- 6 So second, you ought to look at the degree to which
- 7 state lines today artificially inhibit these things. And let
- 8 me point out that in terms of interstate commerce, there is
- 9 no constitutional reason that the health system shouldn't be
- 10 seen as a national system.
- 11 And, by the way, the minute you have a SARS threat
- or an anthrax threat or a new model of flu, we behave like a
- 13 national system. So I think this is when you look at what's
- 14 the additional cost in inhibition, both for lives and money,
- 15 by the current model of state-by-state quild behavior?
- 16 The third is to look at what inhibits the rise of
- 17 the right kind of investigation systems. There's a firm
- 18 called Health Share which has taken the Medicare data and has
- 19 developed an expert system which enables you to pull up
- 20 hospitals based on the Medicare data.
- 21 And it is very interesting that consistently the
- 22 best hospitals tend to be the least expensive. It is the
- inverse of the automobile business. In the health business,
- 24 you very often can get a Ferrari for the cost of a Subaru,
- and if you go to a Subaru quality, you very often pay the

- 1 price of a Ferrari.
- 2 And this is a system which indicates -- and, now,
- 3 it's only Medicare data today; it's not all data -- but it
- 4 really begins to give you an ability to access what are
- 5 outcomes, how many medical errors are reported, how many
- 6 hospital-induced illnesses are there, what do they charge,
- 7 how many days do you spend in the hospital, et cetera.
- 8 There are all sorts of inhibitions against these
- 9 kinds of systems growing up, including -- and I'm going to
- 10 come to it at length -- the liability system, which inhibits
- 11 the development of this kind of information, but also, the
- 12 unwillingness of doctors and hospitals to share data.
- 13 And one should look at the question -- there was a
- 14 huge fight a number of years back about whether or not you
- 15 could put prices on cars. And as with all good guilds, the
- 16 manufacturers and the auto dealers did not want to put prices
- on cars. And this was a big fight over the public's right to
- 18 know what does a car cost.
- 19 Well, let me suggest to you that you're in the same
- 20 cycle right now. Interestingly, in 1999 12 percent of the
- 21 country went online to find the price of a car before they
- 22 bought a car. In 2002, in three short years, that number
- 23 exploded to 58 percent of the country. And on average, they
- 24 save 2 percent on the cost of the car they purchase. So I
- 25 just want to suggest there's no inherent reason that you

- 1 couldn't have an accurate information system about
- 2 capabilities and cost.
- The fourth change, though, is one which you only
- 4 have an indirect interest in but a big interest in the
- 5 market, and that is HIPAA will almost certainly have to be
- 6 modified both for research data and for price and outcome
- 7 data. And there's no reason you can't design it so that you
- 8 can have a patient confidentiality-compliant system.
- 9 But the way HIPAA technically is written right now,
- 10 for example, it's very difficult to do longitudinal research
- 11 under HIPAA rules. And NIH will probably be making
- 12 recommendations on this topic. But again we have to say, to
- what degree does the government become self-destructive?
- 14 Because in the name of protecting your privacy we have
- designed a rule which actually makes it more likely you'll
- 16 die.
- 17 And so I think we have to look at, in the age of
- 18 electronics, how do we both protect your privacy and enable
- 19 the gathering of quantitative data that we need very badly.
- 20 The fifth proposal I want to suggest to you is a
- 21 radically different way to think about purchasing drugs. The
- 22 current drug system -- and this is particularly timely
- 23 because of Medicare, but again, it goes back to the issue of
- 24 how do you get markets to work right.
- The current drug system is wrong on a couple of

- 1 accounts. First of all, there is no pricing for drugs.
- 2 Drugs are almost -- particularly if you're in any kind of
- 3 group purchasing plan, drugs are purchased as a function of
- 4 rebates or kickbacks.
- It is as though the Ford Motor Company announced
- 6 that they had a \$600,000 truck, but for you there was a
- 7 \$560,000 rebate so it's only a \$40,000 truck for you; whereas
- 8 the Chrysler Company said, we have a \$45,000 truck, and for
- 9 you we're willing to take off \$5,000. Somehow,
- 10 psychologically, taking off 560,000 sounds better.
- 11 So the current system actually incents the
- 12 pharmaceutical manufacturers to optimize the price of the
- drug in order to have the widest possible margin to rebate to
- 14 the pharmacy benefit manufacturers.
- The second thing wrong with the current system is
- 16 that requiring copays up front perversely maximizes the price
- of the drug for the person who has the choice. If I'm going
- 18 to put up \$10 as a copay and my choice is a \$40 drug or a \$70
- 19 drug, I actually psychologically want the \$70 drug because I
- 20 get the seven-to-one return on my money. The ideal model
- 21 would be to reverse that, that is, to put the subsidy up
- front, so that every additional dollar cost came out of my
- 23 pocket.
- 24 Two other points. Historically, we couldn't handle
- 25 data as it related to the sheer flow of drugs. And in 1965,

22

- 1 perverse the current system is. This is a system that
- 2 because the doctor gets no psychological reward out of
- 3 prescribing a nonprescription drug -- you went to the doctor,
- 4 you want a prescription.
- If the doctor said to you, you know, last year or
- 6 two years ago this was the second most prescribed drug in the
- 7 world -- I mean, for the FTC to just say, what's wrong with
- 8 this picture and how come the market isn't working, strikes
- 9 me as a very important investigation.
- 10 So here's how it would work. You'd have a
- 11 Travelocity-type page. It would list all the drugs available
- 12 and medically appropriate indicators. Your government, which
- loves you, will pay 100 percent of the least expensive and
- 14 will give you the same dollar value for any other drug.
- 15 So it's an open formulary. You don't get into
- 16 politics. You don't get into bureaucrats picking. You don't
- get into the kind of things we're going to see with all the
- various closed formularies. And the drug company has to tell
- 19 you an honest price. It can't give you a rebated price
- 20 that's totally artificial because it's out in the open.
- 21 NDC Health believes they could provide for the
- 22 government every night the subsidy price for the next day
- 23 because they handle over ten million transactions a day.
- Now, I just offer that as a model, but if you had a model
- 25 like that, the patient would have more information -- it's,

25

1 could report it anonymously and that no disciplinary action

- 2 would be taken unless there was some extraordinary
- 3 circumstance -- you'd been drinking or you were doing
- 4 something really stupid in the cockpit.
- 5 The result was a dramatic increase of reporting
- 6 near-misses and significant systems modifications that
- 7 ultimately saved people from running into each other and
- 8 killing people.
- 9 There ought to be some tie between quality
- 10 reporting, error reporting, being open about things like
- 11 hospital-induced illnesses and protection with a reasonable
- 12 framework for having participated to improve the outcome of
- 13 the system to save lives.
- 14 And again, I draw a distinction. If the doctor is
- drunk, if the doctor is egregiously misbehaving, if there's a
- 16 boundary condition that clearly is what would historically
- 17 before 1963 have been a guilty behavior, then you ought to be
- 18 able to sue in a different fashion. But there ought to be
- 19 protections and structures.
- The last thing I think you have to look at is the
- 21 degree to which -- and you see this now in Pennsylvania, West
- 22 Virginia, and Mississippi and Nevada -- the degree to which
- 23 predatory legal behavior is actually beginning to endanger
- 24 lives because the principles that are being established drive
- 25 people out of practice.

1	I was told recently that in Las Vegas, there are no
2	obstetricians willing to take any new patients. Now, there
3	has to be a public health cost here. An epidemic of lawyers
4	can be as dangerous as an epidemic of SARS, and literally
5	dangerous in the sense that by driving doctors away from
6	behavior they would otherwise engage in. We are killing
7	people. And there should be some way for this to be
8	investigated in a straightforward manner to find out to what
9	degree it is not, in fact, legal behavior but is economically
10	predatory behavior, and to recommend to the Congress ways of
11	thinking about these problems.
12	Because our interest is to have an orderly system
13	in which we optimize the activities that are productive and
14	in which we optimize the desirability to become a doctor or
15	to run a hospital or to provide good health, and in which the
16	individual citizen is guaranteed justice if they are
17	aggrieved, but we don't create classes of behavior as a
18	result of which we are economically self-destructive.
19	Thank you for letting me outline all this.
20	DR. HYMAN: Okay. Well, let me just start by
21	throwing it open to the panel generally and asking any of
22	them whether they have questions, comments. I have a whole
23	series of them, but let me defer to the panel first.
24	Warren?

DR. GREENBERG: I must say it was a very

Warren?

25

- 1 stimulating, very thoughtful group of remarks, and I
- 2 appreciate hearing them myself, and I'm sure everyone else
- 3 did. I'd like to have a world out there, which is perhaps
- 4 close to yours, and just describe it just for a second. It's
- 5 part of my talk, but what the heck, you're here and I'll do
- 6 it now.
- 7 You talked about Wal-Mart first, Wal-Mart the
- 8 department store. And you talked a lot about information,
- 9 the lack of information that we have. How about a world, Mr.
- 10 Gingrich, where we would have Wal-Mart in health care,
- 11 competing against K-Mart, competing against Bloomingdale's,
- 12 competing against Nordstrom's, competing against Lord &
- 13 Taylor.
- 14 Look at the information we would have in that
- 15 marketplace. Look how we know, when we go into K-Mart, we're
- 16 going to get a particular type of good, a particular quality
- of jewelry, perhaps, at a lower price than we would going
- into Bloomingdale's or Nordstrom's, knowing almost nothing
- 19 about jewelry, perhaps knowing very little about men's
- 20 clothes, yet that symbol of the department store that George
- 21 Stigler spoke about 40 years ago, the Nobel Prize-winning
- 22 economist, perhaps can be applied to health care.
- 23 Look at all the information we would get if firms
- of health plans -- if we could name a health plan today that
- 25 we know is the Nordstrom's of health care, that we know is

- 1 the Wal-Mart. Instead, it's ABB, blah, blah, blah, Fidelity
- 2 Mutual. We don't even know how good they are. But why don't
- 3 we have that development of brand names?
- And this is what I'd like to address in my talk,
- 5 and I would ask you if you can believe that maybe this is the
- 6 way we ought to tie in information, and ask you and perhaps
- 7 other panelists, what are the imperfections that we have that
- 8 we don't have health plans. And it's not only the department
- 9 store approach. I'm talking about automobiles. I don't know
- 10 anything about what goes into a Lexus or who the mechanics
- 11 were in making that Chevrolet. But somehow, I know a Lexus
- 12 works better than a Chevrolet.
- Why don't we have these brand names, from good to
- bad, with prices, as a way to provide information to every
- 15 consumer in America?
- MR. GINGRICH: Well, let me say first of all, Dr.
- 17 Greenberg, I agree with your core vision that -- with this
- 18 caveat, which I think you also agree with, because I want to
- 19 make this clear so we don't get some kind of attack on the
 - idea of marketsBut somehow, I knoo5 -blohfs'(14)Tj3rica? ake tmlenil

- 1 If you go back to the rise of the Food & Drug
- 2 Administration under Theodore Roosevelt, this was in fact an
- 3 appropriate response to the need to have a refereed or
- 4 regulated framework within which the market operates and the
- 5 delivery is by the market, but it's a delivery guaranteed by
- 6 the government in terms of quality.
- 7 And I say that because otherwise we're going to get
- 8 somebody attacks us: How can you compare health to -- within
- 9 that framework, you're exactly right. Now, interestingly,
- 10 when we first went out to begin working on "Saving Lives and
- 11 Saving Money" back in 1999, we started by looking for
- 12 branding.
- 13 What are the startups? What are the better
- 14 outcomes at lower cost, et cetera. You have some limited
- 15 branding. The Mayo Clinic is a world-class name. The
- 16 Cleveland Clinic is a very good name.
- 17 But what you discover early on is that the
- 18 inhibitions against their growing, it almost resembles
- 19 Lancashire cottage industries prior to the rise of the mills
- 20 and the degree to which you can't aggregate behavior. It's
- 21 very hard. So that we look at firms -- Visicu is a Johns
- 22 Hopkins spinoff that deals with electronic intensive care
- 23 units.
- 24 Every hospital in the country ought to have either
- 25 their own intensivist or they ought to be attached to an

- 1 electronic intensive care unit, period. I mean, this just
- 2 should be a minimum standard.
- But when you go to the local intensive care doc, he
- 4 says, wait a second. What are you saying to me? Or you go
- 5 to the local group of doctors and you say, well, I don't know
- 6 that I want my hospital to do this, even though statistically
- 7 there is no question: If you go to a -- if you have
- 8 abdominal surgery in a hospital without an intensivist, the
- 9 odds are three times as high you'll die.
- 10 And so what I discovered, to go back to your point,
- 11 is it is very hard to get the rise of these branded
- 12 structures. Probably the Hospital Corporation of America is
- 13 as close as we've come to that kind of a model. But it's
- 14 also really hard to get to the aggregation of behavior. And
- part of it is because of doctors and the way they're trained
- 16 by medical schools, which has to be redone. Part of it is by
- 17 legal inhibitions.
- 18 The other point I'd make is that historically, the
- 19 mistake that was made in the '80s was creating a so-called
- 20 health management approach, managed care approach, which
- 21 actually was about managed cost. There was no data for
- 22 managed care, and so you ended up in the wrong kind of fight
- 23 and you actually -- I think society was pushed back a step
- 24 because the design was backwards.
- DR. HYMAN: Helen?

- 1 MS. DARLING: Yes. I'd like to get back to one of
- 2 the excellent points you made about your vision, and
- 3 particularly combine your history as a politician and your
- 4 current activities as transforming the health system, for
- 5 which I'm sure everybody in the room will be very grateful,
- 6 especially if you can do it.
- 7 Over-the-counter drugs and generics offer the
- 8 consumer much of what you're talking about. First of all,
- 9 the minute they become generic and over-the-counter, a lot of
- 10 other things happen, usually. And just generally, you know,
- 11 you can debate about some of the data and what it shows,
- 12 especially absent the competitive system -- that is, more
- 13 than one generic.
- But generally, consumers and employers will save a
- 15 lot of money to the extent that drugs are moved to over-the-
- 16 counter generics. But the industry, as you know, has, shall
- we say, kindly made it as difficult as possible for that to
- 18 happen even to the extent that trying to use the authority
- 19 that the Congress has given, both the FDA and themselves, to
- 20 limit either movement to generics or anything that could
- 21 possibly work.
- 22 Could you please talk a little bit about your
- thoughts about how, number one, we move that along faster,
- and two, if there are other barriers that we should be paying
- 25 attention to that keeps those kinds of changes from happening

32

- 1 in a timely way.
- 2 MR. GINGRICH: Thank you. I think that's a very
- 3 insightful question that goes to the heart of one of the
- 4 biggest changes that we need.
- 5 Let me start by saying that I think that American
- 6 history is filled with moments when economically very
- 7 powerful entities that forgot that profit is supposed to be a
- 8 by-product of service and began to try to rig the game for
- 9 themselves found that, in fact, this is a stunningly populous
- 10 society. I think of Robert LaFollette and the railroads as a
- 11 perfect example, leading to the rise of the progressive
- 12 movement.
- 13 I very much favor the branded pharmaceutical system
- which has created two generations of therapeutic
- 15 breakthroughs that are extraordinary. But I think that they
- 16 are now trapped in exactly the same crisis that doctors are
- 17 trapped in.
- 18 Several years ago I went and spoke to the AMA when
- 19 I was Speaker, and I got a very nice round of applause
- 20 because I had followed somebody they didn't like. But when I
- 21 got up, I said to them, you're either going to go to Wal-Mart
- or you're going to go to Canada. You're either going to end
- 23 up in a regulated, unionized, government-run bureaucracy, or
- 24 you're going to be in a genuine market where people have real
- 25 information.

- And that's my message, basically, to the
- 2 pharmaceutical companies. I am for people paying the
- 3 appropriate price with knowledge in a competitive setting for
- 4 the drugs they get. I think a system which is dominated by
- 5 detail people, a system which is dominated by rebates, a
- 6 system in which doctors prescribe in ignorance, is a system
- 7 that is doomed to failure. And let me talk briefly about how
- 8 that will happen, I think.
- 9 First of all, I have talked to no audience in the
- 10 last six months where you describe automatic teller machines,
- 11 self-service gas stations with credit cards, and Travelocity,
- and then you mention the phrase "paper prescription."
- 13 They don't just get it. I mean, all of their
- common experiences every day now are that you can have
- 15 electronic interfaces that are stunningly accurate, and then
- 16 you get a paper prescription. And paper prescriptions
- 17 require a massive volume of call-backs. Forty percent of all
- 18 prescriptions require a call-back. And the doctor very often
- 19 doesn't even know what else you're taking. So start with
- 20 that.
- 21 At a large scale, what you want to do is simple.
- 22 You want to take something like Scholar, which is a Stanford
- 23 spinoff that has been certified by the AMA for continuing
- 24 medical education, and you want to have a Scholar-quality
- 25 page, much like Travelocity, so the doctor is an informed

- 1 prescriber. You can put it on a Palm. You can do -- but
- 2 doctors ought to know, here are the nine drugs and here's
- 3 what they cost.
- By the way, in the studies that have been done,
- 5 when doctors do know the cost, they consistently prescribe
- 6 less expensive drugs. I mean, some outliers don't, but as a
- 7 general rule, it does have an impact.
- 8 Second, you want electronic prescribing. My hope
- 9 is that the Medicare drug bill is going to mandate electronic
- 10 prescribing. You want computer order entry in hospitals of
- 11 medications, and you want every drug that you get to have an
- 12 electronic indicator on it so that you automatically can
- 13 match up the drug and the patient.
- 14 And again, Pfizer has taken the lead in developing
- 15 that, but I think you're going to see it happen -- this has
- 16 been going on in grocery stores now for about 40 years. And
- 17 I think it's finally migrating into health. All of these
- things have a big impact on accuracy, safety, and cost.
- 19 But what the country has to say, and I think the
- 20 Medicare drug debate may be precisely the place to start
- 21 saying it, is -- and this is historically how -- we
- 22 historically get change out of two things. We either have a
- 23 grievance, you know, again, Nader versus the big auto
- 24 companies, which whatever you may think of Ralph in terms of
- 25 being, from my standpoint, much too liberal, his crusade in

- 1 the '60s and '70s clearly changed the standard of safety in
- 2 America, despite the fact that the biggest companies in the
- 3 United States were opposed to it. But in the end, they
- 4 couldn't stand up to the public debate.
- 5 Similarly, the most successful companies in America
- 6 right now may well be the pharmaceutical companies, but when
- 7 the country decides, A, this is what I'm missing -- you know,
- 8 why am I paying 65 percent more than I should be paying, or
- 9 why is it that a detail person's ability to get the
- 10 receptionist to schedule ten minutes becomes an integral part
- 11 of which drug I get.
- 12 And so I think you will see a different model
- emerge fairly rapidly, and I think it will almost certainly
- 14 be an internet-based model. It will almost certainly be an
- information-rich model. And it will happen either because
- 16 the government shifts in the direction I'm describing or
- 17 because ten or fifteen large payors shift and decide that
- they'll subsidize 100 percent of the least expensive.
- 19 And again, what I'm arguing for is an open
- 20 formulary. So none of the pharmacy benefit management
- 21 companies are going to like this because it takes away the
- 22 rebate model and the information control model which is at
- 23 the heart of their being an intermediary.
- 24 But the modern information systems take out
- 25 middlemen, empower you to make choices, and drive prices

- 1 output per dollar. So I studied under Deming as a result of
- 2 that experience.
- 3 You start with a premise: If you're really, really
- 4 good, you're probably less expensive. Toyota is less
- 5 expensive than Mercedes. In fact, there's a terrific book by
- 6 Womack called, "The Machine that Changed the World," which is
- 7 the MIT project on automobiles. They make the point that
- 8 Mercedes and Toyota produce about the same quality car, the
- 9 difference being Mercedes rebuilds one-third of their cars;
- 10 Toyota rebuilds 2 percent of their cars.
- 11 Then they make the point that if Mercedes can't
- 12 learn the Toyota production system, that you cannot compete
- very long at the same price, if I have to rebuild a third of
- 14 my cars for quality and you're rebuilding 2 percent of yours.

- 1 selects out for people who want to engage in research -- so
- 2 you have to start with the idea that, I mean, best of class
- 3 very often recruit to best of class.
- 4 Second, they have the professional commitment to
- force themselves to learn things they don't want to know,
- 6 which is very, very difficult. And it's part of the key to a
- 7 quality culture.
- 8 Third, if you in form, do it right, you don't have
- 9 medical errors and you don't have medication errors and you
- 10 don't have hospital-induced illnesses, all of which cost
- 11 money. There are two million hospital-induced illnesses a
- 12 year in the United States. If you stay in a hospital longer
- 13 than four days, the odds are even money the hospital will
- 14 give you a disease which it will then charge you to cure.
- 15 This goes back to perverse incentives.
- The U.S. government ought to pay a bonus to every
- 17 hospital which has significantly less medical error and has
- 18 significantly less medication error, has significantly less
- 19 hospital-induced illness. One specific example: When
- 20 Wishard Hospital went to -- Wishard Memorial went to complete
- order entry of drugs, they reduced the average stay by nine-
- 22 tenths of a day per patient. Now, seen from the standpoint
- of the CFO, they just reduced their income. But they saved
- 24 nine-tenths of a day per patient by going to computer order
- entry.

- 1 Visicu, according to Centera Hospital, has --
- 2 Visicu is the electronic intensive care system -- Centera,
- 3 which has it in five hospitals connected to one office for
- 4 electronic screening, says that they now save 20 percent of
- 5 the time per intensive care patient, on average, in moving
- 6 them through the intensive care unit because there are fewer
- 7 errors, fewer hospital-induced illnesses, better treatment.
- 8 So you actually -- true quality should actually
- 9 improve hospitals, not cost them more. And true quality
- should actually improve doctors' incomes, not make them
- 11 poorer. But the incentive system does, in a perverse way,
- 12 almost incent you to have the errors and have the illnesses
- 13 because you get to charge for them.
- DR. HYMAN: You get to double hit. You're having
- 15 them in first and then again.
- 16 Mike?
- 17 MR. YOUNG: I guess before I ask a question, I will
- 18 say -- you mentioned HIPAA. And HIPAA was a consulting gold
- 19 mine for us in the first -- for consultants for the first
- 20 quarter of this year.
- 21 But I absolutely agree with you that it has clearly
- 22 gone way too far, and we have a number of situations where
- 23 the access to data is very hard to get and seemingly, you
- 24 know, each holder of data makes their own determination of
- 25 how they use HIPAA, either as an excuse or a realistic way to

- 1 protect peoples' rights. So I absolutely agree that it's
- 2 gone too far and I think we need to come back.
- But what I'd like to touch on is this whole issue
- 4 of a lot of the consulting that I do is in rural communities.
- 5 And I've been doing it for many years. And two of the things
- 6 we see are situations -- and I'll use Hot Springs, Arkansas
- 7 as an example. They have 30,000 people there. They have
- 8 three hospitals. They have eight MRIs. And so there's just
- 9 an incredible glut of providers, if you will, more than they
- 10 need.
- 11 And then we see other communities where there are a
- lack of physicians, especially. And I've found with rural
- communities especially, there are two types of physicians.
- One are the people that tended to either grow up in those
- 15 communities and want to give back and go back and work in
- 16 those communities. And, quite frankly, another group that
- 17 goes there to hide from the system.
- 18 And so there's kind of this double-edged sword. In
- 19 some of these communities, there seems to be such a glut that
 - everybody in Hot Springs who2.k otout that

- 1 MR. GINGRICH: Well, you raised a couple of things.
- 2 Let me go through quickly.
- First of all, rather than complaining about HIPAA,
- 4 people ought to start drafting the modifications. Congress
- 5 writes laws so Congress can meet to hold hearings so Congress
- 6 can write laws. I mean, instead of saying, gee, this is now
- 7 locked in concrete, we ought to say, okay. This was a good
- 8 try in the right direction. It's largely better than having
- 9 no law. Now, what do we have to fix?
- 10 And just -- I think people should say certainly by
- 11 early next year that Congress should be holding hearings on
- 12 the better patient safety, better information model of HIPAA
- 13 based on what we're now learning. And this will be an
- ongoing iterative process as we get used to living in an
- 15 information age.
- 16 Second, you reminded me, there really should be a
- 17 nationwide database, for example, of doctors who've been
- 18 disbarred or of doctors who have been heavily sanctioned.
- 19 And it ought to be an accessible database. That is, I should
- 20 be able to find out whether or not I'm dealing with a doctor
- 21 who has lost 14 malpractice suits in 14 different states.
- Today there are state databases, but they're not
- 23 accessible. They're not together. And there's no reason you
- 24 couldn't have a nationwide database. This is pretty easy.
- 25 And at a minimum, it will flush out the worst

- doctors, which ought to be flushed out. I mean, there's no
- 2 reason the worst doctors should be allowed to practice. We
- 3 would not allow the worst airline pilots and the worst
- 4 airline mechanics to practice. We say there is a standard
- 5 above which you have to be or you kill people.
- 6 Third, when you have eight MRIs in a town that
- 7 size, as long as you know what the price is and as long as
- 8 that price is public, the least efficient ones are presently
- 9 going to go out of business unless they're self-directed,
- 10 which gets me to a fourth point.
- But I think this is part of why pricing has to be
- out in the open. Three hospitals won't survive unless they
- 13 can survive. I mean, I don't care how many retail stores --
- 14 back to your point about department stores. I don't ask you
- 15 how many stores there are in a town. You know, if they can
- 16 make a living and they're willing to do it, that's fine. You
- 17 could have 30 MRIs if they can do it. But what I object to
- 18 is that they pass the cost on and it becomes part of an
- 19 embedded base of what we mean by health care costs. I think
- 20 that's inappropriate.
- The other thing that's wrong, where I think the FTC
- 22 could usefully look at, is when you have a doctor-owned
- 23 facility which is also self-referred. And I want to draw a
- 24 real distinction because I think we made a mistake in
- 25 designing this.

- I have no problem with doctors investing in
- 2 hospitals unless they refer to the hospital they invest in.
- 3 But if you end up in a situation, as was described to me the
- 4 other day in another part of the country, where the
- 5 doctors -- the cardiologists are really pretty clever.
- If it's going to be an easy cardiology problem, it
- 7 goes to their clinic. If it's going to be a really
- 8 expensive, hard cardiology problem, it ends up in the local
- 9 general hospital. Now, that kind of behavior strikes me as
- 10 absolutely wrong and unprofessional and inappropriate, and we
- 11 need to figure out how we monitor that.
- The other example is places where hospitals tend
- not to run emergency rooms so that they don't get the heart
- 14 attack patient until the second day when they've stabilized,
- which again means that they have a very high likelihood of
- 16 success rate without having run the big risk.
- 17 The last point I want to make about rural America:
- 18 Rural America will profit more from the rise of internet
- 19 diagnostics and internet-based capabilities than will urban
- 20 America. And properly designed, you could have a Visicu for
- 21 an entire rural state that would literally allow you to have
- 22 an intensivist for all the hospitals in the state
- 23 simultaneously.
- Visicu, for example, is now going to be monitoring
- 25 the intensive care unit in Guam for the Air Force from

45

- 1 Hawaii. And there's technically no reason not to do that.
- 2 So you could imagine two years from now every rural state in
- 3 the country could have a connectivity to an intensivist even
- 4 for very small rural hospitals, and the coaching improvement
- 5 would be dramatic.
- 6 I'd also say for small rural areas -- and again,
- 7 this is the cultural crisis -- you know, you're now talking
- 8 to the local doctor who's been totally in charge for all
- 9 their life. No one has ever questioned them. They're the
- only doctor within 25 miles. And somebody is now going to
- 11 look over their shoulder?
- I mean, this is a -- you know, and what I'm arguing
- is, yes. For patient safety reasons, for public outcome
- 14 reasons, you're right. And the other example I would cite is
- 15 Active Health, which is a very good firm, which works for
- 16 large corporations. And they basically get world class
- doctors to coach your doctor if you have an expensive
- 18 illness.
- 19 And it turns out that by getting the world class
- 20 doctor to work with your doctor, your doctor's quality of
- 21 care goes up dramatically. And again, for rural America,
- these things are potentially doable, but they're only doable
- from the state level down. They're not doable by small
- 24 hospital by small hospital because they never aggregate the
- 25 resources to do it.

- DR. HYMAN: Let me ask a question about
- information. I mean, information is an important part of a functioning market. You've emphasized it in your remarks.

- 1 kind of information in insurance decisions.
- I would argue in part that you want to have -- and
- 3 this may sound contradictory coming from a conservative, but
- 4 I think we want a country that is very close to 100 percent
- 5 insured. And the reason you want that is we made the
- 6 decision we're not going to let people die without caring for
- 7 them, and so to not have them insured just maximizes the
- 8 complexity of the delivery system.
- 9 I think between vouchers, tax credits, and tax
- 10 deductions, you can create a system in which people have
- 11 virtually 100 percent insurance. And then you want to make a
- 12 ground rule for offering insurance that you can't cherry-
- 13 pick.
- 14 And there are a variety of ways to do that by
- 15 having open access. You can have an open access system that
- 16 also incents good behavior. That is, you could have -- you
- 17 could say to people, if you keep your cardiovascular within
- 18 certain parallels, you know, we'll give you \$100 back at
- 19 Christmastime. And you can do that without having cherry-
- 20 picked.
- 21 But I do think you want to say basically that in
- 22 the case of health insurance -- which is really an anomaly
- 23 because it's mostly not true insurance. Health insurance is
- 24 mostly prepaid medical care with some insurance components.
- Now, we go a step further in "Saving Lives and

- 1 Saving Money." We propose that Congress should pass a law
- 2 creating a personal health account, which would in essence
- 3 mean that when you first went to work, you'd get, say, a
- 4 \$1500 deductible and we'd put the \$1500 in your account so
- 5 you're now spending your dollars.
- It would be -- it could carry and have tax-free
- 7 interest buildup. So when you're young, you probably
- 8 wouldn't spend it, and within a very few years, you'd be at
- 9 the 20-, \$30,000 deductible level with it being your own
- 10 money.
- 11 When you got above the value at which you got any
- 12 kind of break on the -- now you would be on a true insurance
- 13 system because now you would have set aside your maintenance
- health money, which you'd be spending, and the insurance
- 15 company would actually be offering genuine insurance.
- 16 The other piece of that is probably we need,
- whether it's designing a government-sponsored enterprise that
- 18 would be competitive or some other model, we probably need
- only to go to a reinsurance system, that is, to create a
 - hat4ohalmphbeemderethwh6tlyou can 0 TD(12)TjoaTj1

- 1 million or something -- probably done by a government-
- 2 sponsored enterprise.
- 3 But I think the inability today to have that kind
- 4 of insurance pool means you get grotesquely expensive small

1	The information burden and the lack of integration
2	and coordination in the highly fragmented model are two big
3	problems. So one question is, how do you see the relative
4	balance between essentially bundling, creating continuity,
5	integration of services which manage, for example, chronic
6	conditions or end-of-life care, complex care, rather than a
7	highly fragmented marketplace?
8	And secondly, what do you see as the balance
9	between the regulatory function on the information
LO	requirements in such a market and the self-issued information
L1	opportunities?
L2	And I'm probably interested in to the extent
L3	that I've become more and more of a believer that there has
L4	to be government standardization of information requirements
L5	and disclosure requirements and so on and of infrastructure,
L6	as you've supported for a long time, electronic
L7	infrastructure to support that information capability.

t8frastructure to sace?

a9frastructure to sr thetnuity informakie,

2nd I'm probabl

- of which are proof that you can have systematized national
- 2 standards.
- 3 There's a -- and I can't remember the name of it
- 4 right now; some of you will know -- there is a national
- 5 association founded, I believe, in 1916 for electric
- 6 standards during a period when the government wanted to
- 7 ensure things happened but didn't want to do it itself. And
- 8 so all electrical appliances in the United States go through
- 9 the same standard-setting, which is actually a private
- 10 association, legally empowered to do that.
- 11 You could -- you know, and whether you have HHS set
- 12 an information standard or you have the government establish
- a freestanding commission for medical information, which may
- 14 be the right parallel -- but your point's exactly right.
- I mean, jumping out five years, or no more than
- 16 eight but within five years, automatic electronic health
- 17 record -- I want to distinguish a health record from a
- 18 medical record. A health record is all the information that
- 19 you should carry with you for the next doctor. The medical
- 20 record is everything the doctor and the hospital need to keep
- 21 for the lawsuit. A very big difference in detail, in level
- 22 of detail.
- 23 Everybody ought to have an electronic health
- 24 record. It ought to be compatible across all the systems.
- 25 All the major providers of these kind of systems should be

- 1 part of an open systems architecture as opposed to I'm going
- 2 to design some cute device so once I have you, you're a
- 3 captive and you can't use anybody else's equipment.
- 4 And again, all of us who use the internet and who
- 5 use laptops are -- you know, everybody who uses a cell phone
- 6 has experienced this. And I want to draw a distinction
- 7 between two different points you made, and then talk briefly
- 8 about managed care.
- 9 The model that Dr. Greenberg described is a model
- of stunning consumer choice. You know, I decide today I want
- 11 to go buy X. I have lots of places to go buy X. It's the
- job of the aggregator to provide me a reputation and a price
- and a convenience I want to go to.
- And then you're exactly right in your analogy. You
- 15 know, there are all sorts of places I can go for what I want,
- 16 and I get signals from the system about reputation, et
- 17 cetera.
- 18 So you could have a consumer-driven system in which
- 19 you had a very high level of common information, more, I
- 20 would say, than you get today. That is, if I had an
- 21 electronic health record so that the next doctor knew what
- the last doctor had prescribed, you'd already be at a quantum
- 23 jump above current behavior.
- The second part, though, I think, is a misnomer
- 25 about what happened with managed care. It goes back again to

- 1 the moral cause. Health is different than buying clothing or
- 2 buying jewelry. There is a moral component because it's
- 3 about my life or my daughter's life or my granddaughter's
- 4 life or my mother's life.
- 5 And so the minute I think that a decision about
- 6 their life will be profit-driven as distinct from profit
- 7 being derived from the right decision, if it is a profit-
- 8 driven decision, I am very suspicious that I am now going to
- 9 have my granddaughter get bad care so somebody has a better
- 10 quarterly report.
- I mean, the analogy -- and by the way, I'm told
- this all the time. Insurance companies will tell you with
- great openness, we don't do preventive care because people
- don't stay with us long enough to justify it economically.
- 15 Well, that's like an airline saying, you know, we're going to
- 16 be as safe as our quarterly report permits. Now, we wouldn't
- 17 tolerate that for one minute.
- 18 So what the insurance company is tell you is they
- 19 are putting your health needs below their profit margin. And
- 20 it is a perfectly rational behavior in the current market.
- 21 And that's why people have this deep suspicion of the
- 22 financing of health care, that a decision will be made, I
- 23 won't get what I want.
- Now, I'll give you a couple of examples. And here
- 25 AARP and others are actually showing some real leadership.

- 1 Comorbidities are the largest single problem in Medicare.
- 2 Five percent of the people on Medicare use up 50 percent of
- 3 the money. That 5 percent has, on average, somewhere between
- 4 five and seven comorbidities. It's very clear they ought to
- 5 get managed as a complete person and not have five to seven
- 6 separate verticals.
- 7 That can be done in a system where you basically
- 8 say, we're going to incent the doctor to have full
- 9 information through an electronic health record. And we're
- 10 going to incent the doctor to deal with all the comorbidities
- 11 at one time.
- 12 And you can design a system that does that while
- 13 still allowing the patient to pick which doctor they want to
- 14 go to. So it's not an either/or. It's not either that we've
- 15 got to trap people into a system where it's controlled for
- 16 them, or they've got to be out here in a chaotic jungle
- 17 without any kind of information.
- 18 If you use the incentives right and you use the
- 19 structure of information right, you can migrate to a system
- 20 in which I still have choice, but it's choice among a series
- of very high value products with much more complete knowledge
- than we have today.
- I would argue if you've got the right electronic
- 24 health records and the right kind of requirements for
- 25 electronic prescriptions, et cetera, you will have

- dramatically better health almost overnight in terms of the
- 2 way in which we minimize medication errors and other kind of
- 3 mistakes.
- 4 DR. COMSTOCK: I do have a comment, actually. I
- 5 think everybody in this room, and certainly around the table,
- 6 agrees with a lot of what Newt has said. And whether you
- 7 believe that there's 30 percent waste in the system or 40
- 8 percent waste in the system and all of these dollars were
- 9 there that could be easily used to do things like create
- 10 access for everybody in this country or create the
- infrastructure, improve the transparency of information, we
- 12 have been involved in a community project across the country.
- 13 And when you talk to health care leaders there,
- 14 fundamentally they say, well, it's all well and good to say
- 15 that money exists, but you can't wait to take all of that
- 16 efficiency and put more efficiency into the system. There
- 17 needs to be an investment now.
- 18 And what we're doing is we're talking about --
- 19 we're not really talking about what we really want to
- 20 achieve. We're talking about where the dollar is coming
- 21 from.
- 22 And I quess I'm wondering whether you have any
- 23 ideas of how you manage that transition from an economic
- 24 perspective. I mean, do we suddenly decide we're going to
- 25 spend X billions more money in order to squeeze the

57

- 1 year. This was some 80 years after the bubonic plague first
- 2 began sweeping through Europe.
- 3 So let's just start with the idea none of us -- and
- 4 we get scared by SARS, which has killed a couple hundred
- 5 people. I mean, none of us has seen what a real epidemic
- 6 would be like, and it would be horrifying.
- 7 So I would argue that under homeland security
- 8 requirements, we need about a \$40 billion investment in the
- 9 equivalent of the interstate highway system. And in our
- 10 book, we quote Eisenhower, who specifically had the
- 11 interstate highway system as a national defense act, although
- 12 it's obvious from the middle class that it has been
- enormously successful in other ways.
- 14 That system should also include a virtual public
- 15 health service which connects all 55,000 private pharmacies,
- 16 all retired nurses and doctors as well as currently active
- 17 nurses and doctors, and includes veterinarians. Because if
- 18 you lose a central city, one of the largest sources of health
- 19 resources in the surrounding countryside will turn out to be
- 20 veterinary hospitals.
- 21 Second, I want to suggest to you that here's a
- 22 place where there are opportunities for huge improvements.
- 23 We work with the people at IBM who do logistics supply system
- 24 modernization, where they take huge amounts of cost out of
- 25 logistics systems.

- 1 And I was talking the other night with doctors at
- the major medical groups, who said that the paper-handling
- 3 transaction cost of getting paid is three or four times
- 4 greater in health care than it would be if you were dealing
- 5 again with the big department stores you were describing.
- 6 Imagine a -- and it's particularly stupid for the
- 7 self-insured. I mean, for a self-insured company to engage
- 8 in a long-time value of money for doctors means the doctor
- 9 will countervail by charging more to make up for the lost
- 10 value of money and will then have to add clerical staff, et
- 11 cetera.
- 12 So imagine a system where doctors filed
- electronically with your health record and your bill
- simultaneously, by one click, and were paid every night by
- 15 electronic funds transfer on a post-payment reconciliation
- 16 system.
- Now, you'd have dramatically fewer clerks. There
- 18 was a study done, I was told, for Blue Cross -- I have not
- 19 seen this, but a study, I was told, was done for Blue Cross
- 20 of Massachusetts that they figured out if you could have
- 21 realtime verification of eligibility, you would eliminate
- 22 one-half of their clerical staff.
- Now, this is not heavy lifting. I mean, if you
- think about what happens worldwide when you use your Visa,
- 25 MasterCard, American Express, you name it, I mean, we somehow

1 are able to stand at a restaurant or at a store buying a

- 1 I'd like, since he's going to have to leave in the middle of
- 2 the presentations, a round of applause for the presentation.
- 3 (Applause.)
- DR. HYMAN: I'm just going to introduce everyone on
- 5 the panel at once, and we can sort of go across. People can
- 6 either speak from where they're sitting or up at the podium.
- 7 The first speaker, since he's over on the far left,
- 8 is going to be Warren Greenberg, who's a professor of health
- 9 economics and health care sciences at George Washington.
- 10 Next will be -- he's going to speak for about ten minutes.
- 11 Next, David Lansky, who is sitting to Newt's left,
- who is the president of the Foundation for Accountability,
- has been the president since the organization was founded in
- 14 1995.
- 15 Following him will be Michael Young, who is senior
- 16 vice president at Aon Consulting, focusing on health and
- 17 welfare issues.
- To my immediate left is Helen Darling, who wins the
- 19 frequent flyer award for the panel because she has spoken
- 20 more than anyone else on the panel, and I think probably more
- 21 than anyone else we've had, she's such a wonderful speaker.
- 22 She's the president of the Washington Business Group on
- 23 Health.
- 24 Seated to Helen's left is Dr. Marcia Comstock,
- 25 who's the chief operating officer and a member of the board

- of the Wye River Group on Health care, who has done a lot of
- work on emerging trends in health care finance and delivery
- 3 and is going to talk about some reports that the Wye River
- 4 Group has released.

- 1 these latter imperfections. My goal, as I believe is the
- 2 goal Chairman of the Federal Trade Commission as well as the
- 3 entire FTC, is to achieve both price and quality competition
- 4 in the health care sector, and I mean the entire health care
- 5 sector, not just the Medicare program.
- The three imperfections I'd like to focus on are:
- 7 the failure to tax employer-paid health insurance premiums;
- 8 adverse risk selection for health plans; and U.S. and state
- 9 "any willing provider" laws. This is filling in the blanks,

- 1 There is a substantial amount of turnover in the
- U.S. labor force. Although this differs by geographic areas,
- 3 location, type of job, age and gender of workers, it has been
- 4 estimated that job turnover is between 12 and 16 percent
- 5 throughout the economy. In higher turnover industries, such
- 6 as agriculture or construction, the turnover rate is even
- 7 much higher.
- And we talk about incentives here. When job
- 9 turnover is high, there is little incentive by the employer
- 10 to invest in health plans, to invest in expensive but perhaps
- 11 better quality treatment and procedures, as well as superior
- 12 physicians and hospitals, which can improve quality of care
- 13 and perhaps lower cost in subsequent periods. Why? Because
- 14 within one or two years, those employees are going off to
- other jobs with other health care plans.
- 16 In contrast, if there were an individual-based
- 17 health insurance system rather than an employer-based system,
- individuals would retain their health plan whether employed
- 19 with the firm, self-employed, retired, or disabled.
- 20 Individuals would choose a health plan from a variety of
- 21 health plans during yearly open enrollment periods.
- 22 Individuals will buy health insurance in the same
- 23 way they purchase automobile insurance without regard to
- 24 employment status. Income-adjusted premiums may be needed to
- 25 help those with lesser incomes if universal coverage is

65

- 1 desired.
- 2 Individual-based health insurance is found in many
- 3 European countries and Israel. In an individual-based
- 4 system, individuals might belong to a health care plan for
- 5 many years or decades, providing incentives for these health
- 6 care plans to do disease management and to try to insure
- 7 quality early on.
- 8 There would be greater incentives for the health
- 9 plan to invest in a person's health and to improve quality of
- 10 care rather than the current system that we have in force
- 11 with our individual -- with our employer-based health care
- 12 system.
- 13 However, under an individual-based system, and this
- was touched on by the Speaker, precautions will be needed,
- 15 however, to insure that health plans are not avoiding high
- 16 risk enrollees. And therefore I would suggest we also need,
- in addition to employer-based health insurance, the idea of a
- 18 case mix risk adjustment system.
- 19 Why? Because if health plans competed on a quality
- of care basis, and we touched on this before, the plans which
- 21 provided the highest quality of care, in the language that we
- 22 talked about before the Nordstrom's, the Lord & Taylor,
- 23 perhaps, would attract the highest risk employees in the
- 24 following opening enrollment period, increasing its cost
- 25 considerably.

- 1 Health plans would be reimbursed by a neutral party
- 2 according to the number and severity of the individual
- 3 enrolled. Those health plans with a great number of high
- 4 risk individuals would be reimbursed at a higher amount.
- 5 This would create incentives for health plans to compete on
- 6 quality in order to attract the higher risk individuals.
- 7 Those health plans which do not necessarily compete
- 8 on quality, and perhaps stress lower premiums, would receive
- 9 little or no risk-based reimbursement. Price and quality
- 10 competition here. Each of the health plans would be required
- 11 to help finance the payments to the health plans which have
- 12 enrolled the high risk individuals.
- 13 Again, I won't repeat what I said before. But
- 14 under these circumstances, I do believe we will see the
- department store approach where health plans are competing
- 16 both on price and quality, the same way we might see a Saks
- 17 Fifth Avenue and Bloomingdale's approach.
- 18 Under this kind of competition, the difficulty in
- 19 determining quality of care would also be less daunting for
- 20 the patient. It is also possible that individuals with the
- 21 same price/quality tradeoffs may differ on their view of
- 22 particular department stores, yet with its faults, many
- 23 individuals are satisfied to make this one of our most
- 24 important buying tools.
- 25 Finally, in the third step, each health plan should

- 1 be encouraged to utilize every avenue to improve both quality
- of care and lower price. This would include selective
- 3 contracting with a limited number of physicians and hospitals
- 4 in the geographic area to attempt to achieve the lower cost
- 5 or higher quality.
- 6 Lower cost may be achieved by playing providers off
- 7 one against another to achieve increased volume and lower
- 8 cost. Improved quality can be maintained by contracting
- 9 only, perhaps, with the Cleveland Clinic or Mayo or a limited
- 10 number of hospitals. And physicians who increase volume may
- 11 translate into higher quality.
- 12 Unfortunately, recently the Supreme Court ruled
- that "any willing provider" laws may be enacted by state
- 14 governments in which a health plan must contract with all
- 15 providers which would like to sign a contract with the health
- 16 plan. "Any willing provider" laws, if enacted by state
- 17 governments, would eliminate the potential for contracting
- 18 with only a limited number of providers.
- 19 In order for health plans to compete based on price
- 20 and quality, states should no longer to attempt to enact
- 21 these "any willing provider" laws, and those laws which have
- 22 been enacted should be repealed. Thus far, in 17 states,
- 23 "any willing provider" laws have been enacted to prevent
- 24 selective contracting with physicians. Thirteen states have
- 25 enacted laws which prevent selective contracting in regards

- 1 to hospitals.
- 2 Health care expenditures, including studies here by
- 3 economists at the FTC, have been shown to be much higher in
- 4 those states where they have "any willing provider" laws.
- I would sum up by saying these three steps -- an
- 6 individual-based health insurance, which could be achieved by
- 7 taxing employer-based health insurance; a risk adjustment
- 8 payment; and selective contracting -- are necessary to
- 9 achieve both price and competition in health.
- 10 Each of these steps is interrelated and is
- 11 essential to competition. Without the possibility of both
- 12 price and quality competition, the health care marketplace
- 13 will remain inefficient. There will be over-investment of
- 14 price competition at the expense of improved quality,
- 15 resulting in economic loss for those who desire improved
- 16 quality. Even those who put a greater emphasis on price
- 17 competition will be confronted with a downward spiral of
- 18 quality if there are no incentives to provide quality of
- 19 care.
- 20 With \$1.4 trillion spent on health care in the
- 21 United States, it is imperative to create incentives for
- 22 improved quality as well as reduced costs and to eliminate
- 23 these three market imperfections to compliment the antitrust
- 24 efforts of the FTC and the Department of Justice.
- DR. HYMAN: Dr. Lansky, your PowerPoint is up on

- 1 the screen. So you can run it from up there if you like.
- DR. LANSKY: Thank you, David and the Commission,
- 3 for letting me join you. I appreciate it.
- 4 My particular area of interest is in the
- 5 information requirements of consumers to be successful in
- 6 this health care system and market. And you had a marvelous
- 7 set of witnesses in the last few months covering much of what
- 8 I would normally have wanted to say.
- 9 So given that, I thought I would take a particular
- 10 slant on a theme, I think, that has not been adequately
- 11 addressed, which is the genuine experience of patients
- 12 seeking and getting health care, and what information is
- 13 needed in the course of our real lives, leaving a little bit
- 14 aside the legal and technical requirements that I think are
- 15 vital but I do think have been fairly well addressed.
- 16 So I'll introduce the term person-centered. And
- 17 the Speaker has certainly emphasized that throughout his

- 1 support competitive purchasing.
- 2 We developed about fifteen different sets of
- 3 measures addressing a number of chronic illnesses, end-of-
- 4 life care. We've done a great deal of work the last five
- 5 years on child and adolescent health, particularly to support
- 6 the CHIP and Medicaid purchasing requirements.
- 7 In the course of doing that, we quickly learned
- 8 that measures and data per se were not sufficient to support
- 9 a successful market, and we had to think about a framework
 - for presenting and communicating information. We developed

- 1 interoperable, it's transportable, and it is lifelong. And
- 2 we are just now working on a project with the maternal and
- 3 child health bureau here to develop what we call a data
- 4 resource center, which allows the consumer or a policy-maker
- 5 to access all the knowledge there is that may help them
- 6 understand and advocate for health improvements.
- We've done about a hundred focus groups in the last
- 8 few years. We've done very large surveys. We do a lot of
- 9 interviewing. And we spend a lot of time working with
- 10 patients, veterans, labor organizations, to understand what
- 11 their constituency may be concerned about.
- 12 So that is context. I think the main theme I want
- to mention today in terms of the quality, information, and
- 14 field that we work in is that the history of the last ten
- 15 years or so in this field -- and the Speaker spoke about the
- 16 idea of guilds influencing the behavior of the delivery of
- 17 care.
- 18 It's equally true in the information field, that
- 19 the information constructs that are often used to communicate
- 20 to the public are actually driven from above, not from the
- 21 experience of the person who needs to make a decision.
- 22 So the categories we use to fund health care and
- 23 the categories of specialty training tend to be the
- 24 categories we use to collect and disseminate information.
- 25 don't think those always serve the needs of a real family

- 1 removal of the section of the lung to remove this tumor.
- Obviously, my mother-in-law and my wife were
- 3 paralyzed with fear and anxiety, and immediately wanted to
- 4 pursue the doctor's recommendations. But my wife, on the far
- 5 right of this picture, being at least interested in the web,
- 6 got online. And this is her weekend's work, between the time
- of the recommended scheduled surgery and the end of the
- 8 weekend.
- 9 She found a lot of resources to try to assess what
- 10 was going on in this case. You'll see the one on the left
- 11 there says "Probability of malignancy in solitary pulmonary
- 12 nodules," which is actually an online calculator that allows
- 13 you to enter the information that you may have from the film
- 14 and get a prediction of whether or not this is in fact a
- 15 malignancy or benign.
- 16 And my mother-in-law's data said it was 24 percent
- 17 chance of being malignant. So whether it was appropriate
- 18 with a 24 percent probability of malignancy to do this
- 19 radical surgery was certainly something needing a little more
- 20 discussion than we'd had the first time around. You also see
- 21 information from the cancer support groups, and a quick
- 22 education on imaging.
- It turns out that one of the articles my wife found
- 24 has an NCBI study that she found in 1999 when this occurred
- of a three-year-old study which talks about the evaluation of

- 1 fourfold difference in mortality if you go to a place that
- 2 does a lot of them versus a place that does only a few of
- 3 them.
- 4 And if you look at this New York City data, one of
- 5 our concentrations of medical excellence in America, only one
- 6 hospital in the entire central area of New York City performs
- 7 above the threshold number of lobe resection surgeries in a
- 8 year. A huge number of hospitals perform one, two, seven
- 9 operations a year in this very complex and very invasive
- 10 procedure.
- 11 My mother-in-law again had no information
- 12 whatsoever provided to her to guide her decision. And as I
- 13 suggested earlier, even in this one story, there are maybe
- 14 ten, fifteen important consumer decisions to be made: the
- 15 primary care doctor, the first imaging center, the second
- 16 opinion, the second imaging center, the facility to have the
- operation done in, the surgeon to have conducted the
- 18 operation, in a moment of enormous anxiety, pressure, and
- 19 fear. It's a very complex set of consumer decisions to
- 20 unravel in the real world.
- 21 A second example I want to give is our development
- of a set of quality measures for HIV and AIDS care. And this
- 23 would -- we had a wonderful commission or advisors, the
- 24 chairman of the President's Commission on AIDS, and a great
- 25 group of experts.

1 And they listed, as you see here, about eighteen 2 things which they think are important to measure to describe 3 the quality of HIV and AIDS care. And if you're a patient or if you're in an oversight position and you want to evaluate 4 5 the quality of care in this arena, here are the things you 6 might want to look at. 7 We asked the experts to rank order which of these 8 eighteen things are the most important to use to assess the 9 quality of care for HIV and AIDS. And you see the rank 10 ordering they have here. The first was that the patients

receive anti-retroviral therapy, the second that they be

11

- 1 was actually given to the doctors, not to the patients.
- 2 But the thing I found most interesting in talking
- 3 to many patients -- these are parents of sick children -- was
- 4 that what they said was, I don't want to choose a new doctor.
- 5 I don't want to be told my doctor is poor. I want to make my
- 6 doctor better. I've been using this doctor for four years,
- 7 ten years, whatever. It's a place I'm comfortable getting
- 8 care. I want to know what they're doing poorly so that I can
- 9 basically beat them over the head with it and I can work with
- 10 them to improve the quality of care they receive.
- 11 So I think the ah-hah for us who had done an awful
- 12 lot of worn on exit, on choice, was that a lot of patients
- 13 really want voice and they want tools to improve their
- 14 interaction with their providers. So it's a much more
- 15 complex use of information than we had previously discussed.
- Just to tie this all together and again reveal the
- 17 complexity of it, this is a map we did with the General
- 18 Electric workforce to identify all the information patients
- 19 want to know in real life -- these are people who've been
- 20 diagnosed with breast cancer. We asked them, what do you
- 21 want to know to get the best possible health care?
- 22 And as you look at a spectrum from the far left,
- 23 where people are at risk of breast cancer but not diagnosed,
- to the far right, where they have had successful intervention
- 25 and are now living with the disease as a survivor, there's a

- 1 lot of information.
- 2 And it's very contextual, not surprisingly. The
- 3 information a young woman who may feel at risk for cancer
- 4 because of her relatives' experience wants to know is
- 5 dramatically different than someone who's about to have an
- 6 operation to remove a vital part of their body or deciding on
- 7 a form of therapy postoperatively.
- 8 So the sensitivity, the specificity, the
- 9 personalization of information is in some ways self-evident,
- 10 but most of our discussions about making the market work have
- 11 not been very finely attuned to where patients are in their
- 12 experience of seeking care.
- 13 And one other footnote on this particular example.
- 14 This is a study done in comparing care in Massachusetts and
- 15 Minnesota for breast cancer. And I think there are two
- 16 astonishing numerical figures on this slide.
- One is that twice as many people in Massachusetts
- 18 as Minnesota are even seeing an oncologist as part of their
- 19 decision-making, let along deciding which oncologist to see
- 20 or evaluating those oncologists. And ultimately, then, twice
- 21 as many women, almost, are not told that they have an option
- of breast-conserving surgery, having been given a diagnosis
- 23 of early-stage breast cancer. And these are in two,
- 24 nominally speaking, excellent states for medical care and for
- 25 the dispersion of medical knowledge.

1	$C \sim$	mtr	aonaluaion	muah	1 - 1-0	+ha	Chaplearla	- 4	~	+ha+
T	20	шу	conclusion,	IIIuCII	TTVG	LIIE	speaker s,	, т	- S	tilat

- 2 we need a modern information strategy which is sensitive to
- 3 these complexities of real life, and one which understands
- 4 that in a democratic consumer culture, people can and must be
- 5 capable of using information.
- 6 Let me just tick off some of the dimensions I think
- 7 we have to address in building such a modern information
- 8 system. First, medical care is very complex. My wife,
- 9 knowing nothing about medicine, is suddenly an expert on PET
- 10 scanning and solitary pulmonary nodules. And she had to be.
- 11 There was nobody else in the entire enterprise of medical
- 12 care in the Seattle area who stepped up and made the
- investigations and decisions to support her decision-making.
- 14 Secondly, we have many, many sub-specialities and
- 15 many, many layered organizations. We have doctors, nursing
- 16 homes, home health agencies, and so on, all of which play a
- 17 part in achieving successful care.
- 18 Thirdly, care is multi-dimensional. There is
- 19 technical care, guidelines-based care, humanistic care,
- 20 patient education care, care in dealing successfully with
- 21 daily living, and simply the service aspects of care, all of
- 22 which have to be addressed by consumer information strategy.
- 23 Fourth, I am increasingly aware, as I mentioned in
- 24 my Vermont pediatric story, that what people are seeking in
- 25 health care are relationships, not transactions. So to treat

- 1 medical care as a bundle of transactions underestimates the
- 2 complexity of the human exchange of information and decision-
- 3 making, let alone therapy, that goes on.
- Fifth, the population is not uniform. Not only do
- 5 we vary where we are in the course of an illness, but each of
- 6 us in this room has a different way of processing information
- 7 and using it. And in a vital area like health care decision-
- 8 making, this is a very subtle and complex problem.
- 9 We did a segmentation model that identifies four
- 10 types of American health care consumers. And we
- differentiate them partly by their level of independent
- 12 action and partly by how much they listen to their doctors.
- 13 And depending on which type of these four groups you see at
- 14 the top of the slide a person may be, that will affect the
- 15 kind of information they want and how they will use it.
- 16 Next is the issue of transparency or, actually,
- 17 lack of transparency. But there simply isn't the information
- 18 available, period. Not only does the patient not know the
- 19 information they would use to make good marketplace
- 20 decisions, neither do the providers. Neither does the
- 21 government. The information does not exist. It's not known.
- Next, the issue of third party payment all of us
- 23 have talked about for quite a while creates a barrier between
- 24 the purchaser, the financial transaction source, and the
- 25 person who actually needs to receive the superior care.

- We have mediating decision-makers. In my mother-
- 2 in-law's case, there was a primary care doctor referring to a
- 3 surgeon, and a surgeon referring to a hospital. The actual
- 4 locus of control had been taken away from the patient. We
- 5 differ in where we are on the trajectory of illness, as my
- 6 breast cancer slide suggested, and we have to target
- 7 information to where a person really is in their decision-
- 8 making.
- 9 Therefore, just as we in getting medical care
- 10 expect personalization -- we want someone to hear our
- 11 history, understand our allergies, understand our values, and
- 12 help us make a good decision -- so in the information arena
- we have to personalize the support of marketplace information
- 14 to the specific needs of each person.
- Now, fortunately, as the speaker suggested, the web
- 16 and related technologies enable us to do that. But we
- 17 haven't really put our effort behind that so far. We've
- 18 tended to have very blanket strategies for public
- 19 information.
- 20 Finally, as I mentioned in my family's case, there
- 21 is nobody else out there who will do this for you. We may
- 22 not be confident that every American can step up, master all
- 23 this information, and make successful decisions. But there
- 24 really isn't an alternative.
- There are some mediating organizations who will

- 1 certainly help. There are information advisors. There are
- 2 ombudsmen. There are a variety of other sources. But for
- 3 the vast majority of us, there's no one else you can rely on
- 4 to take your illness as seriously as you do.
- 5 So what can be done about it, and what can the FTC
- 6 and other agencies do? A couple of focal points I want to
- 7 suggest. First is we need to do more work on outcomes, not
- 8 process. As I suggested in my question earlier, the more
- 9 that we try to have a process measure for every fragment of
- 10 the American health care system, the more crazy we will
- 11 become. We have an enormously rich and technically complex
- 12 system, and we can't possibly cover the landscape with
- 13 everything.
- 14 And unfortunately, most of our research and others'
- shows that there are not good correlations between being good
- 16 at A and being good at B. A clinic may be great at heart
- disease care, and the same group of doctors, nurses,
- 18 technicians, could be terrible as asthma care. And they're
- 19 sitting in the same offices. You can't say because they're
- 20 good at heart disease, I'll go there for my asthma. There's
- 21 no correlation in any evidence we've seen so far.
- So what do you do? Do you expect to have a set of
- 23 quality measures for every conceivable health problem?
- 24 That's not very practical. So the benefit of focusing on
- 25 outcome measures is it drives innovation because people

1 not only to help individuals make personal choices, but to

- 1 between a patient and doctor. We've been working on
- 2 something we call the ASK, the Agreement to Share Knowledge,
- 3 which is actually an agreement between a patient and their
- 4 doctor about the way they will each play their parts in the
- 5 care relationship and the way they will share information
- 6 with each other.
- 7 Using information intermediaries, whether it's AARP
- 8 or senior centers, to distribute information and make it
- 9 usable to people.
- 10 Providing interactive coaching of information on
- 11 the web. And I don't mean just simply portraying a table of
- 12 numbers on the web, but providing interactive decision
- 13 support tools.
- 14 And then finally, personalized choice aids using
- the patient's own values and preferences as a way to help
- 16 them make decisions with this information.
- I just wanted to illustrate a couple of ways on the
- 18 web that we've been approaching that, but let me just
- 19 conclude. Where I think there's a regulatory role per se:
- 20 In particular, I think it's the information infrastructure.
- 21 That does include what to measure and what must be disclosed,
- 22 but I think it goes further than that, and it goes back to
- 23 the Speaker's example of the interstate highway system.
- 24 There has to be a massive commitment and a public
- awareness that we will not be able to improve this health

- 1 system short of centrally managing it in a way that the
- 2 National Health Service or perhaps the VA or Kaiser might do,
- 3 short of a central management system working off a centrally
- 4 allocated budget. Otherwise, there's no way to improve this
- 5 health system short of building an information
- 6 infrastructure.
- 7 So that requires information standards. It
- 8 requires requiring every player in the health system to
- 9 collect and disclose the relevant information. It requires
- 10 that the content be patient-driven and patient-centered. It
- 11 requires that we integrate that information infrastructure.
- 12 It's not enough to say to every doctor, you must
- buy a personal electronic medical record. Those medical
- 14 records, if they can't talk to each other and talk to the
- 15 pharmacy system and talk to the nursing home system and talk
- 16 to the patient in their living room, that's not going to add
- value to the system. So there has to be an integrated
- 18 electronic information infrastructure.
- 19 And I would encourage the regulatory approach to be
- 20 wary of commoditization. That is, if you try to treat every
- 21 health care interaction as a commodity, as a discrete,
- 22 individually-priced transaction, which by itself has a flow
- of information and set of requirements around information,
- 24 that will actually undermine the ability of us to improve the
- 25 health system through what I'll broadly call relationship-

- 1 based care.
- 2 And finally, as public agencies, I hope that these
- 3 groups will realize that there is no one else out there
- 4 representing the patient and family. Everyone else has a
- 5 legitimate but primarily self-directed interest in the health
- 6 care system.
- 7 The public sector, part of why we use public funds
- 8 and why we have election is that someone has to say, we
- 9 represent the interests and the will, and we have means of
- 10 listening to the voice of, the American public in its breadth
- and diversity. That's a very daunting challenge, and I'm
- 12 very concerned that some major initiatives going on at
- present in the government don't fully make the effort to
- 14 listen to the public will.
- 15 Thank you.

for 25 years I've been working with employer groups of all

- 2 sizes, from 50 employees all the way up to 50,000. And
- 3 invariably, each year it gets tougher and tougher to get
- 4 through this process that we go through this time of year,
- 5 which is helping companies strategize about how to deliver
- 6 health care benefits to their employees for the next year.
- 7 So I was really excited to be able to come down and
- 8 share some of the thoughts. And what I did was I actually
- 9 took the questions from the hearing and threw them at some of
- 10 my clients of all sizes to get their perspective. Because
- 11 what I'd like to do today is be one of the panelists that
- 12 kind of shares with you, you know, what the specific employer
- 13 problems are and what their issues are when it comes to some
- of the things we've been discussing today.
- 15 And the Speaker was right. Being from
- 16 Pennsylvania, I will say that not a week goes by that my wife
- or another family member or a neighbor or somebody tells me
- about somebody whose doctor has left the state. It is a very
- 19 serious problem in all of Pennsylvania, more so in Pittsburgh
- 20 and Philadelphia but just in the state in general. So
- 21 clearly, a significant issue.
- 22 What I did is actually -- because I work with
- 23 actuaries, although I'm not one. I'm somewhat anal about
- 24 this, so I actually put the questions into the overhead so I
- 25 knew what they were.

- 1 the standpoint of being covered for a traumatic, large-cost
- 2 situation, employees tend to get that coverage.
- 3 They also get typically some sort of preventive
- 4 benefit covered -- we'll talk a little bit in a minute about
- 5 the move from HMOs to PPOs -- but the Speaker was right.
- 6 It's kind of a mixed bag. What we find is what one company,
- 7 what one client of ours or what their insurance company might
- 8 define as good preventive care benefits versus another could
- 9 vary drastically.
- 10 We have some with very -- schedules of benefits
- 11 based on peoples' ages and the types of tests they have, and
- then we have other clients who basically say, well, we'll
- 13 give you \$300 each year towards preventive benefits. You
- 14 decide how you want to spend them. So although preventive
- 15 benefits seem to make sense to a lot of employers, they don't
- 16 know how to deliver the right kind of preventive benefits.
- 17 What employees would like beyond those is lower
- 18 cost. And I would say clearly the vast majority of our
- 19 clients each year, and certainly this year, are going to be
- 20 passing along larger cost increases for health care coverage
- 21 than they're going to be passing along salary increases.
- 22 So at the end of the day, a lot of our clients will
- 23 have employees whose payroll deduction for health care will
- 24 be greater than their increase in their salary. And what
- 25 happens is their take-home pay becomes less.

- 1 They also would like coverage for alternative
- 2 treatments. As you all know, there are more and more types
- of treatments out there -- you know, acupuncture,
- 4 biofeedback, and all kinds of things that are on the horizon.
- 5 And employees are becoming more savvy. They are reading
- 6 the -- you know, they are going to the internet. They are
- 7 finding some of these kinds of treatments. They are making
- 8 suggestions that they would like to get those treatments
- 9 done.
- 10 Typically, though, the clients we have, the
- 11 companies we have, tend to rely on the insurance company, the
- 12 Blue Crosses, to set the standard as to what's covered and
- what's not covered, what's considered valuable and reasonable
- 14 treatment and what's not. And that tends to lag from where
- 15 the marketplace is. So we have kind of a lag period, and as
- 16 employees find these kinds of information, they tend to get
- 17 pushed back from the plan still not covering them.
- 18 Administrative ease: Yes, we are getting close to
- 19 a world of having all this data pass electronically, but we
- 20 are not there yet. And it still does vary by each of the
- 21 claim intermediaries that exist. Some are better than
- 22 others. Some have spent more on technology and IT than
- 23 others. So it's still -- there are certainly still a lot of
- 24 employees out there who find, you know, working through the
- 25 health care system to still be an administrative nightmare.

- 1 And then finally, coverage after retirement. I
- 2 think the latest study showed that there's only 23 percent of
- 3 large employer who provide a retiree medical benefit for
- 4 retirees after the age of 65, which is a continuing and fast-
- 5 dwindling percentage of employers.
- 6 Employees recognize, I think, at this point that
- 7 that trend is not going to change or reverse. What we see
- 8 now from employers, though, is at least the understanding
- 9 that they've got to educate their employees that even though
- they're not going to provide a benefit, that you're going to
- 11 need to save significant amounts of money during your active
- 12 life to have that money to supplement Medicare, even with the
- possibility of prescription drug coverage, when you do
- 14 retire.
- There's a great article in Fortune, I think it's
- this week or last week, suggesting huge amounts of money that
- 17 need to be put away prior to age 65 that you would need to
- 18 have to cover those expenses as you go forward.
- 19 I also had some other statistics. This is from the
- 20 Robert Wood Johnson Foundation. Again, 43 -- I thought this
- 21 was interesting -- 43 percent of people that were polled said
- they feared that their employer or their spouse's employer
- 23 might eliminate some health benefits within one year, some of
- 24 their benefits.
- 25 Twenty-one percent said they feared that out-of-

- 1 pocket expenses will increase to an unaffordable level, and
- 2 8 percent said that they fear that the company plan may just
- 3 go away in one year. So there's continued fear, there's
- 4 continued uncertainty, as to the role of whether the employer
- 5 is even going to provide a benefit in the near future.
- I don't want to -- we can talk a little bit about
- 7 distortions. Again, I was very intrigued by what the Speaker
- 8 said. I think that there is a role for employers in this
- 9 process, although it does -- today, the way it's set up,
- 10 small employers clearly do not have the same size, the same
- 11 leverage in the marketplace as large employers to get the
- 12 kind of coverage they need.

And benefit levels, types of plans, those things,

- 1 We're hearing more and more of that from employers every day.
- 2 And again, I just wanted to put up this statistic
- 3 because I think it shows that the key problems that smaller
- 4 employers had -- and the Speaker made mention of this --
- 5 because of the risk pools and the abilities for these small
- 6 employers, employers that have 24 employees or less, you
- 7 know, what kind of health coverage can they get?
- 8 And you can see that if you take employers with
- 9 less than 25 lives, 40 percent of those employers do not
- 10 provide health coverage today. And what that means is that
- 11 the spouse's plan has to pay or these people may be going
- 12 uninsured, you know. But in any way, it exacerbates the
- 13 problem in the system.
- What changes have there been? Clearly, there's
- 15 been a move away from the more tightly managed HMOs -- and
- 16 again, the Speaker was absolutely right, it wasn't managed
- 17 care, it was managed cost -- to more loosely managed PPOs,
- 18 which the employees embraced, getting away from the referral
- 19 mechanism and all the paperwork with that, was just something
- 20 that they were very much in favor of.
- 21 But what that led to is, it's led to more cost as
- it's become a more unmanaged system. So what employers have
- done, what our clients have done, is basically used -- you
- 24 know, the good message is, we're getting rid of your HMO and
- we're putting in a PPO, which is less managed. The bad news

- 1 philosophically believe it's the right thing, but quite
- 2 frankly because they have no other option and they're
- 3 desperate. Okay?
- 4 They probably wouldn't know the underpinnings of
- 5 why consumer-driven plans actually work, but their CFO has
- 6 said, we have to cut cost. It is a new thing to try and they
- 7 don't have many other strategies. So I think you'll see a
- 8 great proliferation of consumer-driven plans.
- 9 Is it going? No, it's not. Okay. Here we go.
- 10 Actually, this is from the Washington Business Group on
- 11 Health and I just wanted to touch on some of the access to
- 12 health care information. Again, because we're running low on
- 13 time, I'm going to skip that. Helen can certainly talk about
- 14 that. I think they do a wonderful job.
- 15 The Speaker did talk a little bit about group
- 16 underwriting, about the fact that when you're in an
- 17 employment-based situation you're able to take all risk --
- 18 good risk, bad risk, whatever. Certainly, in the individual
- 19 market we've seen all kinds of issues with employees trying
- 20 to get coverage, questionnaires, you know, being selected
- 21 against, paying higher rates if they have certain medical
- 22 conditions, and then seeing the rates go up maybe on a
- 23 quarterly basis versus an annual basis. So clearly, the
- 24 individual market, unlike life insurance, is not anywhere
- 25 near as competitive as the group market.

- 1 And I think what I would do to summarize this,
- 2 because I don't want to -- I'd like to save time for some
- 3 questions and things -- is just to leave you with the fact
- 4 that employers out there are questioning their roles today.
- 5 They're not ready to give up the ship yet, but they recognize
- 6 that they can't continue to maintain the structure the way it
- 7 is.
- 8 And I think the structure today has a lot of
- 9 inherent problems with it. And if we don't do something
- 10 soon, I think you're going to see employers start to take
- 11 more drastic actions. Thank you.
- DR. HYMAN: Next is Helen Darling from the
- 13 Washington Business Group on Health.
- MS. DARLING: Thank you. Thank you for the
- opportunity for the FTC and the Department of Justice taking
- on these complex issues that have burdened the system since
 - ApppDDWw16TheWalphnesyThenkI'll sk2.92.92 with thts,

1 fact is very true, and especially what Michael was talking

- 2 about. Not just our data but his experience as well sounds
- 3 very familiar.
- 4 Also, you have researchers. Our very own David
- 5 Hyman and others like Judith Lave have done research. And
- 6 for those of us who are real benefits managers at heart or
- 7 have been at some other time, I think we are pleasantly
- 8 surprised to see repeated data of how much employees value
- 9 their benefits.
- 10 Because if you actually manage them, all you hear
- about are the problems. Nobody says, yes, we really think
- 12 this is great. But interestingly, in the last five years,
- thanks to the work of some really great health economists and
- 14 some survey researchers, we have seen evidence that employees
- 15 really do greatly value their health benefit. And we see
- 16 evidence, which again we didn't see till this past five
- 17 years, that employees actually are making decisions about
- where they work, you know, relative to the benefits.
- 19 So if the economy turns around, health benefits
- 20 again could become a competitive advantage, which is one of
- 21 the things that had kind of gotten lost in the shuffle in the
- last two years. I mean, things are just generally so bad out
- there that, in fact, it's hard to sort out what's happening.
- 24 But if what we saw up until about two years ago is
- 25 true and the economy begins to pick up, then the companies

- 1 that offer these better -- as the Speaker said, better
- 2 quality and more choice at a lower cost, those initiatives
- 3 will become far more important.
- 4 What I would like to say is that employers are

obvious. And so people will say, well, I'd rather have the

- 2 \$5 copay.
- 3 So we've got a lot of confusion out there. But
- 4 employers are trying to move us to more cost-sharing, and not
- 5 just in symbolic terms but real cost-sharing.
- 6 We did a survey of our own members recently about
- 7 what they had been doing in the last few years, and this
- 8 won't surprise anybody here. They are doing more cost-
- 9 sharing and generally feel that enough cost-sharing for the
- 10 consumer to have a financial stake is really essential, and
- 11 that coinsurance, not copayments -- many people that I talk
- to and work with and our own members feel that going to
- copayments to encourage people to join managed care
- organizations, where the delivery system did the management,
- 15 was one thing. But copayments have really become the kiss of
- death for much of what we're trying to do in this system now.
- Once you have a wide-open system, which we
- 18 essentially have now -- I mean, even the PPOs are --
- 19 everything is wide open and the data show that -- then
- 20 copayments become truly absurd. So we're moving to
- 21 coinsurance across the board.
- The second thing is that all of our members, our
- 23 large employers, believe and are working hard that consumer
- 24 involvement is essential. And if you've heard some -- and I
- 25 thought David's presentation was just superb on that point.

1 that's there, but we also have to make sure that people can

- 2 access it and know it's there, and you don't have to know the
- 3 system.
- 4 Again, David's point and others about transparency,
- 5 we believe that's essential. And we have a report out on the
- 6 table -- I hope you all have picked it up -- about
- 7 transparency and accountability. It's essential.
- We also believe that in the short term, that it
- 9 would be very easy to require that all currently publicly
- 10 reported information, which is already -- all the battles
- 11 have been fought about whether these are the right measures
- and all those, and they're imperfect, to be sure.
- But they're already in the public domain because
- they have to be reported to somebody, whether it's Medicare
- or the state health department or, like in Texas, the
- 16 commission. If that information just has to be required to
- 17 be available on the website of every hospital, and in
- 18 libraries and things like that, so that people can get to it.
- 19 One of the things that we've found is it's very
- 20 difficult to measure or to get information on cost and
- 21 benefits because the data are limited. We also found that
- 22 disease and health management programs are growing and
- 23 there's a lot of reliance on those, but that's also another
- 24 area where we don't have a lot of information about what
- works and what doesn't and what's effective. And are these

1 the money in, and that can go into retirement, if you want.

- 2 Essentially, it becomes the 401(k) of health accounts, with
- 3 portability and lot more flexibility.
- These are times of great challenge. We are
- 5 struggling with health care cost increases five years in a
- 6 row, 50 percent, this year 14 percent. They say next year
- 7 it's probably another 14 percent on top of that.
- 8 Some people have raised a question about whether or
- 9 not employers will stay in this business. And we would say
- 10 that the likelihood is that they will stay in the business,
- 11 but the account and the allowance and the amount of money
- they pay will grow more slowly than the cost of health care
- will, and therefore the employees and their retirees will be
- 14 spending a lot more money.
- There was a story in today's New York Times, if you
- 16 haven't seen it, an excellent story. It starts on the front
- page, Milt Freudenheim, about how the coinsurance is, in
- 18 fact, beginning to have an effect. So maybe we'll see some
- 19 changes soon. Thank you.
- DR. HYMAN: Dr. Comstock?
- DR. COMSTOCK: Yes. Good morning. When you come
- 22 at this point in the panel, you have to throw out everything
- 23 you were already going to say because it's already been said.
- 24 But I'm not ever at a loss for words, so I'm going to pick up
- 25 a little bit on some of the things that David said. But

- 1 obviously, on your philosophy.
- 2 Another issue that's been talked about a great deal
- 3 this morning is information needs. There just is not enough
- 4 information out there for consumers. And I want to also
- 5 point out that we have to remember that at least 25 percent
- of people in this country are medically illiterate, and they
- 7 are going to need a great deal of help, and that information
- 8 that is relevant and useful to a 45-year-old college
- 9 graduate, woman college graduate, may not be at all useful to
- 10 a 20-year-old Hispanic mother of three who doesn't speak
- 11 English. And so we have to remember that there's got to be
- ways of getting information to people that is useful and
- 13 meaningful.
- I really want to -- what I would like to talk about
- 15 a little bit is a project that is related to this in the
- 16 sense that we have had strong validation that this is a real
- movement that is not the final form of health care, but it is
- 18 a major move in the right direction.
- 19 Wye River has been involved in the past year in a project where we have gone around the country to ten

1 Institute, Senator Lieberman's office, and so on. So it's a,

- 2 you know, bipartisan, multi-stakeholder initiative to talk
- 3 about the values and principles that should drive health
- 4 policy. David Lansky participated in our Portland meeting.
- 5 The first thing I want to -- the first comment I
- 6 want to make about that is that there's much more agreement
- 7 than difference when you get out of Washington and you get
- 8 into communities. These leaders really want to roll their
- 9 sleeves up and work together to move this health care system
- 10 in the right direction.
- 11 There is broad support from liberals and
- 12 conservatives toward a patient-directed health care system.
- 13 But there are some caveats. From the perspective of the
- liberal, they'll say, that's all well and good to talk about
- 15 personal responsibility. But remember that 25 percent who
- 16 need extra help. And also, it only is going to work if it
- 17 comes with system accountability, telling the patient you've
- 18 got to take care of yourself and you've got to be responsible
- 19 for your health behaviors. So that's very, very important.
- The other thing that's very, very heartening to me
- 21 is that the most conservative elements in the meetings are
- 22 saying that the world's richest country cannot afford to have
- 23 40 million people in this country who do not have access to
- 24 health care. And, of course, we all know insurance doesn't
- 25 equal access, and getting care in the emergency room doesn't

- 1 equal coverage. So this has to be balanced.
- We also have heard in our meetings at every single
- 3 community across the country that if there's one thing that
- 4 we need to do, we need to start a dialogue that we've never
- 5 had in this country. And that is, what is it we want from
- 6 our health and health care system? We haven't even defined
- 7 health and health care. And how do we talk about whether
- 8 we're spending too much or too little or what kind of system
- 9 we should have when we don't know what we want out of the
- 10 system? So that's something that they feel very strongly.

And as we move forward into phase twoe

- 1 take responsibility, for providers to educate patients, and
- 2 to provide preventive care services? Because all of the
- dollars being spent on end-of-life care or unnecessary technology could do an awful lot. And that's why I

- 1 these rural areas, whether it's through community health
- 2 workers or lay educators. And this is kind of like, it's
- 3 very low tech but it's high touch, and people love it. And we need to build that into wor Tuwe're29eat i18025

1 coverage. And so the focus of where I'm going to be looking

- 2 at is the federal and state regulations in the small group
- 3 and individual market.
- The individual market, which accounts for about 10
- 5 percent of private coverage, is primarily regulated by the
- 6 states, while the small group market, which accounts for
- 7 about 25 percent of private coverage, is regulated by both
- 8 the state and the federal government.
- 9 Given these different regulatory environments, we
- 10 have guaranteed issue imposed by the states in certain
- 11 individual markets while quaranteed issue is opposed across
- 12 the board by the federal government on the entire small group
- 13 market?
- 14 First of all, what is guaranteed issue? Guaranteed
- 15 issue is a law that requires insurers to accept everyone who
- 16 applies for health insurance, regardless of their health
- 17 condition. Under guaranteed issue, an individual who has no
- 18 health insurance and becomes ill may apply for private
- 19 insurance coverage and must be accepted. This is comparable
- 20 to allowing a person to purchase auto insurance for their
- 21 accident after being involved in a car wreck.
- When people know they can get insurance when
- they're sick, they'll forego it when they're healthy.
- 24 Younger and healthier people cancel their policies. The
- 25 health insurance pool gets smaller and sicker. Escalating

- 1 premiums occur, and eventually the pool is left with just the
- 2 sickest and most -- and people with the most expensive health
- 3 care needs.
- 4 We eventually reach a point where many insurers are
- 5 no longer able to offer a product under such chaotic
- 6 conditions. The end results are: inordinately high prices
- 7 for insurance; considerably reduced choices for coverage; a
- 8 greater number of uninsured; and ultimately, a health
- 9 insurance market where few, if any, insurers are offering
- 10 coverage.
- I want to look at both the states' individual

1 carriers are exiting the market in droves. The General

- 2 Accounting Office recently completed a study that showed a
- disturbing market concentration in the small group market,
- 4 with the top five carriers controlling more than 75 percent
- of the market share in the majority of the states that the
- 6 GAO studied.
- 7 Healthier groups are dropping coverage because of
- 8 escalating prices. For example, in Colorado, the state
- 9 division of insurance has reported a loss of 14,663 small
- 10 groups, covering more than 125,000 individuals, in just the
- 11 last two years. The state attributes much of this problem
- due to the guaranteed issue requirements in the small group
- 13 market. Healthier groups are just leaving.
- 14 While the increases in health insurance costs and
- the loss observe coverage options do not occur in a vacuum,
- 16 quaranteed issue is the one regulation where you can see the
- 17 distinct impact on the cost and availability of coverage.
- 18 Given that quaranteed issue is nationwide in the
- 19 small group market and limited only to certain states in the
- 20 individual market, quaranteed issue is one of the
- 21 contributing reasons why the small group market is more
- 22 expensive than the individual market.
- 23 Contrary to popular conception, the small group
- 24 market is, on average, much more expensive than the
- 25 individual market. For example, even though coverage is not

1 quite as comprehensive always in the individual market as it

- 2 is in the employer-based market, policies sold through e-
- 3 health insurance are on average 25 percent higher for small
- 4 business members than they are for individual members, and
- 5 this is done in a state-by-state comparison.
- 6 So we get into a tricky situation. Results show
- 7 that if you make insurance available to everyone, it's simply
- 8 not going to be affordable. And if you make it widely
- 9 affordable, it's not going to be available to absolutely
- 10 everyone.
- 11 So if we want affordable and accessible policies,
- instead of regulating 100 percent of the market, regulations
- or programs should be designed to address the 1 to 2 percent
- 14 that cannot obtain coverage. For example, high risk pools
- are such programs that allow the market to work for the 98
- 16 percent of the population who can obtain coverage while
- 17 providing a strong and viable safety net to cover the sick.
- 18 States with the least regulatory burden
- 19 successfully rely on high risk pools to cover their
- 20 uninsurables, and have affordable health insurance for the
- 21 rest of the population.
- 22 Since the effects of guaranteed issue, regulations
- 23 on the cost and availability of coverage can be pronounced
- 24 and identified. These regulations can often be repealed.
- 25 For example, on the state level, Kentucky, Washington, and

1 New Hampshire repealed their guaranteed issue laws recently

- 2 after these laws caused a complete dearth of health insurance
- 3 options in their states.
- With the deteriorating state of the small group
- 5 market, Congressman Mike Pence is planning on introducing
- 6 legislation to repeal guaranteed issue in the small group
- 7 market.
- 8 The clearcut effects of guaranteed issue on
- 9 competition, price, and availability of coverage should be
- 10 helpful to policy-makers as they revise these laws, and I
- 11 hope that this examination is helpful to the participants in
- this room as we look at the effects of regulation and
- 13 competition in our health care marketplace. Thank you.
- DR. HYMAN: Thank you. Well, everybody has done a
- 15 great job of staying on time. You're all very public
- 16 spirited. And so we've got about 20 to 25 minutes left to
- 17 have a panel discussion about these various presentations.
- 18 Let me just start, and people can feel free to ask
- 19 questions themselves of other panelists if they want. But
- 20 I'll exercise the speaker's privilege of filling the
- 21 uncomfortable silence that might otherwise result if I just
- 22 threw it out at the start and just ask the following
- 23 question.
- 24 There's been a lot of discussion today and in past
- 25 hearings about the extraordinary saliency when it's time to

1 actually receive health care of the need for information, of

- 2 picking the right provider, of deciding whether the
- 3 recommendations that you're getting are sensible ones, and
- 4 the difficulties of obtaining information about that.
- 5 But the options that you have and who you get to
- 6 see are tremendously influenced by the nature of your
- 7 coverage. And the saliency of the coverage tradeoffs, it
- 8 seems to me, is a different matter entirely.
- 9 So I guess the question I would ask is how do you
- 10 make the coverage tradeoffs more salient to people? Is
- 11 consumer-directed health care a way of finessing that by
- 12 putting the burden on the patient to make those decisions at
- 13 the time they receive care? And is it really realistic to
- 14 expect people to pay close attention to their health
- insurance when they only get to choose once a year and it's
- 16 aggregated for them, for many people, by employers? So
- that's, I think, a range of questions we can start with.
- 18 Helen?
- 19 MS. DARLING: Well, I'd like to take that one on.
- 20 Actually, I'd like to take on your assumption.
- DR. HYMAN: Go right ahead. Then it's a really
- 22 good question.
- 23 MS. DARLING: Yes. Because actually, most people
- 24 have choice. I mean, if you look at the numbers of -- you
- 25 know, you look at visits by coverage, between the fact that

- 1 decisions actually at the very time. Same thing in the
- 2 pharmaceutical business. I mean, if at the point of
- 3 purchasing something you have coinsurance and you make that
- 4 decision, as opposed to later on getting a bill for whatever
- 5 it is, you're not really going to drive good decision-making.
- A couple thoughts. One, when people are really
- 7 sick, that is the great equalizer of everything. They
- 8 want -- they're not in a position, really, to make major
- 9 decisions. But assuming that you have some kind of a
- 10 consumer-directed plan where you have a high deductible
- 11 policy that's pretty broad and that you can basically go to
- whomever you really want, the decision-making, as you say,
- it's really around -- you're trying to drive the decision-
- 14 making toward that discretionary kind of care, not toward
- those critical kinds of things.
- 16 And the other thing that I find quite interesting
- is that almost by definition, quality is incompatible with

- 1 of care.
- MR. YOUNG: No, I agree. I mean, I think we have
- 3 to be careful, though, and make sure we understand that there
- 4 are kind of exceptions to every situation.
- 5 And just as we have exceptions to the fact that not
- 6 everybody is going to be able to use the same level of health
- 7 care information, the other exception is that under the
- 8 current system, there is a need for, in the employer
- 9 marketplace, a claim intermediary, whether it's a Blue Cross
- or an insurance company, but some sort of claim intermediary,
- 11 whether it's an insured plan or a self-insured plan.
- 12 And most employees -- most employers are relying on
- that claim intermediary to not just process claims, but to
- 14 contract with providers and to provide information to the
- 15 employees and do all those things. And what happens is then
- 16 the employee is kind of held to whatever that claim
- intermediary can provide.
- 18 And we have -- and I know you talked about this in
- 19 prior sessions -- but we have areas of this country, fairly
- 20 large areas of this country, where one claim intermediary has
- 21 a stranglehold on that geographic market because the network
- 22 discounts they have with their providers are so great
- 23 compared to everyone else that it precludes any type of --
- 24 any other claim intermediary or any managed care
- organization, whatever you want to call them, coming into the

- 1 marketplace.
- 2 And if that claim intermediary says, I don't
- 3 believe in consumer-driven plans; I don't believe, you know,
- 4 in providing quality health care information to employees,
- 5 then you're stuck unless the employer circumvents the whole
- 6 system and overlays something on top of it, which large
- 7 employers may be inclined to do but small employers won't.
- 8 So, you know, there are a number of claim
- 9 intermediaries, without taking shots, that really have a lot
- 10 vested in keeping the status quo, you know. And so you can
- 11 talk all -- you know, consumer-driven will work for 60, 70
- 12 percent of the market, but 30 or 40 percent of the market
- will not have access to it for a number of years, not from
- 14 their own choosing.
- DR. HYMAN: Well, you'll be pleased to know that
- the claim intermediaries were in here complaining about the
- 17 providers insisting that the status quo is preferable. So
- there's a high degree of finger-pointing, certainly, in this
- 19 industry.
- 20 MS. DARLING: Everybody is a vested interest,
- 21 almost, I think.
- DR. HYMAN: David?
- 23 DR. LANSKY: Another angle on the same issue. I
- think this transition, the bridge between the coverage and
- 25 the care, that creates this tension.

1 I think an interesting thing is going on where

- 2 those who are -- whether it's the intermediary or the payor
- 3 is creating transparency around the criteria of network
- 4 participation. So Leapfrog, I think, was an example where
- 5 they were trying to say you -- in theory, Leapfrog said, we,
- 6 the purchaser, will continue to do business with you, the
- 7 plan, if you in turn prefer -- do preferential business with
- 8 high safety institutions that adopt certain practices.
- 9 And they supported that, with an employee education
- 10 program to help the employee recognize, here's where care is
- 11 superior. And I'm part of a chain of relationships with my
- 12 employer, with the plan, and in a sense with Leapfrog as a
- policy organization, that is trying to help me seek out and
- 14 get the safer quality care.
- 15 I think there's a series of initiatives in which
- 16 the payor or the intermediary can either give visibility to
- or money to entities which adopt elements of superior care.
- 18 And so whether it's transparency or pay for performance,
- 19 either way it's a way to try to make the system work better
- 20 without directly managing care with a heavy hand.
- DR. COMSTOCK: Actually, that just reminded me of
- 22 something I wanted to say earlier that the Speaker talked
- about, and that is, whose job is it and on whom should we
- 24 rely to make certain that data are standardized and things
- 25 like that?

- 1 And I would be very concerned if that became a
- 2 governmental role, except as a purchaser. And to the extent
- 3 that CMS and other powerful buyers in the system as a
- 4 purchaser, as a condition of participation, insist on
- 5 information being collected and analyzed and everything done
- 6 in a standardized way, that's terrific.
- 7 But the organization or organizations that decide
- 8 what those measures are going to be, I believe, has to be
- 9 outside of government, and for a couple of reasons. First,
- 10 there's no evidence that the government -- the government has
- actually essentially owned the health system about 40 to 50
- 12 percent since 1965. They have enormous power. They have
- 13 never used it for those purposes. So counting on them at
- 14 this point to be our guide in that regard is not a good idea.
- 15 It's certainly not going to get us anything before I'm dead
- in my grave, I'm sure.
- 17 The second thing is that a lot of these things, as
- 18 David knows because his foundation has done a lot of work and
- 19 I've been involved with NCQA's committee on performance
- 20 measurement, that you need a lot of people sitting around a
- 21 table working as fast as possible with a nimble approach to
- 22 it to get these things right and to keep making them better
- 23 and better.
- And when you have new information, you do a pilot.
- 25 You can -- you know, FACCT and other organizations can

decide, okay, it's not going to be this. We just found this

- doesn't work out in Colorado, and so we're not going to do
- 3 it.
- So having the organizations, whatever -- you know,
- 5 the private sector arm and how they're put together is less
- 6 important than there are people who have that as their
- 7 responsibility, organizations. They know what they're doing.
- 8 They're able and willing to test. They're able and willing
- 9 to bring from the best and the brightest whatever the issue
- 10 might be, come up with the best measures, pilot them, test
- 11 them, fine-tune them, and then they can be picked up by the
- larger purchasers, including the government and be driven
- 13 that way. But if we try to put it in the government, it just
- 14 won't happen with the kind of speed. The other thing is that
- once it gets in the government, it is so vulnerable to
- 16 pressures from narrow special interests who have no interest
- in seeing progress in these areas.
- 18 DR. HYMAN: David?
- 19 DR. GREENBERG: All right. Let's take the
- 20 government out of that for a little bit and put it in the
- 21 third party payor. And I remember when we used to have HMOs,
- 22 and I remember when women on normal deliveries used to be in
- 23 the hospital for four and five days, and people having
- 24 surgery used to come one or two nights before, and stayed for
- 25 much longer than they are now.

1 That wasn't my doing as a consumer or patient, or

- the person next door's doing as a consumer or patient. I
- don't really know how long a person has to be in the hospital
- 4 after a normal delivery, after a certain kind of surgery.
- 5 How many days, really, does that person have to be there
- 6 before the actual surgery?
- 7 That was done by a third party payor who has
- 8 thousands and thousands of patients, perhaps experts on the
- 9 team, who could make such decisions, provide information to
- 10 that patient. Gee, a normal delivery, two days may be
- 11 enough.
- Okay. We can always debate that the managed care
- firms overstep their bounds, that they have other incentives
- 14 to contain cost and only those incentives. But I would
- 15 maintain that I just can't do it. I can't do it as a patient
- 16 right there before the surgery in the hospital, even a couple
- 17 days before the surgery.
- 18 And we have these experts as managed care firms. I
- 19 still come back to perhaps my earlier point: Without the
- 20 government interference, Helen, let's have those third
- 21 parties -- when we pick them on a yearly basis, we decide
- 22 ourselves, based on a variety of information, brand name,
- 23 signaling, however you want to deal with it, the same way we
- 24 pick automobiles and other difficult -- we have so many
- 25 difficult products that we buy today, cell phones, whatever.

1 Somehow, the market works, a little bit imperfectly, but the

- 2 market works.
- In the comfort of our living room, picking a health
- 4 care plan based on price, quality, brand name, signaling --
- 5 and I think that's the best we could do. I mean, you could
- find things on the Web that says, this cures cancer, and go
- 7 another website and it says, this does not cure cancer.
- 8 DR. HYMAN: And we do enforcement on some of the
- 9 first category for fraud.
- DR. GREENBERG: But anyway, I go back to the
- 11 comfort of the living room, deciding on the third party plan,
- 12 and creating incentives for those third parties to provide
- 13 health care cost containment as well as quality of care.
- DR. HYMAN: Let me follow up on a point that got
- 15 made earlier and see if we can push this in a slightly
- 16 different direction because we could use all of our time just
- 17 to talk on this one.
- 18 On the issue of quality, David asked the Speaker a
- 19 question that I thought was quite insightful, which was, you
- 20 know, there's -- basically, do you fragment or do you
- 21 aggregate? And there are virtues and costs with both of
- those strategies.
- 23 Aggregation allows you to sort of leverage your
- 24 purchasing power for both price and quality, if you choose.
- 25 And I guess the challenge is how do we think about these new

- 1 arrangements for benefit design in the context of trying to
- deal with the problems of integration and quality? And given
- 3 the information that we have, how confident can we be that
- 4 this is going to head off in the right direction?
- 5 MS. DARLING: I'm not sure I understand the
- 6 question.
- 7 DR. HYMAN: All right. I didn't ask it very well,
- 8 then. Do we -- when we disaggregate purchasing pools by
- 9 essentially open-ended choice and by allowing people to make
- 10 their own decisions as to who they go to and how much to pay,
- it makes it much harder for employers to do things like
- 12 Leapfrog because they can't selectively contract, okay,
- unless you're going to do it with everyone, and to impose
- 14 minimum quality standards.
- 15 So I guess I'm really just trying to put a sharper
- 16 point on David's question.
- MS. DARLING: Well, but they could -- you can do it
- 18 two ways. You can give people lots of choice at the point of
- 19 care but still have a plan who administers.
- 20 The other thing is that you could provide
- 21 information that's especially penetrating and useful about
- 22 the providers. And you are allowing the employee or their
- 23 dependents or their retirees to choose, but with information,
- 24 just as they do now -- again, David's example. They suddenly
- 25 have information about different hospitals.

- 1 Your pressure comes from -- and by the way, I've
- 2 actually seen this happen. The pressure comes from the fact
- 3 that the hospital goes on whatever it is, the website or whatever's pubc, therr3ebsite or

- 1 better providers, which in most cases probably has very
- 2 little to do with quality and has a lot more to do with the
- 3 contracting, you know, possibility of contracting between
- 4 that provider and that claim intermediary.
- 5 So you have to be very careful. I mean, there are
- 6 many times -- and this is where I think we have to have
- 7 pressure on -- and I keep coming back to these claim
- 8 intermediaries -- to if they're going to contract, if we're
- 9 going to have a structure where somebody is buying services
- 10 at a unit price discount, that some of -- that the criteria
- 11 for making the decisions of who those networks are has to
- 12 much more involve quality.
- DR. COMSTOCK: I mean, that's all true. Just a
- 14 couple issues. One is we all know that the vast majority of
- 15 health care has not definitive best practice. I mean, so
- 16 much of what is done in health care does not have an
- absolute, this is the right thing and the wrong thing.
- 18 Yes, if you have colon cancer, you need surgery,
- 19 whether to cure it or to keep you from being obstructed. But
- 20 for many other things, there is no definitive answer. The
- 21 real issue is: is the physician engaging with the patient in
- 22 a shared decision-making process around their values and
- 23 what's important for them?
- 24 But I wanted to make the comment -- you know, you
- 25 said the hospitals will respond to information. I know one

- of our supporting organizations is Jack Wennburg's group up
- 2 at Dartmouth. And they've done some wonderful work that
- 3 showed that, you know, physicians don't like to be measured a
- 4 whole lot. But they have a way of doing it that's
- 5 collaborative and collegial.
- And what they do, for example, in the northern New
- 7 England cardiovascular disease project is physicians looked
- 8 at each others' processes of care and they began talking
- 9 about what did they do and what results did they get. And
- 10 they immediately responded. Nobody had to hit them over the
- 11 head with it.
- So I think that getting back to the importance of
- culture when it comes to any of these things related, you
- 14 know, to delivery changes. You've got to recognize the
- 15 culture. The hammer over the head doesn't work well with
- 16 physicians but other kinds of methodologies do work well with
- 17 physicians. So it's just a little bit of a flip side.
- 18 And then I just think we just have to remember that
- 19 quality metrics are great, but there's only so many things
- that you can measure definitively.
- I thought your question to Newt was different. I
- 22 thought -- was it different? Was your question --
- 23 MR. LANSKY: It was a very subtle question. Go
- 24 ahead. I'd like to her your interpretation.
- 25 DR. COMSTOCK: I thought you were asking a very,

- 1 very different question about is it more appropriate when
- 2 you're looking at quality: to look at quality of the entire

1 talking about today may go in a different direction and also

- 2 create a technical problem that measurement becomes very
- 3 difficult if we fragment. And then access to information
- 4 becomes very difficult if we have a high fragmented system.
- 5 So I was concerned about both impulses.
- I wanted to answer your question as well, David, or
- 7 start a piece of it. I think most of us in this field have
- 8 been fairly naive about thinking about the solutions, and we
- 9 need a new way of thinking that is more subtle.
- We've got a system we're talking about here in a
- 11 room among ourselves that accounts for a sixth of the
- 12 national economy, millions and millions of peoples'
- 13 livelihoods, enormously complex. It's not a -- we use words
- 14 like system and managed care and chronic diseases if we're
- 15 talking about a thing that we can implement to address. And
- 16 we just can't.
- So we have to -- we need some other way of
- 18 recognizing that it's a very layered problem. I think it is
- 19 more achievable for federal agencies, the regulatory process,
- 20 the legislative process, to deal with what we would call
- 21 infrastructure, making sure that the highways are there and
- the railroad tracks are the right gauge and that the
- 23 underlying structure is in place that would permit us to do
- 24 all the things we've talked about today, without yet saying
- 25 what those things are.

1	And we've gotten all of us a little bit ahead of
2	ourselves in some of the work we've done the last ten years,
3	fifteen years, in thinking we knew what some of the solutions
4	were rather than building pipes and paving roads that would
5	let us at least drive around a little bit without saying
6	where we drive or what kind of cars we drive in.
7	So I would encourage you and I think the
8	SEC/FASB model that was talked about a lot ten years ago and
9	underlay the President's advisory commission report but was
10	never implemented remains a very important model to think
11	about carefully.
12	In Helen's point, you know, what does the FASB part
13	of that need to look like, in which you have an open dialogue
14	with private sector interests, very involved? And what does
15	the heavy hand of government need to look like, which asserts
	specific requirements upon the entire regulated industry,

- 1 system.
- FEHB, for example, still has 70 percent of the
- 3 employees in fee-for-service models. Therefore, in a sense,
- 4 those who choose the managed care models or the managed care
- 5 plans are punished for participating in NCQA and in doing the
- 6 right things.
- 7 So I think there has to be some government
- 8 standard-setting to ensure full participation and that the
- 9 public really has meaningful information to make decisions.
- 10 But where to draw that line is just a very difficult problem.
- 11 DR. HYMAN: Let me follow up on that point because
- 12 so far we've talked about information at great length. We've
- 13 talked about government purchasing a little bit. But we
- haven't talked about what David nicely called the heavy hand
- 15 of government, the regulation, direct regulation. And to the
- 16 extent we have, it's been concerns expressed about quaranteed
- issue, concerns expressed about the tax treatment.
- 18 And let me use as a springboard David's slide that
- 19 you showed about the number of institutions in New York state
- 20 that performed more than a minimum number of a particular
- 21 procedure. And it really doesn't matter which procedure; you
- see the same patterns in every state and for every procedure.
- 23 So the question is, is there a role for government
- 24 directly in dealing with that? Is that a health planning
- 25 sort of thing? Is that, you can't do this procedure unless

- 1 you have a minimum amount? Or do we want to instead
- 2 designate centers of excellence? And how do we guard against
- 3 the kinds of risks that Greg has talked about in the context
- 4 of quaranteed issue?
- 5 MS. DARLING: Well, I'll be happy to jump in on
- 6 that. A couple of things. The first study I did at the
- 7 Institute of Medicine was of the health planning certificate
- 8 of need program some years ago, and I can tell you that when
- 9 we were done, that even the most liberal people on the
- 10 committee that love that stuff and believe in it in their
- 11 souls concluded that it will never work in this country for a
- whole bunch of reasons, which I could do a whole session on.
- DR. HYMAN: We'll have you back.
- MS. DARLING: Yes. Okay. But that was actually
- 15 when it was a lot easier. I mean, we were smaller by quite a
- 16 bit. We had a lot fewer hospitals. We had relatively few
- 17 surgery centers. And even at that, it just was -- and
- 18 actually, there was more of a belief in those days that the
- 19 government had a role.
- 20 We had PRSO programs developed. You know, there
- 21 was a lot going on. A lot of people even thought we had
- 22 national health insurance around the corner. So it was a
- 23 very different era. But even then, with everything much more
- 24 compatible with the concept, it was generally an utter
- 25 failure, and actually left a lot of people really turned off

- 1 at the idea for the next 20 years.
- 2 Somehow, the government can play a role that is
- 3 both a combination of a carrot and standard-setting at a
- 4 minimum, but the concern is that it will always be the least
- 5 common denominator. If you look at every other program like
- 6 it and everything that's been done -- and I was a senate
- 7 staffer for a while, and among other things, I dealt with all
- 8 these issues from a senator's office.
- 9 And there's just nothing like getting 500 letters
- from all the old ladies in a small town about a doctor who
- 11 has been demonstrated to have been absolutely fraudulent,
- doing terrible things like, you know, charging Medicare for
- 13 30 colonoscopies a day or something like that -- I mean,
- 14 blatant, blatant, blatant fraud and errors, and yet the town
- 15 loved him.
- 16 So that's when you've got all the evidence.
- 17 Ninety-nine percent of the time, you don't have that much
- evidence, and there are all these grey areas. And the second
- 19 you have grey areas, then as long as the government is doing
- 20 it, there will be somebody who says, you can't have the heavy
- 21 hand of government doing this, so a lot of really bad things
- happen.
- DR. GREENBERG: At the same time, David, I think
- there may be a role, a continued role, for the FTC, is when
- 25 the private sector tries to regulate itself. The AMA in the

1 early '70s and prior to that refused to allow physicians to

- 2 advertise or disseminate information, and in fact the FTC did
- 3 bring a case against the AMA, went to the Supreme Court, and
- 4 the FTC won that case, which submitted that the physicians
- 5 should be able to advertise.
- 6 We have something called the Joint Commission on
- 7 Accreditation of Health care Organizations. I submit this
- 8 would be another avenue for the FTC to go into. This Joint
- 9 Commission has acted like a cartel against hospital
- 10 dissemination of real information on hospitals for as long as
- its existence, and should go after these people.
- There have been other sorts of professional groups
- that perhaps the FTC ought to do something as far as its
- 14 Section 5, Federal Trade Commission Act. So this might be a
- 15 role for government because those -- maybe some of these
- 16 accrediting medical schools or whatever might be examined by
- 17 the FTC.
- DR. HYMAN: Greg, you haven't spoken yet.
- 19 MR. KELLY: Yes. Just that separately on what you
- 20 were mentioning a little bit earlier, as the Speaker brought
- 21 up, regulation sometimes is needed. When he goes into
- 22 McDonald's, he wants to make sure that he is ordering beef.
- 23 And it's up to the private market to decide how best to
- 24 deliver that. So some regulation is, of course, needed.
- 25 And going back to guaranteed issue, if you actually

- 1 standards, they are far too low, and frequently the voluntary
- 2 are higher -- you need both. I'm not saying you shouldn't have government doing a certain thing. You need the

1	taken us past our authorized time.
2	We're going to reconvene at 2:00, when we'll be
3	discussing information and advertising.
4	(Whereupon, at 12:30 p.m., the hearing was
5	concluded.)
6	* * * *
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

1 consumers. And we'd like to see how that information is used

- 2 by consumers and how it's interpreted.
- We've already had some hearings on how consumers
- 4 receive and evaluate the information, and I would commend
- 5 that testimony to you. It's available on the FTC's website,
- 6 which is www.ftc.gov.
- 7 So after that incredibly long setup, I'd like to
- 8 introduce the panel very briefly and encourage you to pick up
- 9 the more complete booklet that has the bios of all of the
- 10 panelists. I'm going to keep this very, very short in the
- interest of moving things along so that we'll have sufficient
- 12 time to have a really ample discussion of these issues.
- 13 I'd like to also ask you all if you would please
- turn off your cell phones because I'm sure someone is going
- to be saying something incredibly brilliant and I don't want
- them to be distracted by anybody's cell phone ringing.
- 17 I'll introduce the speakers in the order of their
- 18 presentations. After the presentations go on, we'll take a
- 19 short break and then at the conclusion of the testimony will
- 20 have a panel discussion. Everyone will come to the front and
- 21 we'll be able to have a little bit of a dialogue.
- First of all, we're going to have Bernie Dana, who
- 23 has come all the way in from Ohio. I think he's one of the
- 24 farthest fliers in today. He's an assistant professor of
- 25 business at Evangel University in Springfield -- I'm sorry,

- 1 Springfield, Missouri. Sorry about that.
- 2 Second of all, we'll have Laura Carabello, who is
- 3 with CPRi Communications.
- 4 Following that will be Dr. Thomas Henry Lee of
- 5 Partners Health care.
- 6 Following that will be Dr. Douglas Koch, who's come
- 7 up from Baylor College of Medicine.
- 8 After that, the shortest trip was made by Richard

1 MR. DANA: Well, as was mentioned, my name is

- 2 Bernie Dana. I chair the American Health Care Association's
- 3 quality improvement subcommittee. And I'm representing AHCA
- 4 today.
- 5 I'm also, as was stated, an assistant professor of
- 6 business at Evangel University in Springfield, Missouri. And
- 7 prior to joining the faculty there two years ago, I spent 28
- 8 years as a corporate leader and consultant in all segments of
- 9 the long-term care industry, both nonprofit and for-profit
- 10 organizations.
- 11 Equally important to me, and I hope to others, is
- 12 the fact that I am also a consumer of long-term care
- 13 services. And I'll be explaining that a little bit later.
- 14 When we talk about long-term care, we're talking
- about a dynamic, diverse, and evolving sector of our nation's
- 16 health care system that refers to many settings, not just
- institutional settings like nursing homes and assisted living
- 18 facilities. Yesterday you heard from our sister
- 19 organization, the National Center for Assisted Living. Today
- 20 I will focus our nation's system on skilled nursing services.
- 21 The American Health Care Association represents
- 22 approximately 11,000 long-term care facilities of both
- 23 nonprofit and for-profit ownership. Many of these facilities
- 24 are providing multiple types of services, from post-acute
- 25 services to special care units for those suffering from

- 1 Alzheimer's disease and related dementia.
- 2 Also, our membership includes a very specialized
- 3 area of long-term care that provides services to persons with
- 4 mental retardation and developmental disabilities, called
- 5 immediate care facilities and group residences.
- 6 Let's talk a little bit about our customers.
- 7 Nursing home care is something that most of us are likely to
- 8 deal with at some point in our lives, but is not a service
- 9 that very many of us are actively seeking either for
- 10 ourselves or for any of our loved ones. As a result, many
- 11 consumers end up not being very educated about the complex
- issues of long-term care until they actually or suddenly need
- 13 that service.
- Now, this was the case for my siblings and me when
- 15 we were advised that our mother, at age 89, was going to be
- 16 needing to transfer to a nursing home after a short stay in
- 17 the hospital. I was miles away in Nebraska at that time, and
- 18 my sister and my father in Ohio went through two days of
- 19 unbelievable pressure trying to navigate all of the admission
- 20 process and choose an appropriate nursing facility.
- Our consumers do expect long-term care services to
- 22 continue to evolve and diversify. And we can look forward to
- 23 even more segmentation of the long-term care marketplace than
- 24 has already happened simply because our primary customers,
- 25 the residents and their families, want and demand more

- 1 spectrum.
- 2 Even though many states have continued policies
- 3 that limit the growth of nursing home services, the growth in
- 4 alternatives over the past ten years has reduced the demand
- 5 for nursing home services. And that lower demand for nursing
- 6 home services has reduced occupancy rates, and in many cases,
- 7 prompting nursing home providers to actively compete for
- 8 residents.
- 9 Even within the prevailing paradigm of regulatory
- 10 compliance, the increased competition has brought a renewed
- interest in the expectations of the customers and in
- 12 providing value-added services to them. The lower occupancy
- 13 rates are once again giving consumers a choice in selecting
- where they will receive nursing home services when they need
- 15 it.
- 16 Another important factor in consumer choice for
- 17 nursing homes relates to their ability to pay. Medicare and
- 18 Medicaid programs have become important resources to assist
- 19 nursing home residents with payment for their care. Medicaid
- 20 is a state-administered and federally-supplemented program
- 21 for the poor who can't pay for their own care and have very
- 22 limited resources. Medicare is a federal health insurance
- 23 program for people age 65 and over.
- 24 It's important to note that in both of these
- 25 programs, they determine the rate that they will pay the

1 nursing home for the services being provided. The Medicaid

- 2 rate is usually significantly less than the rates charged to
- 3 people who pay from their own resources, and in some cases
- 4 even less than the cost of providing the care.
- 5 At any one time, approximately 65 percent of the
- 6 nursing home residents in the United States qualify for
- 7 Medicaid assistance, and approximately 10 percent of nursing
- 8 home residents are receiving Medicare assistance. The
- 9 remaining residents pay from their own financial resources,
- 10 and a small percentage of residents -- and it's growing --
- 11 are covered by long-term care insurance.
- Now, even though the Medicaid and Medicare programs
- 13 provide payment assistance to many residents, and they also
- 14 set extensive standards for providers' participation, it is
- 15 the customers -- again, the families and the resident, both
- 16 prospective and current, who choose where to receive those
- 17 services.
- 18 How are consumers informed about these services?
- 19 In addition to having a choice of where to go, consumers need
- 20 appropriate information to make the best choice related to
- 21 their wants and needs. Nursing home consumers rely on a
- 22 variety of sources of information.
- 23 Most nursing facilities do not spend large amounts
- of resources to mass promote their services. Many rely on a
- 25 simple brochure, a Yellow Page advertisement, limited media

1 advertising, a website, and a direct mail newsletter to

- 2 supplement their efforts to reach potential customers through
- 3 staff visits with referral agents such as physicians,
- 4 hospital discharge planners, and social workers for
- 5 congregate living facilities. They also rely on positive
- 6 interaction with staff, residents, and families to promote
- 7 word-of-mouth advertising.
- 8 Most potential customers will visit a facility or
- 9 personally observe and learn about the environment of
- 10 services from a facility staff. Many states severely limit
- 11 the amount of advertising costs that can be included in a
- 12 Medicaid cost report from which Medicaid rates are
- 13 determined. Because of that, many will only allow
- 14 informational advertisements.
- 15 Print or media ads usually include the facility's
- 16 licensure level and may list some of the services or special
- 17 features of the facility. Few if any facilities make quality
- 18 claims other than to announce the winning of a quality award
- 19 or perhaps provide a testimonial from a resident or family
- 20 member.
- 21 The American Health Care Association provides free
- 22 pamphlets for consumers through a toll-free call-in line and
- 23 the web. And many nursing facilities provide these or
- 24 similar tools to help educate and clear up common
- 25 misconceptions.

decision-making. As a component of the Nursing Home Quality

- 2 initiative, which was launched this last year, the site now
- 3 includes the quarterly reporting of eight standardized
- 4 quality measures that are intended to provide meaningful
- 5 insight into nursing care outcomes.
- 6 Unfortunately, many of the quality measures are
- 7 flawed in their construction or they simply report
- 8 demographic characteristics of a nursing home's residents.
- 9 The measures do little to reflect the respect,
- 10 responsiveness, living environment, and quality of life that
- 11 really make a difference in the satisfaction level of nursing
- 12 home residents and their families. As a result, the
- information has dubious value in enabling consumers to
- 14 actually compare and choose a nursing home.
- I know this to be true from personal experience.
- 16 There are three nursing homes in the community where my
- 17 mother needed care six years ago before she passed away. We
- 18 picked the nursing home that had the fewest deficiencies at
- 19 their last inspection. In fact, they had zero deficiencies.
- 20 After Mom was in the nursing home for a week, my
- 21 sister called me in Nebraska and asked me to come to Ohio
- 22 because she was upset with the way Mom was being treated. I
- 23 flew to Ohio immediately, and after all, I, being the
- 24 executive vice president of a company that owned and operated
- 25 32 nursing homes in a five-state region, was the expert in

- 1 nursing home care for our family.
- I was appalled and frustrated at the lack of
- 3 consideration of my mother's needs and preferences simply
- 4 because of the operating policies. This facility was
- 5 compliant with the regulations but they didn't listen to the
- 6 customer very well.
- 7 What are the solutions? Most consumers don't want
- 8 confusing clinical statistics or deficiency information.
- 9 They simply want to know which facilities have the most
- 10 satisfied residents and families. Until recently, this kind
- of information has only been available anecdotally.
- In the last six years, several long-term care
- 13 provider associations have taken the initiative to
- 14 quantitatively measure, compile, and publish satisfaction-
- 15 based information. For example, the three trade associations
- 16 that represent nursing homes in Michigan have collaborated to
- both publish and present on the internet a consumer guide to
- 18 nursing homes.
- 19 This consumer guide is published every two years
- 20 and reports the number of inspection citations for each
- 21 facility, but most importantly, it presents the percentage of
- 22 families that are satisfied with the facility's services and
- the percentage that are willing to recommend the facility to
- 24 others.
- 25 The American Health Care Association affiliate in

- 1 West Virginia publishes a similar consumer guide annually,
- with the same kind of issues addressed. But they have also
- added to the report, to the consumer guide, the percentage of
- 4 staff members who are satisfied with the facility as a good
- 5 place to work.
- 6 The various trade associations in Ohio have
- 7 collaborated with the state health department there to
- 8 require nursing homes to participate in collecting and
- 9 reporting on a state-funded website the results of family and
- 10 resident satisfaction surveys that measure all aspects of the
- 11 services in addition to overall satisfaction.
- 12 My dad's nursing home is in Ohio. Of the three
- facilities in his community, his nursing home has the worst
- 14 record on the Nursing Home Compare website, but by far the
- 15 highest family satisfaction rating in Ohio's new consumer
- 16 guide web report. Interestingly, the nursing home that my
- mom was in had the lowest family satisfaction rating, despite
- 18 having the fewest inspection issues.
- When given a choice, consumers clearly prefer the
- 20 satisfaction results because they understand them. Nursing
- 21 home residents are not merely users of services. The nursing

only be on the nursing care outcomes, it must also include

- 2 quality of life issues such as respect, dignity, and resident
- 3 choice.
- 4 Research conducted by Dr. Vivian Tellis-Nayak in
- 5 1999 analyzed satisfaction survey results of 11,715 families
- of residents in 504 nursing homes across 26 states. The
- 7 research shows that family and staff satisfaction are
- 8 compelling measures of a nursing home's overall quality and
- 9 performance.
- 10 Family satisfaction is a window to that quality of
- 11 care that residents receive, to the stability and devotion of
- 12 the staff, to the way state surveys turn out, and to the
- 13 nursing home's overall operation.
- 14 For this reason, AHCA has developed a model to
- 15 encourage its state affiliates to begin developing a
- 16 satisfaction-based consumer guide. The model focuses on
- 17 reporting a nursing home's three-year trend of family
- 18 satisfaction, family willingness to recommend, and staff
- 19 willingness to recommend, as well as the inspection data, but
- 20 presented as a percentage of the 495 standards that each
- 21 nursing home must meet.
- 22 Our profession is committed to quality and is
- 23 further -- our commitment to quality is further demonstrated
- 24 by the launching of the Quality First initiative in July
- 25 2002. This is a proactive, profession-wide partnership of

1 AHCA, the American Association of Homes and Services for the

- 2 Aging, and the Alliance for Quality Nursing Home Care.
- 3 The Quality First initiative declares that we are
- 4 collectively and individually committed to healthy,
- 5 affordable and ethical long-term care services that are
- 6 rooted in continuous quality improvement, openness and
- 7 leadership. An independent national commission is being
- 8 formed to assess the report to the public -- and report to
- 9 the public our collective improvement on six important
- 10 outcomes.
- 11 So where does all of this take us? Nursing homes
- 12 are facing tremendous challenges. We have 52,000 vacancies
- 13 for certified nursing assistants, the true backbone of the
- 14 long-term care system and the key to customer satisfaction.
- 15 The GAO predicts that the overall demand for nurse aide
- 16 positions in all areas of health care will grow by 38 percent
- 17 between 1998 and 2008.
- 18 Current challenges are compounded by knowing that
- 19 the number of individuals 85 and older are double from the
- 20 current -- will double from 3.5 million to 7 million in 2020,
- 21 and the number will again double to 14 million by 2040.
- 22 We are also facing a crisis in funding for Medicare
- 23 and Medicaid assistance. An analysis by the national
- 24 accounting firm of BDO Seidman found that Medicaid has
- 25 underfunded nursing care nationally by nearly \$3.5 billion

- 1 annually. Many nursing homes are experiencing extensive and
- 2 significant financial strength.
- 3 Long-term care providers are proactively working
- 4 with the federal and state governments to find solutions to
- 5 these critical problems. At the same time, we are also
- 6 actively pursuing ways to provide consumers with the
- 7 reliable, valid and timely information they need to make
- 8 informed choices about the type and quality of care of
- 9 services they need when they need it.
- We are intent on hearing the voice of our customers
- 11 as we continuously improve and design long-term care services
- 12 for the future. Thank you.
- MS. KOHRS: Thank you, Mr. Dana.
- 14 Next will be Laura Carabello.
- 15 MS. CARABELLO: Good afternoon. I am Laura
- 16 Carabello, founder and principal owner of CPRi
- 17 Communications. And I'm located in New Jersey. And when I
- 18 gave this presentation about a year ago in Texas, the doctors
- 19 in the audience wanted to know if I was related to the
- 20 Sopranos. And I am not.

20r thewholearest

20r theWr cufprin. aur Ang

- online marketing, interactive communications including web
- 2 and multimedia development, direct mail programs and market
- 3 research.
- We are headquartered in Teterborough, New Jersey.
- 5 We have a large airport there that serves the DEA
- 6 extensively. And we have an office in Scottsdale, Arizona.
- 7 We have clients in 35 states and strategic partners located
- 8 in London, and we have a global presence and a continuous
- 9 focus on generating results for our customer base.
- 10 I want to commend the Federal Trade Commission on

- 1 advertise their services.
- 2 And several key factors have influenced these
- 3 changes: obviously, regulatory oversight; guidance and
- 4 censure from professional trade associations and
- 5 organizations; increased competition, which is now fierce,
- 6 particularly for non-covered services classified as out-of-
- 7 pocket expenditures; the advent of the internet and website
- 8 communications; the commercialization of medicine; and
- 9 consumer empowerment.
- 10 And I think that all of these areas have had an
- impact on the way physicians approach the marketplace and the
- way that their advisors help them to structure their
- 13 advertising and marketing campaigns.
- 14 If you take a look at Yellow Page advertising, for
- 15 example, and you look back, how many of you in the audience
- 16 can look back to prior to the 1980s when Yellow Pages, for
- 17 example, in the Manhattan Yellow Page book revealed doctor
- 18 listings, including addresses and telephone numbers.
- 19 And if you jump ahead from 1980 to 1990, that same
- 20 section provides small space advertising and full-page
- 21 promotions in black and white promoting specific services.
- 22 And by the way, Yellow Page advertising is not inexpensive.
- 23 The listings became aggrandized with boxed
- 24 information as an upcharge, as well as detailed information
- on practice offerings. And I can tell you that Yellow Page

- 1 advertising gets more expensive because the Yellow Pages
- 2 tells you that you have to be in every single Yellow Page for
- 3 a particular community, and then they narrow those areas down
- 4 so that they have to spend more money.
- 5 And if you fast forward to the present, not only
- 6 did the Yellow Pages triple in size with the sheer number of
- 7 doctors listed, but also the number of color display ads has
- 8 grown exponentially. And if you look in any Yellow Pages in
- 9 any city or states, you will see that doctors advertise
- 10 extensively. And, by the way, the return on investment for
- 11 Yellow Page advertising is high.
- I guesstimate, and I say guesstimate because
- there's nobody really tracking the number of physicians, but
- 14 I would say that 95 percent of all physicians engage in some
- 15 form of paid advertising or marketing. And I will go into
- 16 that in a few moments because I think that the scope of the
- opportunity is far greater than we realize.
- 18 And about 25 percent -- actually, that's an
- 19 approximation; it might even be less -- of all physicians opt
- 20 for public relations activities. When you look at public
- 21 relations versus advertising, public relations is considered
- 22 earned media. Advertising is paid media.
- 23 And consultants are usually offering a range of
- 24 both. They're paying for it. They are consulting with them.
- 25 They are helping them to work with their practices to

1 generate coverage in local, regional, national print and

- 2 electronic media, whether it's press releases complimented by
- 3 outreach to editors, reporters, and producers.
- 4 And the results are mentioned in newspaper and
- 5 magazine articles, appearances on TV and radio, speaking
- 6 engagements and other venues where the physician is
- 7 positioned as an authority or thought leader in his or her
- 8 given field. Many physicians opt for this coverage since it
- 9 offers an opportunity to share quality information and may be
- 10 perceived as a third party endorsement. The credibility of
- 11 public relations versus paid advertising cannot be disputed.
- 12 Many physicians seek both.
- The advent and growth of web-based communications
- 14 has clearly changed the marketplace. And this is taken from
- 15 the AMA. Approximately three out of ten, or 29 percent of
- 16 physicians using the web, currently have a website. And this
- 17 has been increasing every year and has remained constant over
- 18 the past few years.
- 19 Websites are greatest among physicians in solo or
- 20 two-physician practices, and lowest among physicians in a
- 21 hospital-based practice, as you would imagine. And the
- 22 primary reasons that physicians offer why they have a site on
- 23 the web is: 43 percent to promote and advertise their
- 24 practice; 35 percent to provide patient education and
- 25 information; and 11 percent increase in physicians using the

- of fact that is likely to mislead consumers acting reasonably
- 2 under the circumstances.
- I put this ad up because -- and this is not a real
- 4 ad; obviously, the numbers are made up -- but I happened to
- 5 see this in the paper a couple of days before I came to this
- 6 hearing. And is it good taste? Does it give you good
- 7 information? One of the things that sort of turned me off
- 8 was the \$499 for the first 1,000 eyes. You know, how do you
- 9 ascertain that you're one of the first 1,000 eyes? That sort
- of set up a red flag. But the question comes to mind: Is it
- 11 bad taste? A lot of ophthalmologists I know would say yes,
- it is in very bad taste and we wouldn't have any part of it.
- Obviously, there were people that liked it and wanted to use
- 14 it as their ad.
- 15 The AMA also offers policies governing advertising
- 16 and publicity, offering no restrictions on advertising by
- 17 physicians except those that can be specifically justified to
- 18 protect the public from deceptive practices. And it goes on
- 19 to say a physician may publicize him- or herself as a
- 20 physician through any commercial publicity or other form of
- 21 public communication -- newspapers, magazines, telephone
- 22 directories, radio, television, direct mail. I could go on
- and on how physicians market their practices.
- 24 They do direct mail. They announce when their
- office is changing. They announce when somebody is joining

1 the practice. There are lots of ways that they go about it,

- 2 lots of opportunities to advertise.
- When I called the AMA to see how they were tracking
- 4 physician advertising, the quote from their spokesperson
- 5 said, "The AMA is a membership organization, not a regulatory
- 6 body. The FTC put us out of that business in 1980," and had
- 7 very, very little information to offer, in fact, cut me
- 8 short.
- 9 It is evident, however, from their policies that
- 10 the organization is concerned about the quality of physician
- advertising, and throughout the profession, most responsible
- 12 physicians endeavor to adhere to the guidelines cited.
- 13 If you go on the web and you look at all the
- 14 different states, every state has their own little quirks and
- 15 their own little tweaks on what is allowed and what is not
- 16 allowed. So I'll just give you an example here.
- 17 North Carolina, Maryland, Virginia, District of
- 18 Columbia, Illinois. Illinois doesn't allow testimonials or
- 19 claims of superior quality. A lot of states do not allow
- 20 testimonials. New York and Texas also preclude the use of
- 21 testimonials by physicians, but you can see that the trend is
- 22 that they all agree that you cannot use deceptive practices.
- 23 However, advertising is advertising, and they're
- 24 allowed to do so. And what is the purpose of advertising?
- 25 It's designed to spark the interest of the health care

- 1 consumer and prompt the buyer, the patient, to access or
- 2 purchase services. In some instances, consumer expectations
- 3 are elevated, leading to liability for physicians who cannot
- 4 deliver what they promise.
- 5 How do consumers get this access to this
- 6 information? For those consumers who are employed,
- 7 information regarding health care financing and doctors is
- 8 usually provided by their employers. This is a hit-or-miss
- 9 opportunity at best, depending on the individual employer and
- 10 its concern to deliver good information.
- 11 For employers that are bearing the majority
- of costs, particularly in the current economic environment,
- 13 plan selection may largely be a function of price. Large
- 14 employers usually distribute brochures, which are provided by
- the plans, and often sponsor health fairs, offering plans the
- 16 opportunity to provide more information not only about the
- 17 plan but about the doctors.
- 18 Employees have come to count on the fact that their
- 19 employers have reviewed quality aspects of the plan. I'm an
- 20 employer, and employees just guess or have enough faith in
- our power to review these plans, especially since we're in
- the health care business.
- In fact, it's interesting: Because we're in the
- 24 health care business, I think all of our employers think that
- 25 we know everything about health care. I can tell you that

- 1 people call us all the time for doctor referrals, and I keep
- 2 saying, we are not a doctor referral agency. We can't give
- 3 you information. But we must get probably, I would think, 20
- 4 to 25 calls a week from consumers.
- 5 For small employers, which we are a small employer,
- 6 this information can be scant, leaving the consumer more

- 1 friends or colleagues.
- When they select a health plan, when the price is
- 3 the determining factor, the provision of quality information
- 4 means little to the consumer. And consumers often select
- 5 plans based upon the participation of doctors that they know,
- 6 that their friends know, and not necessarily quality
- 7 benchmarks.
- 8 For those who are unemployed and do not have
- 9 coverage, the options to access information are even
- 10 narrower. These consumers must turn to advertising or web
- 11 messaging, and their reliance on personal recommendations is
- 12 heightened.
- We can also look at web messaging, though. If you
- 14 think about the number of doctors that have websites now and
- the number of people that are actually web connected,
- 16 internet connected, there is a disparity. Not everybody has
- 17 access to the web, although we all are electronically
- 18 connected today, here.
- 19 The growth of consumerism, including consumer-
- 20 driven health care plans, medical savings accounts, flex
- 21 spending accounts and other offerings may drive the need for
- 22 more quality information.
- 23 As consumers spend their own money -- and as my
- 24 kids always said to me, "This is my money I'm spending" -- to
- 25 pay for their own health care services, they may be seeking

1 better information regarding quality. This will put more

- 2 emphasis on the advertising and marketing and further burden
- 3 on the providers themselves to establish credibility and
- 4 substitute claims.
- 5 Consumers can access select information regarding
- 6 provider quality. As noted earlier -- and that should be
- 7 NCOA; I'm going to have to smack somebody -- URAC, JCAHO
- 8 accreditations for plans and networks offer benchmarks.
- 9 Many, not all, employers utilize accreditation as
- 10 criteria for offering the plans to their workforce and tout
- 11 these achievements in a variety of advertising venues.
- 12 However, employees and consumers do not really have a clue.
- 13 They really don't understand accreditation, and may not
- 14 regard this as important to the selection process.
- I always am tickled when I ride along the highway
- 16 and see those kinds of JCAHO accreditations and say, do
- 17 people really understand what they're talking about?
- 18 Furthermore, the economics of achieving accreditation or
- 19 issuing report cards often forces plans to forego the
- 20 process.
- 21 Condition-specific advertising dominates physician
- 22 advertising and often includes information about the nature
- of the underlying condition, whether it's chronic or acute.
- 24 Many advertisers play upon the emotional aspects of the
- 25 condition, particularly those that represent life-threatening

- 1 conditions such as cancer or heart disease.
- 2 There is usually a strong call to action with a
- 3 toll-free number or opportunity to respond. Many physicians
- 4 who advertise track the overall response and attempt to gauge
- 5 the return on investment of a particular venue.
- Ads may target the impact on a spouse or loved one,
- 7 or the impact on patient quality of life or appearance. The
- 8 more responsible physicians do not claim to offer a cure, but
- 9 may offer diagnostic, treatment, or management options which
- 10 may be surgical or medical.
- 11 How do you communicate quality? The quality and
- 12 quantity may depend upon the advertising venue. For example,
- 13 billboards offer up to a two-second opportunity to deliver
- 14 the message, two to three seconds at the most, leaving little
- 15 room for information or quality communication. Radio spots
- 16 usually run 30 to 60 seconds, hardly enough time to cover
- details. Here we go. That's the end of the billboard.
- 18 That's as much time as you probably had to get that message.
- 19 And what are the effects on the behavior of health
- 20 care providers? Physicians who advertise often adopt their
- 21 own marketing persona. For every patient generated -- this
- is a rule of thumb -- through advertising, four additional
- 23 patients will be referred by that patient. So they look at
 - it as an opportunity to really drive their practices.

- 1 must also follow through during the patient encounter to
- 2 ensure a pleasant experience regardless of the diagnosis.
- 3 And marketing-oriented physicians often undergo training, not
- 4 only to prepare them for media interviews but also to deal
- 5 with patients.
- 6 Practice management and public relations counselors
- 7 advise on a variety of issues impacting multiple aspects of
- 8 interpersonal relations, from developing appropriate body
- 9 language to eliminating bad breath.
- 10 Physician marketers may encounter some push-back
- from their colleagues or a drop off in referrals. There's
- 12 professional jealousy. Their colleagues who do not engage in
- 13 advertising express disdain by minimizing referrals. For
- 14 successful marketers, however, these issues are no loner of
- 15 grave concern.
- 16 Physicians who run advertising for elective, out-
- of-pocket procedures not covered by insurance usually tout
- 18 benefits, substantiated or otherwise, along with cost-
- 19 competitive positioning and opportunities to charge your
- 20 services to a credit card. Plastic surgery, corrective
- vision procedures, laser hair removal, fertility, and diet
- 22 plans are among those conditions which fall into this
- 23 category.
- 24 The quality or credentials of the physicians are
- 25 not a key selling feature. In some of these instances, the

1 volume of procedures performed or the number of pounds lost

- 2 are cited. Before and after photos are often featured as the
- 3 incentive. This hard-sell approach extolls the volume of
- 4 procedures, not the quality of the outcomes.
- Is advertising driving up the cost of care or
- 6 simply fueling the competitive spirit? Physician
- 7 reimbursement is established by the government, Medicare and
- 8 Medicaid, or set by individual health plans. The fees do not
- 9 change for physicians who advertise. In the area of non-
- 10 covered benefits, however, physicians can use pricing as a
- 11 sales tool.
- 12 The competition for patients remain fierce and
- 13 competitive market forces come into play. What forms of
- 14 advertising are good? Quality pays off in the long term.
- 15 As the competitive climate escalates, there is
- 16 likely to be surge in comparative advertising. And one of
- 17 the things I want to point out is that a lot of physicians
- 18 are dying to be featured as the leading doctor, the best
- 19 doctor, New Jersey Monthly or New York Magazine, U.S. News.
- 20 But they realize this is a popularity contest unrelated to
- 21 performance, not a real litmus of quality. Hospitals and
- 22 health plans also use these ratings.
- 23 Marketing quality services and actually delivering
- 24 quality services are two distinct issues. There are no
- 25 restrictions, which limit the quality of -- limit the

- 1 advertising of health care goods and services based on
- 2 quality, but there are regulations articulating standards for
- 3 avoiding advertising claims that are misleading. These
- 4 standards are widely respected and adhered to by most
- 5 physician marketers, and coupled with guidelines, they know
- 6 what to say.
- 7 The ability to advertise and market health care
- 8 services supports a competitive climate and should ultimately
- 9 drive improved quality. Competition is healthy, even in this
- 10 delicate market niche. And for those that stray from
- 11 restrictions and guidelines, however, there should be
- 12 enforcement that protects consumers. And obviously, selling
- 13 health care services is different than selling vacuum
- 14 cleaners.
- 15 My final thoughts: When developing and
- 16 implementing a marketing campaign, it is incumbent upon
- 17 physicians and their advisors to know and play by the rules?
- 18 Advertising that is in bad taste is simply distasteful.
- 19 Advertising that is false or misleading is illegal.
- 20 Guarantees are simply not allowed. The objective
- 21 is to elevate quality of care goals to the same level as
- 22 financial goals. And advertising that adheres to standards
- 23 set forth by government and others is mandatory. Advertising
- 24 that communicates quality and provides information should be
- 25 the end result. Thank you.

- 1 MS. KOHRS: Thanks very much. We'll have Dr. Lee
- 2 speak.
- 3 DR. LEE: I'm Tom Lee. I'm an internist and a
- 4 cardiologist and the chief medical officer for the network of
- 5 Partners Health care System in Boston. And I'm speaking
- 6 today about direct-to-consumer marketing of high-cost
- 7 radiology tests, at least I will if we can get in slide show
- 8 mode.
- 9 The issue that I'm speaking about are high-cost
- 10 radiology tests that are being directly marketing to
- 11 consumers. And I'm really going to focus on two of them, the
- 12 two most common ones, which are general screening for
- malignancies, the most common being lung cancer screening
- 14 with chest CT versus whole body CT, and then a coronary
- artery disease screening with electron beam CT, EBCT, as it's
- 16 called. It's technology that I'll talk a little about more
- 17 on the next slide.
- To summarize, you know, these technologies are
- 19 marvelous. Technologically, they are really incredible if
- 20 you understand what they're doing, particularly with the
- 21 EBCT. But just because they're marvelous doesn't mean they
- 22 actually help anyone, or at least given our current state of
- 23 medicine. So their value is unproven. They have not been
- shown to make people live longer or live healthier lives.
- In fact, there's concern. There's concern about

1 the impact of false positive rates, the economic consequences

- of false positive rates as well as the anxiety, and even the
- 3 medical consequences of false positive rates.
- 4 And there's also concern about whether the
- 5 advertising is misleading regarding the false negative rates.
- 6 That is to say, if you have a negative CT of your body
- 7 looking for cancer, do you really have -- should you really
- 8 have peace of mind? And as you can probably guess, my answer
- 9 is no. And as I said, there's no evidence that they improve
- 10 patient outcome.
- 11 The insurance companies are completely correct in
- 12 not paying for these tests. The evidence doesn't support it,
- and where there are many things that are supported by
- evidence that need to be paid for.
- 15 As a result, consumers are being asked to pay for
- these tests out of their pocket. A lot of people would say,
- well, if they want to pay for it out of their pocket, that's
- 18 fine. One of my arguments is that we are all paying,
- 19 however, for the sequelae of these tests being performed.
- The sequelae are real, and as evidence I would cite
- 21 the fact that the tests are sometimes offered at very lost
- 22 cost or even free by health care organizations, physician
- 23 groups and other kinds of organizations, with the
- 24 expectations that the follow-up tests are going to be covered
- 25 by insurance, and that is where the health care providers

- 1 will make their money.
- I want to talk first about electron beam CT. I'm
- 3 not going to give you a lecture. I'm just going to try to
- 4 give you the bare minimum. It is an incredible technology
- 5 that was very promising when it was first developed. It can
- 6 detect calcium deposits in coronary arteries.
- 7 And what's remarkable about it is that it takes
- 8 such a quick image that the heart is essentially holding
- 9 still. And the heart is always moving, of course, but the
- 10 image is done so quickly that you can get a picture that
- 11 allows you to figure out whether or not there are calcium
- deposits in the walls of the coronary artery.
- 13 It's not so sophisticated they can look inside the
- 14 coronary arteries and tell you whether the artery is
- 15 narrowed. But it can tell you whether there's calcification.
- 16 And such calcifications are present in virtually all patients
- 17 with coronary disease. And there are very good studies
- 18 showing that the higher your calcium score, the higher your
 - 16 fnd td uauoaemcour5Taf coursugo muheugo muheugs5 0 vingain virtsw

1 the next year is very, very low, like in the 1, 2, 3 percent,

- 2 even if they have coronary artery disease.
- And no study has shown that the treatment of high
- 4 calcium scores improves outcome. There have been studies
- 5 where they take people who feel fine but have high calcium
- 6 scores and randomize them to statin therapy versus placebo,
- 7 and there is no difference in outcome because all of them
- 8 tend to do very, very well.
- 9 There is, however, a very high false alarm rate.
- 10 Let me give you -- this is what the scans look like. This
- is, you know, cut through horizontally the top of your heart,
- 12 and that is like the main artery going down the front of the
- heart, a little segment of it, the left anterior descending
- 14 artery. And you see those bright white shadows are
- 15 calcifications in the wall of the left anterior descending
- 16 artery. And you would rather not have calcification than
- 17 have calcification.
- 18 This is the kind of image that gets people -- there
- 19 are some very good people who are very interested in the
- 20 technology, and this is why they're so interested. You can
- 21 get an image like that, and you would like to think that
- 22 would help you take better care of those patients.
- 23 However, it hasn't worked out that way, but
- 24 nevertheless, these are being advertised. You know, Father's
- 25 Day is Sunday, and you can get both the heart and lung scan

- 1 rolled together for early disease detection. And this is a
- New York Times ad, so it didn't reproduce too well on my
- 3 slide. And there are ads like this all over the country, for
- 4 \$499. My children haven't gotten me one. I don't know what
- 5 that means.
- 6 So what do these results mean? Well, first, if you
- 7 have a low score, there's a 99 percent chance of no cardiac
- 8 events over the next year. If you have a high score, there's
- 9 a 1 to 5 percent risk over the next year. As I said, the
- 10 problem is that no one has shown that you can change that
- 11 risk, because it really is pretty low to begin with, by
- 12 giving people medications.
- But here's what really bothers me most about these
- 14 tests. If you don't have obstruction in your coronary
- arteries and you're over the age of 65 and you're an American
- 16 who's been eating an American diet, what are the chances that
- 17 you have a worrisome calcium score? It's 50 to 70 percent.
- 18 There's a very, very high false positive rate. It really is
- 19 calcium in the walls, but it isn't atherosclerosis that's
- 20 going to cause a heart attack.

1 they're hoping for.

- 1 science. There is no evidence indicating that it is helpful.
- 2 That doesn't stop other websites from telling you a different
- 3 story. And, you know, you don't need to read all this, but
- 4 this is from an organization that's trying to hook people up

1 millimeters in diameter. That's the tip of a pencil point.

- 2 The tip of a pencil point is millions of lung cancer cells.
- 3 And there's plenty of good research -- not some,
- 4 plenty of research -- that indicates that genetic factors
- 5 have programmed those cells so that the ones who are
- 6 programmed to metastasize have already metastasized by the
- 7 time that there's a one- or two-millimeter mass, and the ones
- 8 that are not going to spread very easily are not going to
- 9 spread. And they may reach golf ball size, and you can take
- 10 them out then, and the patient will still have a good
- 11 prognosis.
- 12 So that by the time you can find them on a CT scan,
- it's -- probably the game is going to be over one way or
- 14 another anyway. But it's an unanswered question, and at this
- 15 point I would say somewhere by saying proponents, the
- optimists, say it would be unethical to ask people to wait
- while the big studies are done. The opponents say it's
- unethical to ask people to pay for an unproven technology.
- 19 Again, my problem here is the false reassurance
- 20 issue. A negative CT can easily miss small tumors, and some
- 21 tumors are just not visible by routine CT unless contrast
- 22 agents are given. So anyone who's a clinician here knows
- 23 that you can't find adrenal tumors and renal tumors and many
- 24 other tumors unless you infuse intravenous contrast, but
- 25 those contrast agents carry a small, about 1 percent, risk of

- 1 reactions and they're also very expensive.
- 2 Fortunately, no one out there is doing screening
- 3 CTs with contrast. They're not that irresponsible. That
- 4 said, people walk out thinking that they've got a clean bill
- of health. They may continue smoking because they believe
- 6 that they are getting away with it.
 - So, I mean, this -- I put this slide in here just

1 you didn't know about before has disproportionate value in

- 2 your mind, so that you have people smoking cigarettes while
- 3 worrying about SARS or worrying about, you know, other things
- 4 that are just not, you know, important.
- And, you know, for me the epitome was a car that
- 6 someone pointed out to me in Boston the other day, a sports
- 7 car with a bumper sticker saying, "Ban nuclear power," and
- 8 there was a radar detector in the front. So the chance this
- 9 person will die from a car accident, of course, is much, much
- 10 greater than from a nuclear accident. But the prospect of a
- 11 nuclear accident was much more worrisome. There is this
- whole line of thinking. The bottom line of it is that we're
- 13 not rational animals and it's very difficult for us to put
- 14 risks in perspective.
- 15 Well, what do physicians do? These are my last two
- 16 slides. I did, after being invited to come down here, do an
- e-mail poll of the internists and the cardiologists of Mass
- 18 General Hospital and Brigham & Women's Hospital. And I
- 19 actually got responses from 141 internists, and I asked them,
- 20 have you undergone a CT to screen yourself for cancer? And
- 21 then the follow-up question -- and I asked the cardiologists,
- 22 have you had an EBCT to screen yourself for coronary disease?
- 23 And then the follow-up question was, if so, did you pay with
- 24 your own money? And third question was going to be, did you
- 25 pay with post-tax dollars?

1 But I never got to the third question because not

- one internist at the Brigham or Mass General has had a CT
- 3 scan to screen themselves for lung cancer or other cancers.
- 4 Two out of the 26 cardiologists have had electron beam CT,
- 5 but neither paid. One of them indicated that he would have
- 6 paid, but as my wife said, she'd believe it when she saw it.
- 7 So these were some of the comments I got back in
- 8 the e-mail from the cardiologists on electron beam CT. You
- 9 know, "I would not have done it even if it was covered by
- 10 insurance. It's hype. I discourage my patients from having
- 11 it done if they ask."
- "No. I was asked by my wife's rich uncle in
- 13 Argentina whether he should invest, and I told him if it was
- 14 a good plan to get in and then make sure there as a good exit
- 15 strategy once people figured out the limitations."
- 16 "No. I can't see use for it save to generate
- 17 anxiety and more business for the ETT lab" -- exercise test
- 18 lab -- "which would be good from a purely commercial
- 19 standpoint."
- 20 And the last one is, "Absolutely not. This test is
- 21 not ready for prime time."
- The last comment I'd make is that I wish the
- 23 medical profession was effective enough in trying to regulate
- 24 it. When the leaders of cardiology and general medicine
- don't believe these tests have value, I wish our profession

- 1 was effective in keeping physicians from marketing things.
- 2 But it's not, and I don't have realistic
- 3 expectations it will be in the near future. So I'm hoping
- 4 that these hearings will lead to some other kinds of
- 5 interventions. Thanks very much.
- 6 MS. KOHRS: Thank you, Dr. Lee.
- We're going to have Dr. Koch speak next, if I don't
- 8 have the computer shut down one more time.
- 9 DR. KOCH: Thank you very much. It's a pleasure to
- 10 be here. I was asked to speak because of the notoriety of
- good and probably a lot bad that ophthalmology has with
- 12 regard to LASIK advertising and how it tends to dominate the
- 13 marketplace in terms of the amount of -- proportion of
- 14 medical ads. And I think that was shown or reflected in Ms.
- 15 Carabello's talk as well.
- 16 I'm from Baylor College of Medicine. I also would
- 17 like to acknowledge that I've been discussing this with my
- 18 colleagues at the American Society of Cataract and Refractive
- 19 Surgery, and as a society, we have a lot of interest in this

- 1 results, as you might logically feel.
- It's a big business. In 2002, there were over one
- 3 million LASIK procedures, with a total cost of \$1.9 billion.
- 4 And a marketing cost at about \$140 an eye is about \$160
- 5 million, so there's a lot involved here.
- Now, where do our patients learn about LASIK? The
- 7 American Society of Cataract and Refractive Surgery just
- 8 worked with the Harris Interactive to do a poll, and you can
- 9 see that they learn about it from their eye physicians,
- opthalmologists/optometrists; family and friends; internet;
- other media; and then advertising. And of course,
- 12 advertising -- really, these things probably also are part of
- the advertising, and then less so from the medical
- 14 associations.
- 15 As physicians, obviously, our first role is to do
- 16 no harm, to be the caretaker. And we have a pact with our
- 17 patients as ophthalmologists who are entrusting their vision
- 18 to us. And so cannot advertising be consistent with this
- 19 qoal?
- 20 Absolutely. If it honestly informs the patients of
- 21 availabilities of practices and procedures, describes them,
- 22 and even fair comparisons are doing -- probably are
- 23 beneficial to our patients. They drive costs down. They
- inform patients. We're not opposed to any of that.
- 25 Obviously, there must be no deception, stated or implied.

1 The fundamental problem is this whole thing about

- 2 health care and commodities and is LASIK truly a commodity in
- 3 a free market? Clearly not in the traditional sense, and
- 4 again, this was alluded to earlier.
- 5 You can't test-drive your surgical result. You
- 6 can't try to remove one spot and see if this cleaner works
- 7 better than the other cleaner. You have one crack at having
- 8 surgery on your eyes. And it's difficult to get data
- 9 regarding quality of surgeons and outcomes.
- 10 The ads kind of run the spectrum. There are those
- 11 that are legal and ethical, those that are legal but we would
- 12 consider unethical, and then clearly illegal ads. So an ad
- 13 can be legal but not in the best interests of patients. And
- 14 we're also worried about the profession and about not only
- 15 the image of the profession to the public, but about what we
- 16 try to instill in our colleagues as physicians.
- 17 So the advertising can deceive patients in a
- 18 variety of ways. These are at least four ways that
- 19 advertising in LASIK surgery can deceive patients, the first
- 20 one being price.
- 21 The classic one was already really shown, the
- 22 asterisk, which is a bait and switch: 499 for your eye, and
- 23 all of a sudden you end up using -- the patient realizes
- 24 that's not the laser they want to have used. There's a
- limited refractive range, up to myopia, up to minus 2, for

1 Here's one: "LASIK eye surgery for free. I can

- 2 see clearly now." Their website is seeclearly.com. And
- 3 again, the implication that everything is clear. "Win a free
- 4 laser vision correction." These kinds of inducements that
- 5 are misleading about price. Two-for-one pricing.
- 6 This is one of my favorites: "Guess what I won,
- 7 hon?" And, you know, which media? And you can see, there's
- 8 your fine print. You'd need LASIK surgery just to read the
- 9 fine print.
- 10 And my favorite of all time, and I want to
- 11 acknowledge Dr. Terry O'Brien, who sent me some of these:
- 12 "Kiss a pig and you can win free LASIK vision correction."
- 13 You know, it's a trivialization. It's a kind of -- the humor
- in these kinds of approaches kind of minimize the seriousness
- of the decision that patients make in contemplating this type
- of surgery.
- 17 Well, what about the eligibility criteria? There's
- 18 the implication that the procedure is for everybody. And
- 19 I'll give you one example of that. Here's one -- let's
- 20 see -- "Get rid of your glasses. Cataracts. Nearsigned.
- 21 Farsightedness." So it doesn't matter what you've got, we
- 22 can fix you.
- 23 And again, it draws patients in. It makes them
- think that, gee, I must be eligible for this, and makes them
- 25 less critical in thinking about the applicability of this

- 1 procedure for themselves.
- 2 Outcome: There's implications of the perfect
- 3 result, of the permanent results, of no complications.
- 4 "20/20 for 2995." You can get rid of your contacts for life.
- 5 "The only laser vision correction facility offering a 20/20
- 6 promise." Refund the final fee. "To the best." How do they
- 7 define "best"? There are the glasses. No more glasses. No
- 8 more contacts. Things that are clearly not accurate or
- 9 correct.
- 10 "Participate in our free LASIK" -- dah dah dah
- 11 dah -- "seminar." The "get-rid-of-your-reading-glasses"
- 12 seminar. And learn how it uses -- for the best results. And
- again, no data to substantiate these claims.
- Other claims from recent ads: "Quick and pain-free
- 15 way to eliminate your way for corrective lenses." "The
- 16 world's most advanced ophthalmic lasers." "The only 3-D eye

- 1 poor patient decisions regarding undergoing a procedure. It
- demeans the profession, and is a violation of the implied
- 3 pact between physician and patient.
- As part of this survey, we found that dissatisfied
- 5 patients after LASIK surgery were less likely to know what
- 6 procedure they had -- they didn't even know if they had LASIK
- 7 or another procedure -- or to be knowledgeable about the
- 8 benefits, risks, and expected amount of visual improvement
- 9 that could occur with the surgery. And they were more likely
- 10 to note advertising as a source of information about LASIK
- 11 surgery.
- So how can we better protect our patients? We have
- 13 to provide better information. That falls upon the medical
- 14 profession to do that. And I think tighter scrutiny in
- 15 advertising is important.
- 16 Now, at the American Society of Cataract and
- 17 Refractive Surgery, we've developed the Eye Surgery Education
- 18 Council, and that has a website that has a range of
- 19 materials, including very detailed LASIK patient-screening

- 1 combined with the American Academy of Ophthalmology and the
- 2 American Society of Cataract and Refractive Surgery, they
- 3 were approved by the FTC. They provide a legal framework for
- 4 those issues as you see. And they talk about the kinds of
- 5 claims, and they give good examples about efficacy,
- 6 comparative efficacy, safety, permanence and predictability, and success rates.

1 be -- sorry. It's going to be Richard Kelly from the Federal

- 2 Trade Commission.
- 3 MR. KELLY: Good afternoon. I think the
- 4 presentations so far have really been excellent. Given me a
- 5 lot to think about even before I walked up here.
- It reminds me of the story of why lab technicians
- 7 prefer lawyers to white rats for their laboratory
- 8 experiments. And maybe you've heard this story before, but I
- 9 think it's an interesting one.
- 10 One of them, of course, is there are just much more
- 11 lawyers than white rats. And the second reason is that the
- lab technicians don't get attached to those lawyers. And the
- third one, of course, is that there are just some things you
- 14 can't get a white rat to do.
- 15 So, you know, here I am today, listening to these
- 16 presentations and desires for the agency to do more. And
- certainly we're listening and we want to respond.
- 18 And what I wanted to do today was to talk a little
- 19 bit about the FTC's experience with LASIK, but also to give
- 20 you a little background in case you don't know a little bit
- 21 about what this agency is about and the kinds of things we
- 22 do.
- 23 It's probably useful for this slide to be up there
- in terms of the value, the positive value, of advertising.
- 25 Because inherently, we're going to hear about some negative

- 1 things. These ads are deceptive. These ads have
- 2 misrepresented this or that. These ads lead people down the
- 3 wrong path.
- 4 And I think Laura had mentioned the Supreme Court's
- 5 intervention in the area to open up the doors to advertising
- 6 by health care professionals several decades ago. And that
- 7 was certainly over First Amendment concerns, but it's also a
- 8 recognition that advertising, if done well and right, can
- 9 help the marketplace.
- 10 Obviously, it can do all of those things that are
- on that slide. You yourselves can think of experiences where
- 12 advertising has helped you make a choice or a selection or
- 13 become aware of something new that you just didn't know was
- out in the marketplace. But that last point, that last point
- on that slide, is of course essential. But of course it must
- be truthful and non-misleading.
- 17 You know, it's interesting: When I hear the
- 18 discussions about the FTC, I mean, and all the things that we
- 19 might do or could do, today, right now, we're in court today,
- 20 not on a case involving physician advertising, but we're in a
- 21 court today, right now, seeking a temporary restraining order
- 22 against a marketer of a product called coral calcium.
- 23 And coral calcium was being marketed as to treat or
- 24 cure cancer and other diseases such as multiple sclerosis and
- 25 heart disease. Very widely promoted on television. So we're

- 1 in court today challenging that.
- Just last week we went into court, got a temporary
- 3 restraining order against a marketer of the Q-ray. Q-ray,
- 4 which is being marketed as something to relieve muscular and
- 5 joint pain, even though a very recent Mayo Clinic study
- 6 showed that it was no better than a placebo.
- 7 So there is much to do, and many areas for us at
- 8 the FTC on the consumer protection side to be focused on.
- 9 And that basic mission, as is set out in that slide, is to
- 10 prohibit unfair or deceptive acts or practices, and to go
- 11 against false advertisements for food, drugs, devices, and
- 12 services.
- A practice is deceptive if it's likely to mislead
- 14 consumers acting reasonably under the circumstances, and is
- 15 material to a consumer's decision to buy or use a product.
- 16 And a practice is unfair if it is likely to cause injury to
- 17 consumers, injury as such that cannot be avoided by consumers
- 18 themselves and is not outweighed by some benefit.
- 19 One of my handouts was some pictures of some ads.
- 20 And the first one was for this, this amazing Gutbuster. The
- 21 ad says, "Turns ordinary sit-ups into tummy-tightening power
- 22 stretches." It's an old case from the FTC, old, I guess by
- 23 most standards, 1990. But what was interesting about that
- 24 case, it's a combination of both that unfairness and
- 25 deception concept.

1 It turned out that Gutbuster really didn't do

- 2 anything to tighten your stomach. So those claims were
- 3 deceptive. But the other concern -- and this is a
- 4 Gutbuster -- the other concern about the Gutbuster was that
- 5 it could break upon use and maybe actually bust that gut by
- 6 piercing it or hurting some other part of the body. That
- 7 part of the advertising was unfair because it would cause
- 8 injury that consumers could not reasonably expect or avoid,
- 9 simply by using the product.
- 10 Core advertising principles: I don't think anybody
- 11 could disagree with any of these. Obviously, tell the truth.
- 12 But that's an important point, too: Tell all the truth.
- 13 Don't omit information that's needed to keep what's being
- 14 said in an ad from being deceptive. And, of course, to make
- 15 sure it's the truth, which is a core, very significant
- 16 approach that the Commission takes, and is certainly very
- 17 vital for any health care advertising.
- 18 The concept is, is before an advertiser makes a
- 19 claim in their ads, they'd better have a basis, a reason, to
- 20 believe that in fact that product or service will do what's
- 21 being said. And this standard, which we call the
- 22 substantiation standard as it says here, is flexible. It
- 23 depends on the claim.
- 24 So if you say in an ad, four clinical studies show
- 25 that this does this, well, then, you'd better have four

- 1 clinical studies that show that. If you say in an ad that 98
- 2 percent of our customers or our patients or the consumers
- 3 taking this product achieve this result, that certainly is an
- 4 implication that you've done some kind of study or follow-up
- 5 with your patients to demonstrate that that's true.
- 6 But the point is that the standard is also flexible
- 7 so that if something new has been developed, some new
- 8 technology is being developed that information can get out in
- 9 an advertising about this technology so that there isn't some
- 10 absolute bar that you must have at this point this amount of
- 11 evidence before you can say anything, but still if you do
- 12 choose to do that you've got to present it in a fair and
- 13 reasonable way that consumers would understand what that
- 14 evidence means and what it doesn't mean. And of course, it
- 15 requires competent and reliable, and in the health care area
- 16 scientific, evidence, evidence that an expert would say is
- 17 needed.
- 18 A little concept here about ad meaning. When you
- 19 look at those ads that were being put up on the board before,
- 20 advertisers are certainly responsible for any express
- 21 statement they make in the ad, but also for ones that are
- reasonably implied by the express statements they make.

The net d bm7 ex525mho.925 0 TD(5Te ex52d-o.9aers are cert

1 testimonials. It's worth pointing out that you can't say --

- 2 basic rule: An advertiser cannot say in a testimonial what
- 3 they couldn't otherwise say in an ad. So just because
- 4 someone who has gone through a particular procedure or bought
- 5 the product had this particular result, if the advertiser
- 6 felt, I couldn't say that because I don't have substantiation
- 7 for that, I don't think that's true, just because some
- 8 consumer says it is, you couldn't use it in the ad.
- 9 And testimonials can often contain claims that are
- 10 basically statements of efficacy. We can see it in the area
- of LASIK. We see it in many, many other areas, where that
- 12 testimonial is making some kind of statement that, you know,
- 13 basically says, this product will do this. It did it for me
- 14 and it will do it for you. And, of course, such claims need
- 15 to be supported.
- 16 Let's talk a little bit about LASIK. We've been
- interested, involved, working with others in this area for a
- 18 number of years. And it seems like some of the issues
- 19 continue to be the issues that have been from day one: Throw
- away, eliminate the need for glasses or contacts, has
- 21 certainly been a major question, a major issue.
- 22 Misrepresentations being made about the safety of the
- 23 procedure are certainly of issue. And concerns raised about
- 24 making comparisons.
- 25 And what our approach has been to date has sort of

1 been this multi-faceted approach combining not just one area

- 2 exclusively, but looking at others. So we're going to do
- 3 education, we're going to encourage self-regulation, and
- 4 where needed, going to do law enforcement.
- 5 So we have over the years been working with a
- 6 number of groups, and again trying to come together.
- 7 Absolutely right, we did help and assist in the development
- 8 of guidelines. We have been in discussions and had meetings
- 9 with the various professional groups. We've talked with the
- 10 state medical boards. Again, where we have found examples of
- 11 advertising that have been questionable, we have tried to get
- 12 someone interested in going after it.
- 13 That last point: Bring cases where necessary.
- 14 And -- did I jump ahead? Well, let's go right there. Recent
- 15 Commission cases: We just announced two cases in March
- 16 against national advertisers, and they focus again on some of
- 17 these claims that people have been concerned about for a
- 18 number of years.
- 19 Eliminate glasses and contacts for life. Eliminate
- 20 the need for reading glasses. Risk of glare and halo.
- 21 Significantly less risk than contacts or glasses. It really
- 22 seemed to be an inappropriate thing to be comparing the risks
- 23 of going through a LASIK procedure with what might happen if
- 24 you put a contact on your eye or a pair of glasses on your
- 25 nose. They were really speaking to very different issues,

- 1 and so we challenged that.
- This false claim of free consultation: The problem
- 3 wasn't that the consultation wasn't free. The problem was,
- 4 the consultation didn't have anything to do with your
- 5 suitability for the procedure. Even though the ad expressly
- 6 said, come in for a free consultation to see if you qualify
- 7 for this procedure, when you showed up what you saw was
- 8 someone who basically told you what the price would be.
- And then you had to pay over \$300 if you wanted to
- 10 go to the next stage. At the next stage you would find out,
- in fact, whether you were suitable, and you'd find out about
- 12 the risks. Those cases, again, were put out for comment in
- 13 March, and we're awaiting final action by the Commission.
- 14 Let me finish up here with some key points, and
- 15 look forward to the discussion that will occur later today.
- 16 Truthful and non-misleading advertising: Of course this can
- 17 be of great assistance too consumers. But deceptive
- 18 advertising, misleading advertising, will certainly distort
- 19 consumer choice.
- 20 So what we need, what we think we need here at the
- 21 FTC, is reasonable industry self-policing, informative
- 22 education efforts, and targeted government action, working
- 23 together to protect consumers and encourage fair competition.
- 24 Thank you very much.
- MS. KOHRS: Thanks, Dick.

- 1 Now, I'd like to give you a little bit of
- 2 background, and then I will try to answer some of the
- 3 questions that appeared on the FTC website relating to
- 4 quality advertising.
- 5 Quality advertising is considered by many
- 6 inherently deceptive because it cannot be verified and it
- 7 cannot be precisely measured. The rationale for this
- 8 statement is the striking disparity between the knowledge on

1 as a result of what the health care professional did to the

- 2 patient.
- 3 Many economists in this area and other experts have
- 4 come to the conclusion that the lay public is totally
- 5 incapable of evaluating the quality of medical services. A
- 6 patient's loyalty to his or her dentist also complicates the
- 7 effectiveness of quality advertising.
- In other words, there are bonds between patients
- 9 and dentists and patients and various physicians so that
- irrespective of how you might rate that physician or dentist,
- 11 they will continue to go to that dentist because they have a
- 12 relationship with the dentist or the other health care
- 13 professional.
- Now, as a result, the Supreme Court determined that
- 15 these various significant challenges to informed decision-
- 16 making by the customers for professional services suggest
- 17 that advertising restrictions arguably protecting the
- 18 patient -- this is the requirement for verification of the
- 19 quality advertising -- could not be looked upon in the rather
- 20 cursory manner that the Federal Trade Commission had in
- 21 determining that there was an antitrust violation.
- The Bates case has been mentioned by a couple of
- 23 speakers now, and that was the case that first introduced
- 24 advertising to the professions. But even in the Bates case,
- 25 although it said advertising for routine services was fine --

- Now, how are the ways that Jane Jones can show that
- 2 she is the best dentist in the West? I suppose if something
- 3 like a magazine like Consumers Union did a study and
- 4 determined that she was the best dentist or among the very
- 5 best dentists, that would probably satisfy the fact that this
- 6 advertisement had been verifiable.
- 7 What are the problems that might arise if this type
- 8 of advertising is permitted? Well, a patient may go to Jane
- 9 Jones, believing that she is the best dentist in the State of
- 10 California, and Jane Jones may not be the best dentist in the
- 11 state and may, as a result, leave the patient with lips that
- 12 are sore and a mouth that is sore as a result of this. Well,
- 13 certainly this patient will not return to Jane Jones. She
- 14 will go on and look at other dentists, and it may be trial
- and error before she finds a dentist who she considers is
- 16 best for her.
- 17 Well, that trial and error constitutes search
- 18 costs, which would therefore interfere with the delivery of
- 19 services. And one of the arguments in the California Dental
- 20 Association case was that the elimination of those search
- 21 costs meant that this type of advertising would be pro-
- 22 competitive and, in fact, the Ninth Circuit Court of Appeals
- 23 found that to be the case.
- 24 What is the difference -- here's another
- 25 question -- what is the difference between dentists who

1 advertise and those who do not advertise quality services?

- Well, there may be no difference between them in terms of
- 3 training and skill. It's simply one is advertising that she
- 4 is the best, and the other is not advertising. So it would
- 5 appear as if the advertisement might give the dentist who was
- 6 advertising sort of the ability to say that they are superior
- 7 to the other dentists in the community.
- 8 What role does comparative advertising play in
- 9 dental advertising? There is almost no comparative
- 10 advertising; at least, I've never come across comparative
- 11 advertising in dentistry.
- 12 Are there governmental and association limitations
- on advertising? And yes, as you saw with Mr. Kelly speaking,
- 14 the advertisement does have to be truthful. And in the case
- 15 of the California Dental Association, it also has to be
- 16 verifiable.
- 17 And the question then is, is that -- what effect is
- that on the marketplace? In my judgment, that's a salutary
- 19 effect on the marketplace because consumers in California,
- 20 for example, can rely on the fact that the professional
- 21 association of dentists in that state verify the
- 22 advertisements that are being run in the Yellow Pages or in
- 23 newspaper columns or newspapers in general.
- There's another question: What empirical evidence
- 25 supports this justification? Well, I'm really not aware of

1 any empirical evidence that supports this. However, I

- 2 suppose one way that you could determine that is to run a
- 3 study and see whether or not -- let's take California again
- 4 as the illustration -- whether dentists in California who are
- 5 not members of the California Dental Association run more
- 6 quality advertisements than members of the California Dental
- 7 Association, who cannot run quality advertising unless
- 8 they're ready to verify those.
- 9 As a matter of fact, just as others have said here
- 10 with various physician-type advertising, advertising among
- dentists is flourishing. The last time the ADA survey center
- took a survey on advertising was in 1996 and I'm sure the
- 13 numbers would be much higher today. But in 1996, 65 percent
- of all dentists were advertising. Now, that's not to say
- they were advertising quality, but they were advertising in
- 16 general.
- 17 And the survey further asked those dentists, did
- 18 they believe that their advertising was worthwhile? And 70
- 19 percent of the dentists of that 65 percent stated that the
- 20 advertising was in fact worthwhile.
- Now, the aftermath of the CDA litigation indicates
- 22 that probably the California victory was a pyrrhic victory
- 23 because what has happened because of the expense of that
- 24 litigation, none of the state associations are enforcing
- 25 advertising principles of ethics.

But it's even more significant: They are so

- 2 concerned about anything, any enforcement, any disciplinary
- 3 actions, under the ADA principles of ethics that they are not
- 4 moving forward to try to obtain discipline for any violation
- 5 of the principles of ethics.
- Now, I'd like to make one other statement for the
- 7 record. There was a dentist here yesterday, I guess during
- 8 the Noerr Pennington discussions, whose name -- I'll leave
- 9 his name out. But he made a statement which I would like to
- 10 challenge.
- 11 His statement was that a dentist may not advertise
- 12 that he is a mercury-free dentist. And although the ADA
- 13 Judicial Council has never been called upon to resolve that
- issue, nor am I aware of any state association ever being
- 15 called upon to make a determination with reference to this
- 16 ad, the likelihood is that that ad, without more -- mercury-
- 17 free dentist, John Smith is a mercury-free dentist -- that
- 18 would not violate the principles of ethics.
- 19 On the other hand, if that dentist went further and
- 20 stated that he or she were mercury-free dentists because of
- 21 the toxicity of a certain type of restorative material, that
- 22 very likely would violate the principles of ethics because
- 23 that claim is untruthful and it's not verifiable.
- In fact, the Food & Drug Administration, Health and
- 25 Human Services, has an extraordinarily large body of

- 1 literature, that supports the notion that that form of
- 2 restorative is not harmful to patients and, in fact, except
- 3 for a very small element of the population who may be
- 4 allergic to that restorative.
- 5 But with reference to history, that restorative has
- 6 been used for 150 years. All the governmental agencies, the
- 7 scientific bodies, all conclude that it does not harm
- 8 patients. And therefore, if this dentist were to go further
- 9 and say he is a mercury-free dentist because of the toxicity
- of a certain restorative, that probably would violate the
- 11 principles of ethics.
- 12 Let me conclude by telling you a joke that I used
- to tell all of the dentists when I litigated with the Federal
- 14 Trade Commission. And that litigation lasted for a number of
- 15 years. And that was, how many lawyers does it take to screw
- 16 in a light bulb? And the answer is, as many as you can
- 17 afford.
- 18 And I would tell the dentist that the United States
- 19 government has many, many lawyers that it affords who work
- 20 for them in litigation with the FTC. Thank you very much
- 21 for permitting me to speak to you today about this subject
- 22 matter.
- MS. KOHRS: Thanks, Mr. Sfikas. I think we're just
- 24 going to take about a ten-minute break to give everybody just
- 25 a chance to get up and stretch your legs and think a little

- 1 bit before we come back for the final speakers. So we'll
- 2 reconvene, actually, at about 4:00 by this clock here on our
- 3 wall.

1 Earlier this year as well, I had the opportunity to

- 2 serve on a panel at the NCQA that dealt with the issues of
- 3 provider referral and what kind of directory information
- 4 should be available to consumers. So hopefully I have some
- 5 insights onto some of the issues we're dealing with today.
- 6 I'm also going to talk a little bit about the
- 7 company. We provide a couple services, one of which I think
- 8 is directly germane to today's discussions. And I would
- 9 submit the other one is as well, but perhaps not as obvious.
- 10 And we're going to focus primarily on my Quality Coach, which
- is a provider service -- or a service that we provide to
- 12 health plans and large self-insured employers.
- DoctorQuality was founded in 1999 during what I'd
- like to refer to as the apex of the dotcom toga party. I
- 15 actually represent the second generation of management. The
- 16 academic physicians who founded the company are back in
- 17 academic medicine, and doing so, they were able to double
- their salaries and they now have 401(k) matching, to which I
- 19 say God bless America.
- 20 Even though we have a very -- we're very young and
- very new on the scene, we do have a very strong customer base
 - made up of some reputable clients who have really helped us

One is a gentleman named Chuck Buck, who actually is a member

- of the Institute of Medicine, who published the frame-
- 3 breaking report in 1999, "To Err Is Human," which really kind
- 4 of blew the covers off of medical errors. And the other is
- 5 Dr. David Nash. Dr. Nash heads up the Center for Health
- 6 Policy and Outcomes Research at Thomas Jefferson University,
- 7 nationally known as one of the experts in quality and patient
- 8 safety.
- 9 We are a company that uses health care technology
- 10 to improve quality and safety. We believe in the transparent
- 11 marketplace. We believe that there's an opportunity to get
- more information into the right hands as people try to either
- monitor performance or make critical decisions.
- To that end, we have a hospital and physician
- 15 selection tool that helps consumers choose resources based on
- 16 performance and quality. We also have a hospital incident
- and adverse event reporting tool which is used for quality
- 18 assurance purposes, and from that activity we today house the
- 19 largest database that we know of -- we've looked everywhere
- 20 to find anything comparable, and we haven't been able to --
- 21 we've got the largest database in existence for medical
- 22 errors and near-misses. And I'll talk a little bit about
- 23 that.
- 24 The two products that we offer are Risk Prevention
- 25 and Management, or RPM -- this is the hospital error

1 collection tool. It's used for quality assurance purposes.

- 2 And we also have My Quality Coach, and that's the physician
- 3 and hospital selection tool.
- I'd like to emphasize, it's very important as we're
- 5 trying to provide information to consumers to make informed
- 6 decisions. You must know that there is an impermeable wall
- 7 between these two platforms. The information that we collect
- 8 in the conduct of the RPM program is private, confidential
- 9 information for quality assurance purposes only.
- 10 Frequently I get the question, so you collect
- 11 hospital error information and tell consumers who makes the
- 12 most mistakes? That's not the objective of the program, nor
- 13 will it ever be.
- I want to start by talking about the hospital error
- 15 reduction program. I think it's important -- maybe not
- 16 directly in the context of today's discussions, but I think
- it's important in the context of: at some or another every
- 18 one of us here is going to be a patient or has been a
- 19 patient.
- 20 Between 44,000 and 98,000 people are killed
- 21 annually in the United States as a result of an unnecessary
- 22 medical error. Let's put that into context because 98,000 a
- 23 year is a big number. It's hard to really figure out what
- that means. I've been given 15 minutes today. Three people
- will die while I'm up here. And that's a pretty sobering

- 1 fact. So it's a very significant problem.
- 2 The other thing that's very interesting is of the
- 3 numerous medical errors that are made, it's been estimated
- 4 that only about 5 percent are actually reported, reported in
- 5 the context of trying to analyze why the mistakes happened so
- 6 preventive measures can be taken.
- 7 Not only is it a tragedy, but it costs a lot of
- 8 money, too. Medical errors cost this country about \$140
- 9 billion a year, both in terms of repeated procedures and the
- 10 costs for those procedures, and there's also a growing
- 11 concern, a crisis in many states, with respect to malpractice
- 12 insurance. And this is a piece of it.
- Now, it's very encouraging to see that many of the
- 14 states in this country are now requiring some form of
- 15 mandatory medical error reporting. About 20 states today
- 16 actually have some legislation on the books requiring error
- 17 reporting.
- 18 I think two in particular are, I think, very near
- 19 and dear to DoctorQuality's heart. In New York, there's a
- 20 program called NYPORTS, and it might not be generally known,
- 21 but every single hospital in New York has a dedicated NYPORTS
- terminal at which the hospital employees are required to
- 23 report certain errors to New York State.
- 24 Also, in Pennsylvania, I'm very proud to say that
- 25 yesterday our company submitted the bid to provide error

- 1 reporting across the state to a new regulatory agency in
- 2 Pennsylvania known as the Patient Safety Authority. And
- 3 Pennsylvania is really going to be the first state of its
- 4 kind that is going to encourage not only what's known as
- 5 serious events -- in other words, the things that harm
- 6 patients -- but Pennsylvania wants to know about the near-
- 7 misses as well. And I think it's a big step forward in terms
- 8 of really being able to find ways to be proactive about some
- 9 of these problems.
- The problems that we see here are not necessarily
- 11 individual acts of negligence or incompetence. The problems
- 12 that we see, we believe, most often are the result of a
- 13 system of care.
- 14 Here's a very startling statistic: From the time
- 15 that an individual is admitted to a hospital for what's
- 16 become a fairly routine procedure, coronary artery bypass --
- from the time that person is admitted to the time they're
- 18 discharged, about 400 people are going to be involved in
- 19 delivering care to that individual, 400.
- Not all of these are going to be hands-on. Some of
- 21 these people are going to work in the lab, some in the
- 22 pharmacy, some in the kitchen. Some are going to work in
- 23 maintenance, and they're going to clean up the operating room
- 24 after the fact.
- 25 But 400 employees of the hospital are involved in

1 to change that, help our clients change that, and start to

- 2 gather the information to help them figure out where the
- 3 problems are.
- So we start with culture. We move to data capture.
- 5 Once we know -- once we have the data, we can start to
- 6 analyze the data to figure out what the solutions are,
- 7 implement the solutions. And we find among a lot of our
- 8 clients, once we've nailed down one solution, another one
- 9 pops up. Health care technology changes constantly. Or once
- 10 you've solved a problem on the surface, it might expose
- 11 several other problems underneath.
- So we believe that it's important at every level,
- and I think in particular with respect to health care policy,
- 14 legislative policy, something has to be done to really evolve
- 15 the culture of health care.
- 16 I mentioned a little bit earlier the database that
- 17 we have. Earlier this week we crossed the line. We now have
- 18 a little more than 80,000 medical errors. Next week, it will
- 19 be more than 81,000, collected from more than 150 health care
- 20 facilities across the country.
- 21 You'll see that about two-thirds fall into either
- 22 the adverse clinical or medication areas. And I think the
- 23 statistics on the right-hand side are pretty telling as well.
- 24 The one I like the most is that of all the items that are
- reported to us, 43 percent involve a near-miss.

1 You know, this might be a situation where in the

- 2 middle of the night you see the nurse come into your hospital
- 3 room and say, "It's time for your pill," and she hands you a
- 4 yellow pill. And maybe you're going to be awake enough to
- 5 say, "Wait a second. Mine is blue." That's a near-miss. It
- 6 was caught in time. And there could be about 15 people
- 7 someplace in the chain that somehow put a yellow pill on that
- 8 tray for you instead of your blue one.
- 9 We've seen numerous cases where our clients being
- 10 able to quantify the recurrence of near-misses has led to
- 11 some very significant improvements in their procedures. And
- we were able to prevent similar recurrences in the future.
- 13 I'm just going to say one more thing about the
- 14 medical error situation before we roll into the physician and
- 15 provider selection tool that we provide. But I get a lot of
- 16 questions very frequently about why should anyone really want
- 17 to report a medical error?
- 18 The first one, you know, why should you want to do
- 19 it? Well, I believe that doctors went to medical school to
- learn how to do a good job. And there's a little bit of a
- 21 Pollyanna in me about that. I don't believe doctors go to
- 22 medical school so they can golf on Wednesday. There are
- cheaper ways to golf on Wednesday.
- 24 I think that health care professionals try very
- 25 hard to do a good job, and I think it's harder and harder to

do a good job. And what we provide is an improvement tool

- 2 that helps people understand where their weaknesses are and
- 3 be able to react to them.
- 4 Next question: Won't error reporting lead to
- 5 lawsuits? A very, very common misperception. And the answer
- 6 is, in 49 states, no. In 49 states, any information that's
- 7 collected as part of a quality improvement is protected by
- 8 the peer review statutes, which means you cannot subpoena it.
- 9 I'm sure that will be challenged, and it's probably a
- 10 question that we're going to have to wrestle for a long time.
- 11 But I'm very pleased to say that at a policy level, in 49
- 12 states the answer is no. This does not lead to lawsuits.
- 13 This leads to better health care.
- Who would want to report on a coworker? Well, let
- 15 me tell you about one of the programs that one of our clients
- 16 has in place, which I think is just the perfect embrace of
- 17 the kind of culture that we hope our clients are promoting.
- 18 We have a client who has a program called the Plant a Flag
- 19 program, and what happens is the hospital gives lapel pins
- 20 and collar pins to the doctors and nurses that report an
- 21 error.
- 22 They take the attitude that the errors are like
- 23 potholes in the road. If you stepped in the pothole, please
- 24 plant a flag so that your coworkers don't step into the same
- 25 pothole. And we see hospitals give out gift certificates for

1 cookies in the cafeteria, movie tickets, anything to promote

- 2 a culture of blame-free reporting.
- And does this offend doctors? Well, it doesn't
- 4 offend doctors if they've embraced this culture of blame-free
- 5 reporting. It's very important that we look at error
- 6 collection data in a non-punitive fashion. And I go back to
- 7 my first point: 98,000 people die because of medical errors.
- 8 It seems pretty apparent to me that blame has not worked. We
- 9 need to try something else.
- 10 Let me turn to our second product, My Quality
- 11 Coach, which is an online consumer decision support system
- whereby consumers can choose physicians and hospitals based
- on quality and satisfaction data. With this program, we
- 14 encourage consumers to log on and prepare ratings on their
- 15 doctors. And we also invite doctors and hospitals to present
- 16 certain information about themselves.
- Now, this information, we think, is pretty
- 18 important in the context of how resources are chosen, VHA
- 19 did -- the Voluntary Hospital Association, that is, did a
- 20 study last year and it seems pretty clear that health care is
- 21 becoming more consumer-centric. I won't go ahead and read
- 22 all those, but you can probably them.
- But in other words, this slide makes the point that
- 24 consumers are interested in finding out quality information.
- 25 They would be very pleased to make decisions based on the

1 standards of performance and the quality of care that's

- 2 delivered.
- 3 It's also becoming an increasing trend that
- 4 employers are very interested in this as well. It doesn't
- 5 cost more -- in fact, it actually costs less -- for the
- 6 employees to go to better quality doctors and better quality
- 7 hospitals. And to the extent that this both is a way to
- 8 reduce health care cost and to bolster employee satisfaction,
- 9 this is something that large employers in particular are
- 10 increasingly becoming very interested in.
- 11 This last point on the slide: Network size is
- 12 taking a back seat to network quality. Actually, that's
- backwards, and the person who drafted that is going to be in
- 14 big trouble tomorrow morning when I get back to the office.
- 15 Network quality -- no. I'm sorry. I'm backwards.
- 16 Start again. Network size is taking a back seat to network
- 17 quality. It used to be that when you'd get into a health
- 18 plan, you'd look at the book and say, is my doctor in here?
- 19 Well, now people are increasingly trying to figure out, is
- the good doctor in here?
- Just a snippet from the Philadelphia Business
- 22 Journal, where last year the Blue Cross organization in town
- 23 has actually developed an incentive program based on quality.
- 24 If institutions are delivering certain quality metrics,
- 25 they're paying bonuses, cash from a health plan, for doing a

- 1 good job.
- We have a number of prominent clients -- I see the
- 3 two-minute sign is up, so -- we have big clients and we're
- 4 proud of them. I do want to point out that Patient Choice,
- 5 Luminos, and Destiny Health are all in the defined
- 6 contribution, defined consumer choice plans.

1 this performance data has had a very positive impact on the

- 2 actual performance of the physicians themselves.
- And I'll end with the last one from a fellow you
- 4 might know of, Dan Rather. "When it comes to choosing a
- 5 heart surgeon, Pennsylvania is on the cutting edge in helping
- 6 consumers pick the right one."
- 7 So we like the idea of making information
- 8 available. We think it has a good impact on the institutions
- 9 themselves. And we think it's a trend that consumers are
- 10 continuing to demand. Thank you very much.
- 11 MS. KOHRS: Thank you, John.
- 12 I'll ask all of the panelists to come up. Helen,
- 13 you're going to speak. You don't have a PowerPoint, but
- 14 everyone else can come up and have a seat. You can choose to
- 15 speak from your seat or from the podium, whichever you would
- 16 prefer. Helen has been here all day.
- MS. DARLING: I just -- obviously, the satisfaction
- 18 of what I have to say will be inversely related to how long
- 19 it takes me to say it. So I will try to make it as fast as I
- 20 can.
- 21 I'd like to mention that two of our Washington
- 22 Business Group on Health public policy goals, two of our
- 23 highest, are to increase transparency in the system -- and
- there is a report out there; if you haven't gotten it, I hope
- 25 you will read it. It talks a lot about what's now available.

I think for anybody who hasn't worked in this field

- 2 recently doesn't really appreciate how much incredible
- 3 information, DoctorQuality.com being one of the best
- 4 examples, is available to especially companies. I know one
- of the companies that uses them is G.E. And they are a very
- 6 demanding purchaser and very sophisticated purchasers.
- 7 So they have a product. Others have products. The
- 8 interesting thing is how many are emerging, how all of them
- 9 are getting better, how -- I mean, they have data and tools
- 10 that would just make us salivate even as recently as five
- 11 years ago.
- 12 And the ability -- it's probably one of ours,
- too -- but the ability to put in something like your personal
- 14 zip code, and say you want a hospital within ten or fifteen
- 15 miles, and these are the things you care about, like
- 16 complication rates and things like that, it will create its
- own report for you, ranking all the hospitals in your
- 18 immediate area.
- 19 And again, if you're not familiar with that, what's
- 20 amazing is what's available and how critical it is that we
- 21 keep moving. They're now using data that I hear now, but
- we're not going to have more data unless we have more
- 23 pressure to have more data.
- 24 We certainly think as an organization that
- advertising can be fine, and we certainly wouldn't want to

- 1 squelch that, whether it's First Amendment or not. But we do
- 2 think that the role of FTC -- and the FDA, by the way, and we
- 3 met with the Commissioner the other day about the role they
- 4 can play from where they have authority to try to drive the
- 5 system to more fact-based information, and also, obviously,
- 6 certainly no deceptive advertising.
- 7 If anybody has -- you should see Tom Lee's letter

- So one of the things we'd like to see in every
- 2 piece of legislation that goes through any time in the next
- 3 two years are requirements around reporting. At a minimum,
- 4 of all currently publicly reported information, that such
- 5 reporting would be easily accessible to consumers. But we'd
- 6 like to go further and eventually have even better
- 7 information.
- 8 There is evidence, as we just heard from John a
- 9 minute ago, that public disclosure of provider performance is
- 10 resulting in clinical quality improvement, in Pennsylvania
- 11 but also in New York. In fact, in every state that has such
- information available, we are seeing improvements and people
- do pay attention. The interesting thing is that providers
 - pay attention because they don't like looking bad, and for

1 protecting the consumer, especially in these complex areas,

- 2 at a time when consumers, employees will have much more of a
- 3 role to play, whether they want it or not; they will be
- 4 playing a much bigger role, and they're going to have to have
- 5 information. And the only way they're going to have it is if
- 6 we keep the pressure on. Thank you.
- 7 MS. KOHRS: Thank you very much, Helen.
- 8 It's sort of the policy here to give the first half
- 9 of the panel an opportunity to respond to some of the things
- 10 that were said after they spoke. To make things a little bit
- 11 easier for me and to move these things a little bit easier,
- if you're interested in speaking, just tilt your name tent on
- its side so that I can see. If it's tilted like that, I'll
- 14 know that you want to participate and ask a question.
- 15 So we'll go ahead and just start down the line, if
- 16 you want to just make a comment briefly. Bernie Dana had to
- 17 leave, so we have a fill-in. Ms. Condeelis?
- 18 CHRIS CONDEELIS: Thank you. I guess one of the
- 19 things that I'd just like to share, a couple points, is that
- 20 I think with the panelists today, we do in long-term care
- 21 share some things in common, in that our residents, our
- 22 consumers, come to us with a very critical need. We are not
- 23 an elective care service.
- 24 The fact that 75 percent of our customers are
- 25 coming to our homes and their payments are capped does have a

- 1 very specific influence on the way we provide our services
- 2 that is -- you know, it kind of caps competitiveness. And I
- 3 think that's different from the other panelists.
- We do for our consumers have quality measures.
- 5 There is difference in the marketplace about how good those
- 6 measures are, but I think that as a profession, we have
- 7 pioneered the consumer satisfaction data that is then
- 8 allowing us to give yet another indicator of quality to those
- 9 that are seeking our services.
- 10 MS. KOHRS: Great. Laura?
- MS. CARABELLO: If we are to insist upon getting
- 12 quality information out to the consumer, what is going to be
- 13 the best way to get it out there? Whose responsibility is it

to do so? Is it incumbent upon the physician himself? Is itbility

- 1 generally. Helen, you look like you're --
- MS. DARLING: Well, I can always answer a question.
- I think on that one, it's a good example of where the complex
- 4 system that we have will govern. That is, all purchasers
- 5 should make certain that it's available to the people they
- 6 purchase for -- Medicare to its beneficiaries, the states for
- 7 their Medicaid beneficiaries, and private purchaser employers
- 8 for their employees.
- And many of the companies, as you saw, some of the
- insurance companies that provide coverage for lots of middle-
- 11 sized and small employers, provide these tools as well. So
- 12 that is who's paying should pay for it.

DR. LEE: You know, I would actually add that I

- 2 think the professional societies, they should be challenged
- 3 more by the business community and by others to pick up the
- 4 role and really show some leadership in this area about
- 5 making even stronger statements about what is and isn't
- 6 supported by evidence.
- 7 And I actually think they're ready for it. I mean,
- 8 I do a lot of stuff with the American College of Cardiology,
- 9 and I think they're primed. They're actively discussing
- 10 having -- you know, taking stands on -- you know, to try to
- 11 reduce waste. Because frankly, they know they need to. You
- 12 know, providers need to show that they are also trying to
- 13 make the system work because they haven't been doing that
- 14 much thus far.
- 15 I'd also that, you know, people don't usually think
- 16 of physicians being in synch with the business community.
- 17 But I would say that in general, our physician -- at least
- 18 our leadership is very much in synch with what Helen said on
- 19 both counts, in that first, we would be very supportive of
- 20 strong action to try to reduce, you know, misleading
- 21 advertising that generates demand where there isn't really
- need, and we'd do everything we could to try to support that
- 23 with our, you know, experts and so on.
- And then the second half, which is that how do
- 25 physicians feel about public disclosure of data related to

- 1 quality, and there's certainly a bit more neurosis and
- 2 ambivalence about that. But I would say that times have
- 3 changed, and that many of our physician leaders accept it and
- 4 are for it. They think that it's -- you know, it's like
- 5 having your teeth cleaned. It's, you know, uncomfortable, it
- 6 draws some blood, but it's good for you.
- 7 And then there are others who just understand that
- 8 it's going to be this way, and they're not going to resist it
- 9 any more. So I actually think that there's enough people who
- 10 understand that it's a tremendous driver for improvement, and
- 11 that wherever something isn't -- wherever we are against data
- being made public, we'd better have a good internal sense of
- accountability. And that's sort of where we've arrived in
- 14 our system.
- 15 So I actually think the providers are in synch on
- 16 both counts: better quality data being released to the --
- made available to the public, while a reduction in the poor,
- 18 misleading information that makes up a lot of advertising.

tion that makes u2f where we've arrivetng 5c, becauseD(12)

our sy0 TDso falseDeading info, p0 Trtt6

1 its perspective, whether those types of claims would be

- 2 allowed now.
- And you said that there was a reticence on the part
- 4 of the California Dental Association, or indeed any dental
- 5 association, to pursue any types of claims. How do we
- 6 encourage them to get involved in the process, as Drs. Lee
- 7 and Koch would want an association to be involved, without
- 8 causing anticompetitive problems?
- 9 MR. SFIKAS: Well, it's a real irony because, of
- 10 course, we prevailed in the California Dental Association
- 11 case. We won. The Court said that it was not an antitrust
- 12 violation.
- I think you've heard that in the case of
- 14 guarantees, that they're really not a solution. If someone
- is injured, the mere fact that they get the cost of the
- dental services back is not really anything that's extremely
- 17 helpful.
- 18 How do you encourage the associations to get
- 19 involved? I think if the FTC -- I think from the standpoint
- 20 of the dental profession, it would be very helpful -- and
- 21 there's really no way to do this, I mean, because the
- 22 principles of ethics are already out there. But it would be
- 23 very helpful if we could present the principles of ethics to
- 24 the FTC where they would say, excluding the advertising -- we
- 25 wouldn't give those to you because we've already won that, in

- 1 our opinion -- but if we gave everything else to you and you
- 2 said, you know, none of these would raise antitrust
- 3 concerns -- and many of these certainly would not raise
- 4 antitrust concerns.
- 5 For example, some of the things that are not being
- 6 done today, in the case of peer review, peer review was
- 7 always used as an alternative dispute resolution mechanism.
- 8 A patient comes forward, says they're unhappy with what the
- 9 dentist did. They don't like the procedure that was done.
- 10 The association hears it, often agrees with the patient,
- 11 would make the dentist reimburse the patient.
- Now, because it's no longer obligatory since it's
- not being enforced, the patient is left to file a lawsuit,
- 14 which is not a good way out of that. Consultation and
- 15 referral, when it is in the best interests of the patient,
- 16 certainly that doesn't raise any antitrust issues. This is
- 17 the dentist determining that the dentist ought to refer, more
- 18 likely than not, to a specialist. That's not being enforced.
- 19 And even a very recent one, the dentist should
- 20 avoid interpersonal relations that could impair personal
- 21 judgment, sort of something on the order of sexual
- 22 harassment. None of those are being enforced, and I'm sure
- 23 that we could agree that none of those would raise antitrust
- 24 issues.
- 25 So it's a real irony. It's the expense of the

1 California Dental Association having to litigate that case,

- 2 first before the administrative law judge, then before the
- 3 Federal Trade Commission, then in the Ninth Circuit Court of
- 4 Appeals; then, because the first time, as you know, the Ninth
- 5 Circuit Court of Appeals ruled for the Commission, a two-to-
- one decision, then the Supreme Court takes the case. The
- 7 Supreme Court reverses, and then sends it back down to the
- 8 Ninth Circuit Court of Appeals before that litigation came to
- 9 an end.
- 10 Well, the other state associations, not as large as
- 11 the California Dental Association, are saying, we just don't
- want to get into that. So there is a great reluctance to
- 13 enforcing not only the advertising restrictions in the
- 14 principles of ethics, but other provisions as well.
- 15 MS. KOHRS: Go ahead. Dick?
- 16 MR. KELLY: Yes. I'm not an antitrust lawyer. I'm
- 17 not in the Bureau of Competition. So to directly respond to
- some of those issues would be foolhardy on my part.
- 19 Clearly, in the California Dental case, there was a
- 20 debate as well as to what kind of record needed to be in
- 21 evidence to justify or not justify those restrictions. And
- 22 ultimately, that case, at least, turned in significant part
- 23 on what approach was being used. There's something called a
- 24 per se approach to evaluating restrictions, and then there's
- 25 a truncated rule of reason. And the Court was saying the

1 where do you draw the line? What do you focus on? And we

- 2 try to focus on claims that are making representations about
- 3 curing dread diseases, for example. And that's where our
- 4 focus is.
- 5 So it requires consumers, it requires the groups,
- 6 it requires government, in some sense working together to try
- 7 to address some of these problems as best as possible. And,
- 8 you know, I remain hopeful.
- 9 In the coral calcium case I mentioned today, one of
- 10 the things we're doing at the same time we were going into
- 11 court seeking this temporary restraining order, the FTC and
- 12 the FDA were together sending out letters to marketers on the
- web, trying to get them to stop making similar claims for
- 14 coral calcium products.
- 15 So, you know, there is hope. There is approaches
- 16 that can be taken. And, you know, hopefully we're all
- 17 willing to try to work together to achieve that.
- 18 MS. KOHRS: And speaking of things going on on the
- 19 web, John, you have dealt with the gamut of physicians and
- 20 consumers and various entities. Can you talk a little bit
- 21 about what that experience has been like? Do you have a
- 22 minimum pool of doctors? If I wanted to look up my doctor,
- John Smith, and I see that 100 percent of the comments have
- 24 been negative and I click on it, does it tell me that there's
- only been one comment made, something like that? How do you

- 1 assess -- how does a consumer assess the data?
- 2 MR. GEBHART: We try to make everything as
- 3 transparent as possible. So if one person has submitted the
- 4 rating, it will say one. You know, whatever the number of
- 5 ratings have been, that's obvious to the consumer when
- 6 they're using our site.
- 7 Some of our clients have actually asked us to
- 8 suppress any rating information until 30 ratings are
- 9 submitted, so at least there can be some semblance of an
- 10 average. Now, of course, you get into a little bit of a
- 11 Catch-22 game when that happens because if you submit a
- 12 rating but you can't see the results right away, then it's

- 1 So you're at risk. We keep our own data, for
- 2 example, and for a while we used to put it up on the website.
- 3 But no matter whatever number we put up, the next person down
- 4 the street somehow had a number that was a little bit better.
- 5 And so unless you have some kind of an external, objective
- 6 measure of quality, either in terms of results or risks or
- 7 incidence of complications, it's a difficult problem. And
- 8 it's particularly difficult when you're not in a hospital or
- 9 other type of setting where you have other people overseeing
- 10 and monitoring your outcomes.
- DR. LEE: You know, it's a very tough area and I
- think you have to have realistic expectations about what you
- 13 can do. I mean, another area where a lot of numbers get
- 14tltuthrownarewundsescpidesestelstrigenby Toragrews13te cancer, and

Ank ydon'foreaeryoread a tie usat billboardstal or13 thrown arolem. hp, s. 13111213

10

1 not an area where investment in energy and time is going to

- 2 have a great return. I mean, I'm not against going in there,
- 3 but I would be realistic.
- 4 One thing that ran through my mind that I -- you
- 5 know, this is going to sound like a, you know, like a
- 6 physician-like, Taliban-like perspective on things. But I
- 7 think that in the interests of promoting fair competition in
- 8 the health care marketplace, I think a number of my
- 9 colleagues would be -- they would support a ban of
- 10 advertising of anything which required a physician decision,
- 11 that is to say, a prescription being written, a test being
- ordered, with the logic being that if the decision-making is
- 13 supposed to be restricted to a physician, then the lay public
- doesn't have the expertise to judge their need for it. And
- this obviously would limit all direct-to-consumer advertising
- 16 in pharmacy.
- 17 And I think that that kind of thing does provide --
- 18 have some small benefit. I think it creates much more demand
- 19 where there isn't much need. You know, the ratio, you know,

1 billboard that they may be able to read or not because it

- 2 wasn't in their language?
- 3 Are they going to get it from, you know, the health
- 4 club? Are they going to get it from some other source? Or
- 5 have they lost total confidence in the quality components of
- 6 advertising?
- 7 MS. KOHRS: Dr. Lee?
- 8 DR. LEE: My response is that I'm not really
- 9 worrying that much, actually, whether the consumer really
- 10 understands it. I think that if solid quality measures get
- 11 put out there, it produces the desired effect, which is it
- makes consumers like, you know, me in my day job, you know,
- sweat bullets and try to create systems to make it better.
- 14 So that it will be great if the consumers
- 15 understand it, but to me it doesn't really matter if your
- 16 goal is to actually improve care.
- MS. KOHRS: Well, going back again to that Cal
- 18 Dental decision, when "gentle dentistry in a caring
- 19 environment" was seen as a quality assessment that Cal Dental
- 20 was not willing to allow dentists to advertise, how would you
- 21 assess what quality advertisement really is? Do you have
- 22 a -- can you give us a sense of what that might be?
- 23 MS. CARABELLO: Well, in my mind, anything that
- 24 flies in the face of the regulations is not quality. So that
- 25 has to be the first benchmark, whether it's the state

- 1 regulation or it's the FTC or it's your association or some
- 2 guideline that you're following, as long as you're in the
- 3 quidelines.
- It's a question of good taste versus bad taste. I
- 5 mean, there are doctors who are advertising regularly who are
- 6 advertising in good taste and promoting quality. And I think
- 7 quality wins no matter what. That's the bottom line.
- 8 And I somewhat take issue with the fact that, do we
- 9 care whether the consumer gets it? I think we have to care
- whether the consumer gets it because ultimately, when they
- 11 get the right information, they take better care of
- themselves, the outcomes are better, and it costs the system
- 13 less money.

- 1 behind giving that information.
- 2 How expensive that is becomes a different story,
- and I think as far as the employers go, they sort of, from
- 4 what I hear, have had it up to here as far as assuming more
- 5 cost. So I think there's got to be a buy-in from other
- 6 sources as well as far as getting the information across.
- 7 MR. SFIKAS: I think quality is very important in
- 8 the hospital, in the physician's office, in the dentist's
- 9 laboratory. But quality advertising, it's pretty clear that
- 10 the difference between what a physician or dentist or other
- 11 health care professional knows and what the consumer knows,
- there is a striking dissimilarity in their ability to
- 13 understand that.
- So I think it's very, very difficult to use quality
- advertising as you would some of the other types of
- 16 advertising, like price and other things, because of the
- 17 difficulty in consumers understanding it.
- 18 MS. KOHRS: Helen?
- MS. DARLING: Well, I think we have a lot more
- 20 positive experience than the tone of this conversation is
- 21 headed. A number of people have been working on HEDIS

- interesting -- because we've got about seven years'
- 2 experience now -- is that the health plans that allowed their
- 3 information to be reported publicly initially got better and
- 4 better; that the ones who were doing -- basically, people who
- 5 did a good job and made it available did better in lots of
- 6 ways. They got better.
- 7 The plans themselves in many instances, we know
- 8 from reports that if they didn't do well one year on
- 9 something inside the plan, then a lot of things happened. A
- 10 lot of steps were taken to improve it.
- We do know that there are companies that pay a
- differential and provide information. When I managed health
- care at Xerox, we actually provided data from the HEDIS report, and we had an allowance, and our employees had

- decisions and interactions with the system, they're very
- 2 personal, very intimate interactions. And I think to the
- 3 extent that different age groups and different cultures have
- 4 different needs, we think one expression of quality is that
- 5 the services are appropriate for the individual
- 6 circumstances, not just their diagnosis.
- 7 So I think it's a very important component of it.
- 8 It hasn't been demanded of us yet at DoctorQuality, but, you
- 9 know, sure enough, it will be coming.
- 10 MS. KOHRS: Helen?
- MS. DARLING: Actually, it's become the hot topic.
- 12 And cultural competence is the current language on this.
- 13 It's actually a big issue and very important, and large employers who especially -- like the hotsl2smfs cy theg'r theike trl

- 1 the HR material is done in Spanish or -- you know, they are
- 2 particularly good on, if you will, the easier languages for
- 3 us now as a country, where we have a lot of people speaking
- 4 that language in a lot of different places. It's easy to get
- 5 the resources.
- 6 But they're recognizing that there are many, many
- 7 categories of people from different cultures. It's going to
- 8 be very expensive, though, to deal with it. But employers
- 9 really think this is extremely important.
- 10 MS. KOHRS: Dr. Koch?
- DR. KOCH: I want to just touch base again on this
- issue of doctor quality and quality health care provision.
- 13 And I'm very intrigued by your website and what's occurring,
- and also a little concerned about the possibility that, you
- 15 know, unhappy patients can try to get in multiple ways. And
- 16 certainly in the LASIK world, there are whole websites
- devoted to complications, and then certain physicians will be
- 18 spoken of, you know, based on one case.
- 19 And when we try to think about who is best capable
- 20 of evaluating quality of care, it's really our peers, our
- 21 peers in our specialty and, to a certain extent, peers not in
- 22 our specialty.
- 23 And I quess maybe my request for your next project
- 24 is, why not have doctors evaluate doctors? Don't do it
- 25 through the best doctors of America, which is one way to do

1 it, but why not have doctors evaluate doctors and have those

- 2 ratings become available? I know that's all the competitive
- 3 and all that sort of issues, but who else better than those
- 4 in their own peer group?
- 5 MR. GEBHART: I think that's a very valid
- 6 observation. And let me respond to that a couple of ways.
- 7 And I failed to mention this earlier.
- 8 It's interesting: We do not have enough ratings to
- 9 really see what the true pattern is going to be yet. But the
- 10 overwhelming majority of ratings that we have are quite
- 11 favorable. So we find there's probably a greater propensity
- for people to get online and help their doctor out with, you
- 13 know, thank you for a good experience.
- 14 Having any kind of a peer review function, it would
- 15 be great to be able to present it. My immediate reaction was
- 16 to try to figure out how to organize it, and that would take
- a little bit of work. But what we do provide is a survey
- 18 that both the doctor and the patient can use that for any
- 19 given condition displays what the evidence-based standard of
- 20 care is. And an evidence-based standard of care is prepared
- 21 by peers.
- The doctor is able to get online and indicate
- 23 whether or not they follow that standard, and then that
- 24 standard is displayed to the member, to the user, so they can
- determine if what's happening in the process is indeed in

Τ	accordance with that standard.
2	So, you know, whether or not your doctor has a nice
3	office staff and free parking and things like that, that's
4	good to know. Whether or not you're actually going to get
5	the treatment you need and they're going to follow a pattern
6	that's been proven to be effective in the past, that's really
7	where the rubber meets the road. And we try to help people
8	with that as well.
9	MS. KOHRS: Well, I'm afraid that that's going to
10	have to be our last word on the topic today. I'd like to
11	thank everyone who was able to come and be a part of this
12	panel, and I'd like to ask everybody to join in a round of
13	applause at this point. Thanks very much.
14	(Whereupon, at 5:02 p.m., the hearing was
15	concluded.)
16	* * * *
17	
18	
19	
20	
21	
22	
23	
24	
25	

1	CERTIFICATION OF REPORTER
2	
3	DOCKET/FILE NUMBER: P022106
4	CASE TITLE: HEALTH CARE AND COMPETITION LAW AND POLICY
5	DATE: <u>JUNE 12, 2003</u>
6	
7	I HEREBY CERTIFY that the transcript contained herein is
8	a full and accurate transcript of the tapes transcribed by me
9	on the above cause before the FEDERAL TRADE COMMISSION to the
10	best of my knowledge and belief.
11	
12	DATED: JUNE 11, 2003
13	
14	
15	LISA SIRARD
16	
17	CERTIFICATION OF PROOFREADER
18	
19	I HEREBY CERTIFY that I proofread the transcript for
20	accuracy in spelling, hyphenation, punctuation and format.
21	
22	
23	SARA J. VANCE
24	
25	